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Abstract
The Bioartificial Liver Devices (BAL) could provide treatment for acute liver failure by supporting
patients awaiting transplantation or aid the process of liver regeneration. For use within a clinical
setting, a number of regulatory criteria must be met, including controlling DNA, endotoxins and
particulates. The aim of this thesis was to begin the development of a system to control plasma quality
returning to the patient.
Methods for DNA, endotoxin and particulates detection were established with human plasma to
measure sensitivity for use with the BAL system. DNA detection by QPCR using Alu repeats were
validated for use as an analytical method to demonstration DNA removal, achieving a Limit of
Quantification (LoQ) of 0.1ng/ml DNA. Endotoxin analysis utilised a fluorescent derivative of the
widely used LAL assay to increase sensitivity, enabling 2EU/ml to be detectable. Particulates down to
1µm were measured using laser light obscuration.
Initially the removal of particulates from alginate as a starting material (alginate prior to
encapsulation) was shown, using filtration by depth charge filter, sand bed filtration and gas solid
cyclonic filtration. Encapsulated bead integrity, cell function and growth were compromised with all
techniques of filtering alginate in solution, including depth charged and sand bed filtration.
Conversely, gas solid cyclonic filtration maintained bead integrity, cell growth and function.
Testing potential DNA levels in the large scale BAL system required the development of a scaled
down model of the BAL treatment phase, replicating the large scale BAL system with cell number to
plasma volume ratio. This provided an indication of the DNA challenge a removal system at a large
scale would need to contend with, predicted to be 68ng/ml for a full scale BAL. A scaled down
filtration model was then established to model the DNA removal capability of different 3M® Cuno®
DNA depth charged filters. This established a requirement for a predicted surface area of 1300cm2 to
achieve complete DNA removal. The volumetric capacity of the filters were calculated using
established filter blockage models, in order to scale the capacity to the full BAL system size.
Finally, the chosen depth charge filter was tested at a large scale with the extracorporeal BAL system,
spiking human plasma with DNA and endotoxin, whilst measuring endotoxin and DNA removal over
8 hours of treatment.
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Chapter 1General Introduction
This Chapter will present the background of the liver,
liver disease, and substantiate the need for clinical
development of the bioartificial liver device.
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Chapter 1 General Introduction The Liver
1. General Introduction
The fields of human organ replacement and regeneration using bioengineered solutions have
blossomed into potential treatment for many diseases, from bioartificial tracheal, lung and
heart transplants1-3 to extracorporeal bioartificial kidney and pancreas4. The central tenet of
these approaches is that organ replacement is drastically improved by using living cells that
are able to replace functions that are often insufficient in artificial organ replacement or
intensive care treatments alone.
Worldwide, the annual mortality rate of patients suffering from hepatic liver failure is over 2
million5, which clearly illustrates a need for better liver replacement therapies.
1.1. The Liver
In order to understand the pathology of the liver, this section will briefly discuss the relevant
macroanatomy, microanatomy, and function of the liver.
1.1.1.Structure and Function of the Liver
The human liver is one of the largest organs, situated at the top of the upper abdomen, beneath
the diaphragm, it is protected by the ribcage (Figure 1-1A)6 and comprises of two main lobes,
the right and left, separated by the falciform ligament (anterior view on Figure 1-1B), and two
smaller lobes, the caudate and quadrate lobes (posterior view Figure 1-1B). The liver mass is
on average 1500g and taking around 25% of cardiac output, second only to the brain, arriving
via the hepatic artery at ~400ml/min. It is connected to the small intestines by the portal vein
transporting blood at 1000-1200ml/min from gastrointestinal tract and spleen to the liver7. A
second blood supply maintains the liver with oxygen saturated blood from the heart via the
aorta8.
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Figure 1-1: Morphological anatomy of the Liver. A; Showing the location of the Liver in the
upper abdomen protected by the rib cage. B; Magnification of the liver, illustrating the
morphological anatomy of the liver, comprising of the left and right lobe separated by the
falciform ligament, shown in the anterior view, with the posterior view showing the
hepatic vein, proper hepatic artery, the portal vein, and the common bile duct. (Modified
from the Encyclopaedia Britannica and www.fattyliver.com)
Branches of the hepatic artery and portal vein feed the dual blood supply through the liver
lobules, constituting segments that are defined at histological scale9 (Figure 1-2C). The area
between the hepatic venule and the hepatic artery is comprised of both hepatocytes and non-
parenchymal cells (e.g. Kupffer cells and stellate cells). Blood passes from branches of the
hepatic portal vein and the hepatic artery, during which over 500 different synthetic and
detoxifaecatory functions occur, before entering the systemic blood supply via the central
vein10.
The presence of an oxygen, hormone and substrate concentration gradient, from the portal
vein to the hepatic artery, causes zonal Hepatic heterogeneity shown in Figure 1-2B11-13
(Figure 1-2C). For example, the oxygen concentration changes from ~85µmol/L at the
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Chapter 1 General Introduction The Liver
hepatic artery to ~40µmol/L at the hepatic venule14, leading to hepatocytes in the specific
zones performing distinct functions related to the environment, which form the basis for the
model of the acinus functional unit illustrated in Figure 1-2C.
Figure 1-2 : Microanatomy of the liver. A; arterial and venous branches supply ~ 1 x 106
liver lobules (in the whole liver), a morphological unit of the liver. B; a detailed section of a
lobule illustrating the blood entering through the portal vein and hepatic artery to flow
through the sinusoids which are lined by hepatocytes, exiting through the hepatic vein.
Hepatocytes distributed across the sinusoid are split into three functional zones: 1, 2, and
3. C; the acinus as defined by the orientation around the afferent vascular system of the
portal vein and hepatic artery, describing the smallest functional subunit (Modified from
American College of Surgeons 15, and American National Institute of alcohol Abuse 16)
An important hepatic function is bile production, regulated by hormonal and molecular signals
carried in venous and arterial blood17. Bile drains into the biliary system (Figure 1-2B), which
is formed by a network of channels connected to the common hepatic duct, (Figure 1-1B
posterior view and Figure 1-2B) before being released into the small intestines 18. It contains
many organic salts as well as exogenous and endogenous amphipathic compounds, such as
bilirubin, fatty acids, drugs, and toxins, both aiding excretion of toxins and emulsification of
lipids for adsorption. 19,20.
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Chapter 1 General Introduction The Liver
1.1.2.Cell Numbers, Types, and Function.
The liver is commonly segmented into 8 functional subunits each of which contains
approximately 1 million lobules (Figure 1-2A). A single lobule contains, on average, between
100,000 and 200,000 hepatocytes, giving a total of 1 x 1011 – 2 x 1011 hepatocytes in the liver.
However, with only 35% of the original cell volume of 7 x 1010 hepatocytes, the liver can
sustain a healthy individual21,22. Other cell types, which form part of the liver and play a vital
role in a functional system are summarised in Table 1-1.
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Cell Type Function Description
Hepatocytes
Oxidative metabolism O2 gradient dictates leveldepending on proximity to portalvein14,23Carbohydrate metabolism Aerobic respiration is favouredhepatocytes in periportalregion24,25Lipid metabolism Hypoglycaemia induces formationof ketone bodies, and inhibition oflipid metabolism26Amino acid metabolismand Detoxification Excess is catabolised into ammonia.Gluconeogenesis occurs whenglycogen and fatty acids areexhausted26,27Bile formation Bile production is stored in the gallbladder before being excreted intothe digestive system to aid lipidemulsification, and digestion andexcretion 26Biotransformation anddetoxification Cytochrome P450 proteins areresponsible for detoxification,biotransformation include T4 to T3de-iodinisation stimulated bythyroid stimulating hormone (TSH)28
Kupffer Cells
Macrophages residing inthe liver sinusoid Antigen presentation, cytokinerelease and mediation of pathogenresponse29
Liver Sinusoidal
Endothelial Cells
Barrier forming thesinusoid and the space ofDisse
Line the inner wall of the sinusoidcontaining fenestrations of 100 -200nm to allow diffusion20
Stellate Cells
Produce extracellularmatrix for hepatocytesgrowth
Located in the space of Disseproducing matrix proteins such ascollagen30
Table 1-1 Summary of cell type and function making up the human liver.
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Chapter 1 General Introduction Liver Failure
1.2. Liver Failure
Liver failure is a condition where the liver can no longer perform normal metabolic and
synthetic functions. The development of liver failure is categorised into either chronic or acute
liver failure, depending on the nature of the insult and the progression of the disease. Chronic
liver failure develops due to progressive liver injury followed by regeneration over a long
period, resulting in development of cirrhosis and fibrosis replacing functional hepatocytes31.
Acute liver failure occurs through the death of large numbers of hepatocytes, in a short period
of time leading to compromised liver function as defined by hepatic encephalopathy and a lack
of protein synthesis. The leading global cause of acute liver failure is viral Hepatitis, with the
exception of the UK and USAwhere acetaminophen (Paracetamol) is the primary cause32.
1.2.1.Chronic Liver Failure
Despite chronic liver injury causing widespread cirrhotic tissue damage the liver has
functional capacity for prolonged periods before acute-on-chronic liver failure ensues,
exhibiting the aetiology of acute liver failure described in section 1.2.2.
1.2.1.1. Toxic Substances Leading to Chronic Liver Disease
Long term abuse of toxic substances such as alcohol can lead to different hepatic conditions
including alcoholic liver disease where hepatocytes swell and change their metabolism, and
fatty liver disease with excess fat builds up in the liver. As a result of persistent hepatitis
caused by these conditions, liver cirrhosis develops, eventually leading to organ failure33.
1.2.1.2. Viral Hepatitis
Currently five main categories of viral hepatitis have been defined: A, B, C, D and E, of which
B, C and D are parenterally transmitted and have shown progress to chronic hepatitis. Infected
patients can be treated with anti-viral drugs but persistent infection can lead to progression of
chronic hepatitis whereby the liver sustains inflammation and damage 34.
1.2.1.3. Metabolic Disorders of the Liver Disorders
Metabolic disorders often do not directly cause liver damage, but lead to either a build-up of
toxin, an increased susceptibility to pathogens or manifestation of carcinoma, ultimately
causing development of cirrhosis and fibrinogenesis and potentially acute-on-chronic liver
failure. An example of fibrotic metabolic disorders is hemochromatosis, which arises from
excess iron accumulation in the liver and pancreas, leading to cirrhosis and potentially acute-
on-chronic liver failure35.
1.2.1.4. Treatment of Chronic Liver Disease
Most chronic liver diseases mentioned are treatable with relevant drugs only causing major
problems if they are not diagnosed or are neglected, allowing cirrhosis and fibrosis to develop.
Eventually, the liver becomes decompensated leading to acute-on-chronic liver failure36, which
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the Liver Group BAL system could treat, although it is primarily targeted at acute liver failure
patients.
1.2.2. Acute Liver Failure
1.2.2.1. Toxic Liver Injury
The liver is vulnerable to toxic injury due to its pivotal role in biotransformation and
metabolite processing for excretion into the bile, potentially leading to hepatic necrosis and
acute liver failure 37. Two aspects dictate hepatotoxic effect, dosage and the properties of the
metabolite for biotransformation. For example, a relatively high concentration (200mg/kg
person) of acetaminophen (Paracetamol) can cause acute liver failure 38, whereas a
comparatively low concentration of carbon tetrachloride (200µg/ml)39) leads to the same
outcome. Both are metabolised by the CYP-P450 group of enzymes to form toxic compounds
carbon trichloride and dichlorocarbene (from CCl4), and N-acetyl-p-benzoquinoneimine (from
acetaminophen) causing hepatotoxicity40.
1.2.2.2. Viral Induced Injury
Of the five main types, Hepatitis B (HBV) is the main cause of viral acute liver failure41,
attributable to the immune response through a substantial induction of pro-inflammatory
interleukin-12 release from Kupffer cells42.
1.2.2.3. Treatment of Acute Liver Failure
Treatment of acute liver failure is predominantly focused on intensive care practices, based on
four principles: prevention and treatment of complications; substitution of substances no
longer synthesised; promotion of liver regeneration; bridging the gap before transplantation or
regeneration. Liver transplantation was first reported in 196743 and is now the treatment of
choice, if liver regeneration fails, but is limited by inadequate donor numbers. A report to the
UK house of Lords in 2008 stated that despite increases in donor availability, 15% of people
on waiting lists die before receiving a transplant44. This is reflected in the USA where in 2007,
6494 liver transplants were performed, with 17,000 remaining on the waiting list, of which
2000 died. Furthermore, the longer a patient is on the transplant list the less favourable the
transplant outcome is, due to the deterioration of their condition45.
Page 25
Chapter 1 General Introduction Extracorporeal Liver
Replacement Technology
1.3. Extracorporeal Liver Replacement Technology
In order to bridge the gap prior to transplantation or to support patient physiology to promote
liver regeneration, liver replacement technologies seek to replace vital liver functions, with
one or a combination of mechanical, chemical or biological means.
1.3.1. Artificial Liver Systems
Artificial liver systems aim to cleanse the blood or plasma through physical or chemical
means, in order to mimic the detoxifacatory function of the liver. They are usually based on
membrane separation associated with columns or suspensions of sorbents such as charcoal or
ion exchange resins or albumin exchange.
1.3.1.1. Liver Dialysis
Liver dialysis works on the principle of a concentration gradient between a semi-permeable
membrane removing toxins from the blood. For example, HemoCleanse® uses a semi-
permeable membrane with a 4-5kDa cut-off, which separates patient blood from a solution
containing sorbent activated charcoal and cation exchange resin. Toxins in plasma from
fulminant hepatic failure (FHF) patients, in particular non-ionic compounds, adsorb onto the
charcoal, with the cation exchange resin binding to ionic compounds. Unfortunately, the
technique shows no survival benefit in patients suffering from FHF, although an improvement
in transplant recovery of 71% vs. 35.7% was shown, with treated vs. untreated FHF patients.
Despite the modest improvement, it shows that the principle of removing toxins by
substituting for liver function may work46.
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Developments in dialysis technology used more sophisticated approaches, essentially based on
dialysis with the incorporation of sorbent technologies. One such device named MARS®
(Molecular Absorbance in a Recycled System) shown on Figure 1-3, uses a 50kDa membrane
for dialysis of lipophilic, albumin bound toxins from patient albumin, to extracorporeal
albumin present on the counter side of the membrane. However, no significant survival benefit
was seen, in of 90 patients treated with MARS before transplantation, a significant
improvement in life quality was observed for post liver transplanted patients, which showed to
be more cost effective than conventional hospital treatment47. This illustrates that the concept
of replacing liver function has great potential; the question now is how to make it more
effective.
Figure 1-3: Molecular Adsorbent Recycling System (MARS®). Patient plasma passes by a
50kDa dialysis membrane with clean albumin, facilitating the absorption of hydrophobic
toxins from the patient’s albumin, whilst preventing protein transfer. The albumin is then
partially rejuvenated by passing through an anionic exchange and activated charcoal
column.47
1.3.2.Bioartificial Liver Machines
Artificial liver systems cannot perform the full gamut of functions necessary to substitute liver
function for therapeutic benefit, as defined by a definite improvement in survival outcome.
With over 500 functions provided for by the liver26 the only practical approach is utilising a
biological element. As a consequence, the focus of system design shifts from dissection of
individual liver functions for artificial replacement to designing a system which can sustain
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Sufficient living cells adequate for treatment. These aspects are inextricably linked with cell
type, the growth media and the ability to achieve and maintain a cell mass comparable to a
third of a native liver, normally sufficient for maintaining liver function in humans48.
Furthermore, the system needs to be a bedside treatment, with fully regulatory approved
components available at extremely short notice, requiring a means of long term cell storage
through cryopreservation49
1.3.2.1. Cell Source
The biological element to the bioartificial liver is crucial for treatment efficacy, requiring a
balance between proliferative potential in cell culture, functional capability, possible patient
immunogenicity, and cell source availability. Table 1-2 summarises different considerations
that are important for cell choice.
Cell Source Advantages Disadvantages
Autologous cells harvested
from patients (primary
Hepatocytes from patient)
 No immune reaction
 Low risk of infection
 Near native level of hepatic
function
 Prohibitively limited
availability
 Potentially poor quality
of cells
 Limit proliferative
capacity
Allogeneic cells collected
from donors (primary
hepatocytes from donors)
Better availability compare
to patient source
Ability to pool cells
Near native level of hepatic
function
Risk of immune response
Risk of disease
transmission
Limit growth capacity
Allogeneic cell lines
(Carcinoma cell line)
High availability
Almost infinite cell growth
capacity
High cell density achievable
Loss of cell function
 Potential tumourigenicity
 Potentially undesirable
protein expression
Regulatory issues with
use
Xenobiotic cells source
harvested from different
species, e.g. pigs
High availability
Near native functionality
Risk of pathogen
transmission (e.g. PERV)
Non-human protein
production
Regulatory issues with
use
Table 1-2: Potential cell sources for Bioartificial liver systems. Outlining advantages and
disadvantages.
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The use of primary human hepatocytes, either from the patient or from donors would
immediately appear to be the best choice, due to their near native level of hepatic function,
low risk of infection and lack of immune induction. However, limited availability of primary
human hepatocytes, especially from the patient, coupled with a limited ability to culture them
to the required cell density and maintain differentiation for prolonged periods, present major
obstacles for their use in a BAL system50-52. Animal primary hepatocytes solve the issue of
availability, but bring with it many other issues, not least the potential risk of transferring
endogenous retroviral elements, as well as increasing the probability of bacterial and viral
infections crossing the species barrier52-54.
Other cell sources include a burgeoning area of stem cells, where groups have induced
differentiation of mouse induced pluripotent and embryonic stem cells into cells of hepatic
lineage. The cells are then cultured for application to a hollow fibre cell matrix, constructed
from polyethersulfone, to produce functioning cells with comparable function to primary
mouse hepatocytes52,55.
A popular cell source for BAL systems is the HepG2 cell line and various derivatives
including; C3A cells, HepG2/tk, and HepG2 cells56-59. The advantage of these is an
inexhaustible source of cells, although function may be compromised in comparison to
primary hepatocytes56,60. However, many of the lacking functions can be up regulated using
genetic modification58,59, oxygenation and chemical induction, e.g. refampsin 61,62.
1.3.2.2. Hollow Fibre Bioartificial Liver Systems
Hollow fibre bioreactors were the first generation of bioartificial livers entered into clinical
trials. They are based on the design for kidney dialysis, where the specific cells types are
suspended in cold collagen, then injected into the hollow fibre cartridge, which is then
perfused with warm media causing gelation of the collagen and contraction cell-collagen
suspension. This provides a space for the plasma/blood to pass adjacent to the cells/collagen
matrix63.
A multitude of cell types have been used with this technology, such as the HepaAssist BAL,
using cryopreserved primary porcine hepatocytes64, the ELAD BAL (extracorporeal liver
assist device) using C3A cells, a HepG2 cell line derivative 65, the MELS-BAL (modular
extracorporeal liver support) and utilising primary human hepatocytes from donors66, amongst
many others. A recent study with 1 x 108 primary human hepatocytes in a hollow fibre system
showed maintenance of viability over two weeks, although physiological and function
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parameters, such as urea production, glucose consumption, and non-essential amino acid
synthesis rapidly declined during this time51.
1.3.2.3. Microfluidics
An area of increased interest is the use of micro-fluidics with micro-electro-mechanical
(MEM) technology, working on a micrometre to millimetre scale to mimic the liver
vasculature, by etching silicon wafers with channels and attaching electrodes and other
chemical functional groups such as cell adhesion proteins52,67. One such microfluidics device,
is designed to form an artificial micro-liver, provides capillary like space where hepatocytes
(HepG2 cells) are seeded, forming tissue similar to that of a native liver, showing a
maintenance of cell viability and up regulation of function68. A polyethersulfone membrane
barrier, containing 0.22µm pores, also provides a structure analogous to the fenestrations of
the endothelial layer.
Recent developments have the ability to mimic sinusoids by introducing a co-culture system
into a precisely etched chamber by positioning cells through di-electrophoresis, showing the
same flow characteristics as a sinusoid52,69. Despite some exciting developments, a
microfluidics device would currently be impractical to manufacture a device at a large enough
scale for human clinical application, due to the low cell numbers relative to the size of the
devices. However, it does illustrate the importance of improving intercellular contacts to better
model the native liver architecture.
1.3.2.4. Examples of BAL Systems in Clinical or Pre-Clinical Trials
A number of bioartificial livers have gone through pre-clinical and clinical trials, but none
have reached full clinical use. Some of the hollow fibre devices previously mentioned is
outlined in Table 1-3. A development away from hollow fibre technology has been to apply
hyper-fluidisation methodology on encapsulated spheroid cells to increase mass transfer and
allow direct perfusate contact with cells. A recent study using HepG2 cells encapsulated in
alginate beads, showed improved survival times in pigs suffering from fulminant hepatic
failure. The alginate beads were coated in chitosan, increasing the stability of the beads in
plasma, and housed in a chamber which induced bead fluidisation when passing plasma
through70. Other Bioartificial Liver systems recently involved in clinical trials are summarised
in Table 1-3. .
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Name of technology Bioreactor Type Method of Perfusion Cell type Clinical Trials
HepAssist64 Hollow fibre with two compartments,
cells attach to dextran micro carriers on
outside of hollow fibre, includes
charcoal perfusion chamber and
oxygenation by perfusate
Plasma passes through
fibre lumen
Human Hepatocyte
C3A cell line
Phase I Randomised trial, ALF survival: 73% vs.
59% control
ELAD65,71 Hollow fibre with 2 compartments,
dialysis style cartridge, oxygenation by
perfusate
Plasma passes through
fibre lumen
Primary porcine
hepatocytes
Randomised phase I trials: improvement in survival
between controls
MELS66,72 Hollow fibre capillary system with 4
interwoven compartments, with
independent function; media inflow,
media outflow O2/ CO2/ heat exchange.
Plasma through fibre
lumen
Primary human or
porcine hepatocytes
Phase I trials: 7 of 8 patients carried to liver
transplant with 100% transplant success rate after 3
years
Radial Flow
Bioreactor73
Two hollow fibre compartment,
oxygenation by direct cell contact with
perfusate,
Radial plasma flow
through mesh across
cells
Primary porcine
hepatocytes
Phase 1 trials: improvement to encephalopathy
ammonium levels
Table 1-3, Summary of Bioartificial Liver systems which have undergone clinical trials. All are based on hollow fibre technology.
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1.4. The Liver Group BAL
The Liver Group BAL currently utilises HepG2 cells (Heptoma blastoma cell line sub group),
but is able to accommodate other proliferative cells lines, encapsulated inside 500µm alginate
hydrogel beads to form cell spheroids, cultured to optimal function, which can then be
fluidised by perfusion with plasma at ~400 ml/min in the same extracorporeal chamber.
1.4.1.Bulk Cell Growth
The growth phase commences by seeding the alginate hydrogel with a low number of cells per
bead. After which, cells proliferate to between 30-100 million cells/ml of alginate beads in a
fluidised bed configuration, being sufficient to achieve at least 35% of the native liver cell
mass for a 75 kg individual (7 x 1010), with ~1.2L of alginate beads. Growth is maintained
over 9-12 days of culturing in modified culture medium, applying microgravity fluidisation to
form multi-cellular spheroids with cell-to-cell communication via gap junctions, desmosomes,
and microvilli, illustrated in Figure 1-4. As with other 3-D technologies, this too shows an
increase in cell proliferative and functional performance compared with monolayer74.
Figure 1-4: HepG2 cell encapsulated in alginate grown in modified media over 12 days to
form multi-cellular spheroids. Cell viability was measured by green FDA staining, overlaid
with red PI staining for non-viable cells. Cells grow out from single cells to form multi
cellular spheroids with cell-to-cell contact, as illustrated in the transmission electron
microscope images.
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1.4.2. Microgravity
A microgravity environment is provided by movement of each bead in a stable continuous
loop, with drag created by the upward fluid velocity forcing beads from the bottom of the
fluidised bed to the top, where gravitational force due to the density of beads eventually
becomes greater than the force of the plasma drag (Figure 1-5). The chamber provides a
consistent environment between growth and treatment phase, allowing cell growth, washing
and bead perfusion with human plasma, thereby removing risk of contamination from
exchanging chambers.
Figure 1-5: Microgravity in the BAL chamber. The small beads represent the bead bed, one
bead is enlarged for clarification. Drag as a result of flow velocity causes the beads to move
to the top of the fluidised bed. The density of the bead becomes sufficient to overcome the
drag, through gravitational forces to fall to the bottom of the bead bed.
1.4.3.Treatment Phase
The biomass grown in modified culture medium is washed in human plasma before
installation into a dual circuit system, as illustrated in Figure 1-6. In the primary circuit, blood
from the patient is separated into plasma using the Cobe® Spectra® plasmapheresis system.
Plasma is then passed into the secondary circuit, which contains the fluidised biomass
providing nourishment and detoxification for the plasma.
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Figure 1-6: Liver Group BAL treatment phase, comprising two circuits. The primary circuit
separates plasma from the patient using the Cobe® Spectra® aphaeresis system. The
secondary circuit contains the cell biomass, which nourishes and detoxifies the plasma
supplied by the primary circuit a number of times before returning to the Cobe® Spectra®
Aphaeresis system and the patient.
Treatment can occurs for up to 8 hours where preliminary studies in rabbit models of hepatic
failure showed high levels of liver specific function as well as improved systemic parameters
indicative of liver failure (diastolic blood pressure and transjugular venous oxygen
saturation)57,74. In addition to this, beads exposed to an in vitro model of human acute liver
failure plasma showed maintenance of viability, bilirubin conjugation, CYP450-1A activity
and urea synthesis 75. In addition to this beads were tested in a large pig trial with full results
pending, but did show improvement in clotting function, protein synthesis, and bilirubin
conjugation amongst others. .
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1.5. Further Liver Group BAL Developments
To provide adequate nourishment and detoxification to patient’s plasma, whilst maintaining
patient safety, a balance needs to be struck between cell function, viability and number, as well
as integrity of beads and clinical safety. One particularly crucial balance is that of cell function
and proliferation. In comparison to primary human hepatocytes some HepG2 cell functions are
down-regulated, whereas the contrary is true for HepG2 cell proliferation compared with
primary hepatocytes76. For the BAL system, sufficiently sized and stable cell bulk is necessary
to provide treatment. As previously mentioned, HepG2 function can be up regulated, whereas
stability of cell function or proliferation cannot be easily maintained for a BAL application
using primary hepatocytes.
A key aspect to market approval of the BAL medical device is the characterisation, evaluation
and control of contaminants 77. There are two vital features to control contaminants in the BAL
system: patient safety, and regulatory compliance. These points are not mutually exclusive;
regulatory bodies provide a framework for research and manufacture standardisation through
stipulating requirements for compliance, by entrenching safety through traceability, stringent
testing, and validation of efficacy. These criteria are delivered by implementing particular
management tools through quality manuals, validated research, and validated analytical tools
implemented through well-defined Standard Operating Procedures (SOPs) and personnel
training documentation. SOP’s are standard manuals and protocols to institute standardisation,
not only as part of experimentation but through to laboratory practices and management
structures.
It is important to incorporate safety and efficacy by establishing quality systems, beginning
with the development of validated analytical methods to support them. Three contaminants,
which are of significant regulatory importance and are cell associated will be the focus of this
thesis; cell debris, DNA and endotoxin. Another important contaminant is particulates within
the alginate starting material and will also be discussed. Some of the health aspects of these
contaminants will be mentioned as an explanation for the regulations relating to these
contaminants in a medical device.
The aspects of BAL bead integrity and clinical safety mainly relating to contamination transfer
from components of the device to the patient. This includes alginate/cell fragments from the
biomass, DNA from HepG2 cells, various components from the alginate matrix and endotoxin
within the system. This will be the focus of this thesis with each chapter detailing the specific
concerns related to the aforementioned contaminants. An overview of aspects not dealt with in
later chapters will be outlined now.
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1.5.1. Alginate
Alginate is a family of linear anionic polysaccharides, which form linear chains by covalent
linking through the 1-4 carbon of -D-mannuronate (M) and its C-5 epimer α-L-guluronate (G), 
both in pyranose ring form. It is relatively abundant in nature, mainly produced by
Pseudomonas bacteria and Macrocystis pyrifera, Ascophyllum nodosum, and various types
of Laminaria seaweed78. For commercial use, however, extraction from seaweed is most
common. Alginate solubilisation in water, when in linear chains, is achieved by forming the
monovalent salt during extraction and processing. Once solubilised the electrostatic anionic
repulsion between chains produces an intramolecular extended random coil structure, forming
a gum with relatively high dynamic viscosity79. Dynamic viscosity increases exponentially
with increased molecular mass, whilst the flexibility of the linear chains increase in the order
of GG < MM <MG. As a result, the ratio of G and M directly influences the dynamic viscosity
of the solution at a given concentration80.
1.5.1.1. Ionotropic Gelation of Alginate
Ionotropic gelation of alginate (referred to as encapsulation), to form insoluble beads, can use
Calcium as the divalent cation, to form cross linkers between anionic polymeric chains. Other
alkaline earth metals can also be used, with the affinity decreasing thus; Ba2+ > Sr2+ > Ca2+ >>
Mg2+ 81, but increasing in biocompatibility. The gel forms by alginate chains linking between
carboxylic acid groups on adjacent chains with the calcium in between78.
1.5.1.2. Important Alginate Parameters for the BAL
Alginate beads are most commonly produced using a variety of techniques to form droplets or
beads that undergo cross-linking in a polymerisation buffer containing calcium ions. This is
termed external gelation, as the greatest Ca2+ concentration is on the outside of the bead,
causing an increase in alginate chain formation on the edge of the bead82. As a result, this type
of encapsulation provides an external protective layer for cells whilst providing sufficient
internal space for cell growth74,75.
The non-toxic nature of alginate itself and the process of making beads lend itself to use in a
biomedical device. Bead formation occurs at neutral pH with no need for organic solvents,
which maintains cell viability. Despite this, the use of relatively high Ca2+ concentrations
required to facilitate cross-linking can be damaging to cells if exposed for a prolonged periods
of time83. Furthermore, conditions that may cause excessive levels of shear stress to the cells
during encapsulation may lead to a reduction in viability, although some shear stress can be
tolerated84.
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For application to the BAL system, the formation of beads relies on the correct viscosity of the
unpolymerised alginate, to form suitable bead morphology to facilitate cell growth and
function, whilst maintaining a robust matrix over 8 – 12 days of growth, and up to 12 hours of
plasma treatment, as well as cryopreservation and storage over long periods49. The ability to
form a non-homogenous alginate cross-linking environment with adequate pore size to allow
sufficient mass transfer between the cells and media/plasma is also crucial.
Anions with the ability to chelate Ca2+ such as citrate, EDTA, and phosphate need to be
controlled in the BAL environment to maintain bead integrity81, which is the reason for
supplying additional calcium to FFP (fresh frozen plasma) that uses citrate as an anticoagulant.
1.5.1.3. Alginate Purification
During the development of the Liver Group BAL system, a set of alginate parameters have
been carefully established, which are crucial for the successful encapsulation and growth of
HepG2 cells, as well as bead integrity during the treatment phase in plasma75. Currently,
analytical grade alginate is used, which has been perfectly adequate for research purposes, but
requires purification to become clinical grade (detailed further in Chapter 3), as amongst other
issues visible particulates can be seen under a phase contrast microscope at between 1-20µm
in size, which cause alginate discolouration.
Many groups have undertaken purification protocols to produce medical grade alginate, for the
purposes of reducing, or eliminating biocompatibility issues, mainly related to long term cell
transplantation into a patient78,85-87. These applications include alginate encapsulation
providing protection against immune rejection for islet cells for the treatment of diabetes88,89.
This requires the pore size to be regulated to prevent cellular and IgG penetration to prevent
immune response90. The methods used to attain the required grade of alginate focus on lengthy
phenol, acetone and ethanol extraction steps, followed by filter sterilisation, which cause
changes to alginate properties, particularly viscosity and M: G: MG ratio87.
One focus of this thesis will be the removal of particulates from alginate which cause
discolouration, without affecting alginate properties, cell growth, function and viability for
incorporation into the BAL system.
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1.5.2. DNA release from the Biomass
1.5.2.1. Justification for DNAControl
There exists some debate about the true risk of circulating DNA in the blood supply, named
cell free circulating DNA (cfcDNA)91.The presence of cfcDNA has been shown in healthy
human blood at relatively low levels, first defined by Mandel and Metais92, and confirmed
many time since 93-99, suggesting cfcDNA in an autologous setting poses little risk to health.
One report showed 59±15ng/ml of DNA, using Picogreen fluorescence 94.
Despite the apparent lack of risk, other sources of cfcDNA have been reported to have
originated from active cellular DNA release by lymphocytes, releasing double stranded DNA
as part of a immunogenic homeostatic mechanism100. In addition to this, some cfcDNA from
necrotic cell death has contributed to the total cfcDNA in healthy patients as well as patients
with various forms of carcinoma 98,99,101,102. Since DNA may have a role in immune response
and is associated with release from carcinoma cells, the World Health Organisation (WHO)
has proclaimed DNA from cell lines as a contaminant, forming the basis for the guidelines
adopted by the major regulatory bodies103. Consequently, HepG2 cell DNA released from the
extracorporeal biomass into the patients’ plasma during BAL treatment must be controlled.
1.5.2.2. Origin of cfcDNA
The origin of cfcDNA in healthy patients is predominantly from apoptotic cell death as
opposed to necrotic cell death 98,99,101,104. However, the mechanism of cfcDNA release from
cells having undergone apoptosis remains relatively unclear. Apoptosis is a tightly controlled
process of cell death, producing apoptotic bodies, which house the DNA fragments of between
180-200bps 105. By DNAse I activity, apoptotic bodies are endocytosed by macrophages,
where membrane fusion with lysosomes results in complete degradation of the apoptotic
bodies, with DNAse I breaking DNA down into nucleotides106. The logical conclusion is that
DNAwould not be detectable, which is clearly not the case.
Detectable levels of cfcDNA spawned an entire field concerned with quantifying DNA in
plasma, from forensics 107,108 to disease diagnostics107,109. For diagnosis of disease, either an
increase in total cfcDNA levels is measured inferring increase in cell death, or DNA markers
for specific disease states are detected within background cfcDNA. These include detecting
higher cfcDNA levels with autoimmune disease 110 and trauma 111 or detecting a specific DNA
cancer marker99,104,112-114. In liver disease, there may be potential in using plasma DNA levels
as an indicator of disease, where apoptotic and necrotic cfcDNA were shown to have been
released from mice that have had liver injury, 3 hours after induction 115.
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1.5.3. Endotoxins in the BAL
1.5.3.1. Bacterial Endotoxins
Endotoxins describe lipopolysaccharides (LPS) or lipooligosaccharide (LOS) that originate
predominantly from the outer cell membrane of various gram negative bacteria, such as
Escherichia coli, Salmonella, Shigella, Pseudomonas, Neisseria, Haemophilus influenzae,
Bordetella pertussis and Vibrio cholera. Endotoxins mainly remain associated to the cell
membrane until the organism undergoes disintegration due to complement and phagocytic
immune responses. LPS are complex amphiphilic molecules approximately 10kDa in size,
varying widely depending on bacterial species, although all sharing the common architecture
of a lipid A region, as well as O and R polysaccharide regions. The Lipid A region contains the
hydrophobic intra-membrane spanning domain allowing anchorage onto the bacterial outer
cell membrane. The polysaccharide regions vary depending on the bacterial species,
particularly with the O polysaccharide region and are associated with bacterial virulence,
phagocyte resistance, and protection against complement and anti-body reaction116.
1.5.3.2. Endotoxin Contamination in the BAL
With the clinical use of the Liver Group BAL system, the majority of endotoxin contamination
is likely to originate from the patients rather than from the BAL system itself. To be compliant
with ISO (International organisation for Standardisation) and GMP (good manufacturing
Practice) standards, that define how devices are manufactured for market approval,
construction of the BAL will be performed in an aseptically controlled environment 77,117,118,
reducing the endotoxin to negligible levels. The endotoxin levels in patients can contribute to
the aetiology of ALF. Patients suffering from ALF who underwent liver transplantation,
showed an elevated level of endotoxin before and during anhepatic phase (46.5 ± 6.7 pg/mL
endotoxin), only significantly reducing after 24 hours (to 19.3 ± 1.5 pg/ml endotoxin), and not
returning to normal levels until 7 days later (13.2 ± 1.0pg/ml endotoxin vs. 10.6 ± 0.8pg/ml for
healthy patient). In addition to this, patients with the highest endotoxin levels exhibited greater
numbers of complications during treatment119.
The normal physiological response to endotoxins and pathogens is mediated by Kupffer cells,
residing in the liver sinusoid, coming into contact with materials absorbed by the
gastrointestinal tract, being the principal liver cell for phagocytosis, cytokine release and
antigen presentation. They are crucial to the liver function by mediating pathogen response as
well as tolerance, and are associated with release of inflammatory mediators growth factors
and reactive oxygen species 29,120. Kupffer cells, and LSEC, are involved with uptake and
clearance of endotoxins. In response to endotoxin or bacterial presence, Kupffer cells produce
cytokines, chemokines and reactive oxygen species, which mediate a pro-inflammatory
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responses and can contribute to further liver injury120. However, under non-inflamed
physiological conditions, Kupffer cells develop endotoxin tolerance121 by expressing anti-
inflammatory mediators such as IL-10, and endogenous prostanoids and TGFβ.   
The levels of endotoxin reported in ALF patients compared with those permitted by regulatory
authorities for parenterals, are lower, i.e. 25EU/ml (2,500pg/ml) endotoxin in 1ml of
parenteral solution compared with 10.6 ± 8pg/ml in 75kg patient. The rationale behind this
may be the systemic dilution of parenterals when administered to a patient with 3L of blood.
The regulatory requirements for removal of contaminants from the BAL system predominantly
focus on measurement and control of levels. Therefore, methods of measurement and control
will be discussed. .
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1.6. Contamination Removal
1.6.1.Current Approaches to Contaminant Removal
As mentioned previously, artificial livers have been used to remove toxins in the plasma of
patients suffering from ALF. Other groups working bioartificial liver systems have recognised
the problem of potential cellular contaminants, particularly when using xenogeneic cell
sources. In these cases, Pig Endogenous RetroViruses (PERV) were shown to be expressed in
the supernatant of microencapsulated porcine hepatocytes cell cultures in a BAL system, and
then proceeded to infect primary human hepatocytes and cell lines when exposed to the same
supernatant54,122. In these studies, the suggestion is made that altering the pore size of the
alginate beads could prevent PERV escape, a tactic that may negatively influence nourishment
of plasma from the ALF patient.
The AMC-BAL, which utilises primary porcine hepatocytes, performed a small trial on 14
patients, collecting plasma after treatment to assess PERV infection by QPCR. In no cases was
infection detected123. A comment made at the end of the Yang group summarised the results
well: “We therefore suggest that more extensive preclinical studies focused on bio-safety to be
conducted.”54
Although indications are that DNA, or specifically PERVs in this context, does not pose a risk,
in vitro studies do show a potential risk. Furthermore, the fact that no BAL has attained FDA
approval is not exclusively due to contamination risk, but taking a proactive approach to
contaminant removal is surely preferable to performing extensive bio-safety studies to
establish the lack of risk.
Other contaminants such as endotoxin have been removed from sepsis patients using charcoal
adsorption, immobilised protein column, and ion-exchange filtration. A particular study
immobilised the anti-biotic polymyxin B, which has been shown to be toxic to the central
nervous system and the kidneys, but was immobilized on polystyrene fibres, to render it safe.
Perfusing patient plasma through the column with the immobilised polymyxin B alleviated
symptoms associated with sepsis, by hydrophobic and ionic binding to endotoxins124,125.
Overall, the use of activated charcoal has been used to remove toxins in plasma from ALF
patients, such as endotoxins. However, they have been shown to be non-specific, also
removing beneficial products such as fibrinogen and amino acids124. Another approach must
therefore be found that is more selective toward particular toxins, whilst allowing transit of
important synthetic compounds.
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1.6.2.Filtration
The uses of filtration for removal of toxins from blood and plasma have been previously
established, providing a potential means of contaminant removal for the Liver Group
BAL124,126,127.
Removal of contaminant from blood by filtration can take two approaches, either crossflow of
dead end filtration. Dead-end-filtration describes the method passing the entire feed solution
through a membrane or bed, with particulates being retained on the filter, as illustrated in
Figure 1-7a. This has been extensively used for removing large and small particulates (~100’s
of µm to ~0.05µm) from solutions using a variety of media from sand, weaved cellulose,
paper, and cotton amongst many others128.
Cross flow, filtration uses a membrane situated at the lower point of the laminar flow,
adsorbing particles that come in to contact with the filter as, illustrated Figure 1-7b. The
technology originates from reverse osmosis for desalting sea water and has progressed through
ultra-filtration of macromolecules, to microfiltration of particles between 0.02 -10µm129.
Figure 1-7: comparison between dead end filtration and crossflow filtration. Dead-end
filtration passes entire liquid volume through the filter. Crossflow filter remove particles
from the section of laminar flow in contact with the filter, allowing some liquid to pass
through the filter. Obtained from Brainerd et. al130.
1.6.2.1. Dead End Filter ApplicationMembrane Filtration
The most common material used for this type of filter is cellulose and polyethersulfone (PES)
with filtration relying on physically retaining particulates in the liquids by size exclusion.
Micro-filters are defined as porous membranes by exhibiting a specific cut-off, usually
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removing particulates is above 0.1µm, such as bacteria whilst allowing protein transit, thereby
producing a sterile solution. Ultra-filtration usually concerns particles of less than 0.1µm. The
main problem with membrane filters is the low volumetric capacity due to a reliance on
physical retention and rapid spoiling in complex liquids131Depth filter
Depth filters are composed of porous interwoven media, able to retain particles throughout the
matrix of the filter. They are commonly used in pharmaceutical applications to remove larger
insoluble particulates whilst maintaining a high volumetric capacity. Unlike membrane filters,
which would quickly foul with high particle feed streams, the depth filters have a level of
graded density across the filter media. The grading often decreases in density from the top
layer of the filter, although sometimes the greatest density is found in the centre of the
filter132,133.
Due to variable gradation, the porosity of the depth filter is referred to as nominal porosity.
Porosity is defined by the ratio of open space relative to the volume of the filter media,
measuring the porosity as either absolute porosity or nominal porosity. Absolute porosity is
measured by electron microscopy, where the actual sizes of the pores are measured. For depth
filters this cannot be accurately performed, so nominal porosity is used. For this, a challenge
using a defined range of particle size is applied to the filter, the range being determined by
statistical significance for removal, providing a nominal porosity range133,134.
Two types of depth filter are commonly available: fibre woven and sintered. Sintered filters,
such as ceramic, metal, or porous plastic filters, are formed by fusing particles together under
heat and pressure, with the spaces between the particles forming the flow path. Fibre filters are
formed by spinning or weaving cellulose or polypropylene into a mesh or cloth-like structure,
using an adhesive to retain the fibres in the capsule132-135.
Depth filters rely on a torturous liquid path across the depth of the filter to retain particles, as
there is little uniformity of structure across the membrane, as illustrated in Figure 1-8. One
problem with depth charged filters is the relatively unpredictable nature in comparison to
membrane filters. When testing charged depth filters, a series of destructive challenges are
applied to representative samples to assess volumetric capacity, particle retention, and general
rating of the filter for a particular environment{Baker, 2004 531 /id;Cuno, 2007 242
/id;Stacey, 2007 530 /id}.
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Figure 1-8: Representation of the fluid flow through a depth filter. Different non-uniform
paths cause retention of specific porosities.
Improving retention capacity of these filters often utilises charged molecules, referred to as
filter aids, bound on the surface of the fibres or sinters, to adsorb opposing charged
compounds in the fluid. The filter aids comprise a combination of activated carbon,
diatomaceous earth (SiO2H2O), or perlite. These increase the efficiency of filtration compared
with size exclusion alone, having the ability to adsorb compounds smaller than the pore size of
the filter135. Therefore, a positively charged onto the filter aid can remove endotoxin and DNA
from water and cell broth137-139. Virus particles added to pure protein solutions were also
removed by depth charged filters140.
1.6.2.2. Cross-Flow Filtration Application
Cross-flow filters have been widely utilised in blood purification, particularly for
haemodialysis in place of centrifugation. The membranes have a pore size of between 0.2-
0.8µm to retain platelets and blood cells whilst allowing the transit of plasma and proteins
such as immunoglobulins. This provides an un-traumatic separation method for blood cells,
and is often used for this purpose, although the cost of replacing the filter due to fouling is
considerably more expensive than centrifugation, so is used on rare occasions131.
In other fields, however, the running cost of centrifuging large quantities of cell broth for
biopharmaceutical processing can contributed to a third of running costs. In these cases, a
distinct advantage of cross-flow filtration in comparison to other filtration types was the
ability to separate solutions with large suspended particles from the liquid containing the
compound of interest141.
During the cross flow filtration processes used for the purification of process fluids, a
recirculating system is often used, where the fluid that did not penetrate the filter re-circulates
and re-enters the filter, as illustrated in Figure 1-9.
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Figure 1-9: Recirculating crossflow filtration. The inflow of liquid passes into the crossflow
filter, where some penetrates the filter and is taken to the next stage of the process. The
unfiltered liquid is re-circulated for re-entry into the crossflow filter.
Although this type of filtration greatly increases capacity, due to less membrane fouling
compared to dead-end filtration, the concentration of contaminant and process fluid can be
problematic over long periods of time. For the BAL application, using a filter capsule with a
recirculating system may not be practical due to a potential build-up of contaminants and
protein from the BAL system. Furthermore, the flow rate of the outflow may not be as
controllable as dead-end filtration, even during blockage of dead-end filters, a pump system
can compensate for changes in flow. If excessive pressure is placed upon the crossflow filter,
to balance flow rate the efficiency of filtration may be severely compromised142.
Consequently, although crossflow filtration is a potential solution for contaminant removal in
the BAL, (due to use with blood products), for the ability to remove molecules such as DNA
and endotoxin, whilst allowing transit of proteins, (as with bioprocessing fluids), depth
charged filters appear to be more suitable. .
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1.6.2.3. 3M® Cuno® Depth Charged Filters
A series of depth charged filters have been developed by 3M® Cuno® to filter cell broth and
bioprocessing fluids, as illustrated in Table 1-4 .
Zeta Plus®Formulation Filter Media Filter Aids PharmaceuticalGrades Primary ApplicationA Grade Glass
microfibers &
Cellulose
None 01AP Coarse pre-filtration
Front end of blood plasma
fractionationC grade Cellulose DE,
perlite
10CP, 30CP, 50CP,
60CP, 70CP
Blood plasma fractionation
Haze removal
Endotoxin reductionS Grade Cellulose DE,
perlite
05SP, 10SP, 30SP,
50SP, 60SP, 90SP
Final sterile membrane
protection
Buffer/solvent pre-filtration
Chromatography column
protection
Reduction of contaminating
DNA
Endotoxin reduction
LA/CA/SA/Aluminiumseries Cellulose DE, Pre-extractedacid
washed
30LA, 60LA, 90LA,
10CA, 30CA, 50CA,
60CA, 70CA, 30SA,
50SA, 60SA, 90SA
Blood plasma fractionation
Endotoxin reduction
DNA reduction
Extra low levels of extractables
Membrane protection
Post fermenter clarificationLP series Cellulose
(optimised for
no β-glucan 
release)
DE,
perlite
30LP, 60LP, 90LP Blood fractionation
Membrane protection
Endotoxin reductionZA series Cellulose DE, Pre-
extracted
acid
washed
30ZA05A,
60ZA05A,
90ZA05A
Endotoxin reduction in water
DNA removal
ZetaCarbon™ Cellulose ActivateCarbon R11SP, R12SP,R31SP, R32SP,
R51SP, R52SP
Decolourisation
Blood fractionation
Endotoxin reductionDelipid Cellulose Precipitat
ed silica,
perlite
DEL 1 Lipid reduction from blood
plasma fractions
Pre-chromatography column
lipid reduction
Table 1-4: filter grades and description of properties136,142. DE refers to diatomaceous
earth.
Each type of filter has a specific application to biopharmaceutical and medical applications
based upon specific properties, balancing filter nominal porosity and charge. The nominal
porosity will dictate the manner of filter blockage and the resulting volumetric capacity. As
described previously, a disadvantage of dead-end filtration compared with crossflow filtration
is the potential for fouling due to particles depositing deep within the filter. The correct filter
nominal porosity is crucial in providing volumetric and contaminant capacity.
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Some of the filters are available as double layered filter capsules, which provide a convenient,
clean, and low dead volume solution for protecting smaller nominal porosity filters with a
larger porosity filter directly upstream. By testing the ZA, S and LP series filters, in Table 1-4,
which are designed for DNA removal in complex solutions, for volumetric, DNA and
endotoxin capacity in plasma a viable filtration system for the BAL could be established.
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1.7. General Aims and Hypothesis
Hypothesis:
Contamination removal from the BAL system is possible using different filtration methods.
1.7.1.Thesis Aims
The development of a research stage medical device to be fully licensed for humans use
requires a series of developments to ensure safety and efficacy of the device according to
regulatory stipulations. One approach in ensuring that licensing occurs in a timely fashion is to
incorporate regulatory stipulations, where appropriate, into the research process.
Measurement and control of extraneous contaminants, from the medical device, which may
enter the patient, are important factors in gaining regulatory approval and to demonstrate
device safety. For the BAL system cell debris, including DNA from the BAL system is an
important contaminant to measure and control, as is particulates present within the alginate
starting material.
The aims of the thesis are:
1. Establish models of the BAL system to gain statistical significance.
2. Establish a contaminant quantity in the BAL system.
a. Detect DNA and endotoxins in BAL Plasma.
b. Validate protocols, where possible.
3. Using the scale BAL model, determine the level of contaminants present
4. Remove contaminants.
a. Use detection protocols to show contaminant removal by filtration.
5. Test removal system in the large scale BAL.
6. Remove particulate contamination from alginate as a starting material.
The Next chapter details the general methods used in the thesis.
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GeneralMethods
This Chapter describes the methods used
in all subsequent chapters. Greater detail
will be provided at the beginning of each
chapter for methods specific only to that
chapter
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2. Methods
All items are from Sigma-Aldrich® unless stated.
2.1 Cell Culture Methods
2.1.1 Monolayer Cell Culture
2.1.1.1 Monolayer HepG2 Cell Culture
HepG2 cells were primarily utilised for the majority of the cell based work as the current cell
line of choice for the BAL.
Materials
 Supplemented Culture Medium
o α-MEM with Ribonucleosides and Deoxyribonucleosides (Invitrogen™)
o HepG2 cells (ECACC, Wiltshire, UK)
o 10% Foetal Calf Serum
o 1.25g/ml Fungizone
o 0.04g/ml Hydrocortisone
o 9.5g/ml Insulin
o 2mM L-Glutamine
o 50g/ml Linoleic Acid BSA
o 100Uml/Penicillin/0.1mg/ml Streptomycin (Lonza®)
o 0.002g/ml Sodium Selenite
o 0.04g/ml Thyroid Releasing Hormone
 Other Materials
o 2% Trypan Blue in PBS
o PBS
o 137mM NaCl
o 2.7mM KCl VWR International (BDH 101983K)
o 8mM Na2HPO4.2H2O
o 1.76mM KH2PO4
o Haemocytometer
o Nunc™ 175cm2 Flasks
o HBSS
o 2% Trypsin in PBS
o PBS as Above
o 17mM Citrate
o 0.53mM EDTA
o 111mM Glucose
o All α-MEM supplements were pooled per 500ml media bottle and filter sterilised, 
through a 0.2µm membrane filter.
HepG2 Cell Seeding
HepG2 cell culture was initiated using a seeding density of 2 x 106 cells/ml suspended in 30ml
supplemented culture media, contained in a T175 flask. Laying the flasks flat in a humidified
incubator at 37°C, 95% air and 5% CO2, cells naturally attached, leaving them for 4-5 days until
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60-80% confluent. Every 2 days the culture media was replaced using supplemented α-MEM 
media pre-warmed to 37°C.
HepG2 Cell Passaging
Passaging cells began with 3 washes with 10ml HBSS to remove residual protein; followed by
adding 10ml filter sterilised and pre-warmed (37 °C) Trypsin and incubating the flask for 1-2
minutes at 37°C, periodically knocking the side of the flask to assist cell detachment. To
deactivate the Trypsin, 30ml α-MEM with 10 % FCS at 37 °C was added, followed by 
decanting into 50 ml Nunc™ centrifuge tubes, for centrifugation at 300 g for 4 minutes at room
temperature. Discarding the supernatant, the pellet was re-suspended in 5ml supplemented α-
MEM culture medium, passing the cell suspension through a 27G syringe 5 times, to disperse
cell aggregates.
The required cell density was added to a culture flask, of relevant size, to provide the required
final cell numbers after a designated time of culture. This number was calculated based on an
empirically derived assumption that HepG2 cells on average double in number every 2 days.
For example, if 8.0 x107 cells are required for encapsulation, then a Nunc™ triple would be
seeded with 5 x 106 cells and cultured for 8 days.
2.1.1.2 Cell Number and Viability using Trypan Blue Exclusion on a Haemocytometer
Cell number and viability were measured using the Trypan blue exclusion method, by adding
20µl cell suspension to 160µl HBSS, then 20µl of 2% Trypan blue in PBS, incubating at room
temperature for 2 minutes. Taking 9µl of the cell suspension and adding to a haemocytometer
slide, at 10 x magnification, fully stained blue cells were counted as non-viable and unstained
cells as viable, calculating percentage viability using the ratio of these counts. This was repeated
5 times from the same suspension to obtain a mean and standard deviation.
2.1.2 Monolayer Primary Liver Cell Culture
Primary liver cells were obtained from patients with liver metastasis, and isolated and frozen in
liquid nitrogen.
Materials
 Williams E media (PAA®)
o 10% FCS
Cells were revived as described in Section 2.1.2.2, and cultured on collagen coated plates as
described in section 2.1.2.1, in Williams E media as in section 2.1.1.1, with medium changes
every day. The purpose of this was to isolate DNA so cells were cultured for up to 4 days then
harvested as in section 2.1.1.1.
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2.1.2.1 Collagen Coating Plates for Primary Liver Cell Attachment
Materials
 Tendons from rat tails
 10 mM Acetic acid (Sigma-Aldrich®)
 6 well plate (Nunc™)
 HBSS (Lonza®)
 0.9% NaCl (Sigma-Aldrich®)
Collagen Extraction
Rat tail tendons removed from cadaveric rats were weighed and dissolved in 300ml 10mM
acetic acid for every 1g of tendon and stirred over 2-3 days at 4°C. Collagen solution was
centrifuged at 800g for 2 hours to remove any remaining undigested rat tail and stored at 4°C
for 1 up to 1 month.
Plate Preparation
To each well of a 6 well plate 2ml of the collagen was added to each well and incubated at room
temperature for 5 minutes. Each plate was washed 3 times with 4ml of HBSS, using the final
wash to check for any changes in the phenol red colour, confirming the absence of acetic acid.
Traces of HBSS were removed by washing with 2ml of 0.9% NaCl, checking for any remaining
red colouration. These plates were sterilised using 30 minutes of UV-C exposure, and sealed
with parafilm® for storage.
2.1.2.2 Cryopreservation and Revival of Cells
Materials
 DMSO (Invitrogen®)
 FCS (Thermo-Scientific® Hyclone®)
 Cryovials (Nunc™)
To minimise variation in cell function and growth characteristics, cell lines were maintained in
culture for a maximum of 10 continuous passages. Accordingly, a small cell bank was
established to standardise the cell source, which was used for cell encapsulation.
Cryopreservation
Immediately after trypsinisation, cells were re-suspended in culture medium at a density of
1x107 cells/ml, and divided into 1 ml aliquots. To the aliquots, an equal volume of freezing mix
(90% FCS + 10% DMSO) was added and transferred to Cryovials®, placing at -80°C overnight,
in a polystyrene container lined with cotton wool, causing the freezing rate to reach
approximately 1°C/minute. The cells were then transferred to liquid nitrogen (-196°C) for long
term storage.
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Cell revival
Cells in Cryovials® were thawed quickly by placing in a 37°C water bath, immediately
transferring to a 50 ml centrifuge tube, as soon as the last visible ice crystal melted. To this,
10mls of medium was added drop wise over 5 minutes, followed by centrifugation at 300g for 4
minutes at room temperature. Discarding the supernatant, cells were re-suspended in 15mls of
medium and then transferred to a Nunc™ T80 flask. Following attachment, medium was
replenished and cells maintained in monolayer culture as described in 2.1.1.1.
2.1.3 3D HepG2 Cell Culture
3D cell culture was either achieved through encapsulation using the Inotech® micro-
encapsulator for smaller scale experiments from 10 – 50ml of beads (section 2.1.3.5) or
GeniaLab® Jetcutter™ (section 2.1.3.6) encapsulation system, from 100ml to 2L beads.
2.1.3.1 Cell Culture for Encapsulation
For small scale experiments, using the Inotech® micro-encapsulator, 100ml of alginate/media
mix was prepared, as outlined in section 2.1.3.2. In order to grow sufficient cell numbers, a
triple layered Nunc™ culture flask was seeded as in section 2.1.1.1, which at 60-80% confluency
provided between 6.0 x 107 and 1.0 x 108 HepG2 cells, sufficient for 120 – 200ml of
alginate/media mix at 0.5x106cell/ml seeding density.
Provision of larger scale culture for the GeniaLab® Jetcutter™ encapsulation was performed by
other member of the group and is described in Section 2.1.3.6.
2.1.3.2 1% alginate solution
Materials
 2% Alginate solution (1% final concentration when in 1:1 ratio with medium)
o Alginic acid powder (cat no. 180947)
o 150 mM NaCl
o 15 mM HEPES
o NaOH for pH adjustment
Preparation and sterilisation of 1% alginate
A 2% solution was made by gradually adding 2g Alginic acid-sodium salt, to 100ml, sterile,
150mM NaCl and 15mM HEPES solution, under constant agitation (pH 7.4 with NaOH), and
left stirring overnight in the dark. It was then sterilised at 121°C for 10 minutes, the size of the
vessel during autoclaving was scaled (e.g. 250ml glass reagent bottle for 100ml alginate, and
2.5L bottle for 1L alginate), thereby maintaining identical heating treatments between
encapsulations. If the Jetcutter® system was used, 2% 10-50µm glass beads (dry sterilised by
heating to 180 °C for 3 hours) were added to the 1:1, alginate: cell/medium mix.
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2.1.3.3 Cell number using Nucleocounter® Spectrophotometer for 3D culture
Materials
 PBS pH 7.4
 16mM EDTA/0.15M NaCl, pH 7.4
 Nucleocounter® nucleocassettes (Chemometec®)
 Reagent A100: Lysis buffer (Chemometec®)
 Reagent B: Stabilising buffer (Chemometec®)
 Nucleocounter® YC-100™ cell counter
Isolation of Cells from Beads and Cell Number Determination using Nucleocounter
A 0.25 ml aliquot of beads was transferred to a 2ml Eppendorf® micro-centrifuge tube, then
washed with HBSS, carefully removing as much liquid as possible before making up the total
volume to 2ml with 16mM EDTA/0.15M NaCl and incubating for 10 minutes at 37°C, causing
the dissolution of the alginate and release of cells. The cells were then pelleted by centrifuging
at 13000g for 5 minutes. Discarding the supernatant, the pellet was re-suspended by vigorous
vortexing in the volume of PBS outlined in Table 2-1, reliant on numbers of day of growth.
Days of growth in
Culture
Re-suspension volume
(µl)
0-1 200
2-3 300
4-5 600
> 6 1000
Table 2-1: Re-suspension volume of cell isolated from Beads grown for different days in
static culture
An equal volume of lysis Buffer Reagent A100 was added, vortexing for 1 minute to ensure
uniform cell lysis. The same volume of stabilisation buffer Reagent B was added, mixing by
briefly vortexing and loaded onto the Nucleocassette® then inserting into the Nuceocounter®.
The Nucleocounter provides a cell/ml value below 2 x 106 cells/ml LoD, requiring back
calculation to derive the original cell number/ml of alginate beads.
Equation 2-1: N x Z = Cell Number
Where N (cell/ml) is reading from Nucleocounter and Z is the multiplication factor to account
for dilutions.
Equation 2-2: Z = 3 x VPBS
VB
Where VB is the volume of alginate beads (mL) and VPBS is the volume of PBS used to re-suspend
the cell pellet (mL).
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2.1.3.4 Determination of Viability in Beads using FDA, PI staining for 3D culture
Materials
 FDA (fluorescein diacetate)
 PI (propidium iodide)
 PBS Ca+ Mg+ (Lonza)
Cell Viability Protocol
A 200µl sample of beads was taken and added to a 1.6ml micro-centrifuge tube, washing with
1.4ml PBSCa+Mg to remove residual culture medium; if the sample was in 100% plasma, the
wash was repeated. The beads were re-suspended in a final volume of 500µl PBSCa+Mg to which
20µl of PI and 10µl of FDA were added in quick succession, gently agitating for 90 seconds on
the bench. To remove excess stain, the beads were washed with 1.4ml PBSCa+Mg, finally re-
suspending in 500µl PBSCa+Mg. A portion of this was transferred to a microscope slide,
removing excess liquid, to be visualised using the Nikon® Eclipse microscope with the DX1200
camera and Lucia G imaging software. An excitation filter of 510-560m and an emission filter
of 590nm was applied for PI fluorescent measurement, and an excitation filter of 465-495nm
and an emission filter of 515-555nm for FDA. The viability was calculated using the Lucia
software measuring integral pixel density of the images, deriving viability using equation 1:
Equation 2-3: % viability = FDA integral density x 100
FDA integral density + PI integral density
Where FDA integral density counts pixel density of living cells stained with FDA and PI
integral density is the pixel density of dead cells stained with PI.
2.1.3.5 Inotech™Cell Encapsulation
Materials
 Alginic acid solution
o Alginic acid Sodium salt
o 150 mM NaCl (Invitrogen™)
o 15 mM HEPES (Lonza®)
 Polymerisation Buffer
o 204 mM CaCl2
o 150 mM NaCl
o 15 mM HEPES
o 0.05% Pluronic acid
 High Glucose (HG) Media
o α-MEM as described in section 2.1.1 
o 25 mM of D-Glucose,
 Volumetric flasks
 Schott bottle
 Magnetic flea
 Syringe filter
 Baked Pyrex beakers (3 hours at 180°C)
 Stainless steel forceps
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 Inotech syringe pump system (Inotech, Dottiken, Switzerland)
 Bottomless beaker and Elastic band
 Nylon mesh
 DMEM supplemented with 10% FCS,
 100Uml/Penicillin/0.1mg/ml Streptomycin (Lonza®)
 1.25 µg/ml Fungizone
 Inotech IER-20 Cell Encapsulator (Inotech, Dottiken, Switzerland),
Inotech™ Principle
To provide sufficient volumes of beads for small scale experiments, the Inotech IER-20 Cell
Encapsulator system was used, which operates by passing the alginate/media mix through a
small nozzle to create a laminar liquid flow that is broken into equally sized droplets by
superimposing vibrations. An additional electrostatic dispersion unit generated a uniform charge
on the surface of each droplet, by passing through an electrostatic field, causing droplets to
repel, thus preventing agglomeration, and forming a coned shaped descent into the
polymerisation buffer. Upon contact with polymerisation buffer containing Ca2+, cross linking
between β-D-mannuronate (M) and α-L-guluronate (G) polymers occurs, fully forming the 
alginate beads.
Figure 2-1: Schematic diagram of the Inotech® microencapsulator. 50:50 alginate/media
mix is passed through a 200µm nozzle (5) creating a laminar flow, which is broken to
equally sized droplets by superimposed vibration (11), it then passes through an
electromagnetic field to impose charge on the droplets (4), giving a cone shaped descent into
the polymerisation buffer.
1) Syringe
2) Syringe pump
3) Nozzle input
4) Electromagnetic pulsation unit
5) 200µm nozzle
6) Electrode
7) Reaction vessel (open vessel used)
8) Waste and bypass unit
9) Polymerisation buffer input (not used)
10) Pressurisation value (not used)
11) Vibration frequency generator
12) Electromagnetic charge generator
13) Stroboscope
14) Stirrer
15) Collection vessel (not used)
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2.1.3.5.1 Inotech™ Encapsulation Protocol
Cells were cultured as in section 2.1.1, harvested and diluted in media and were added to the
alginate in a 50:50 ratio, with a final seed density of 0.5 x 106 cells/ml of mix. A 50ml syringe
with the mix was placed onto the Inotech system at position (1) in Figure 2-1; the parameters
listed below were applied to the system to produce beads of ~500 µm in diameter:
 1295Hz on the vibration frequency generator, (11) Figure 2-1.
 0.5 volts on the electromagnetic charge generator, (12) Figure 2-1.
 12.7ml/min on the syringe pump, (2) Figure 2-1.
The beads then fall into the polymerisation buffer containing Ca2+ promoting polymerisation of
the homopolymer sugar residues, incubating for 10 minutes, prior to being poured through a
200µm mesh sieve (prepared using a bottomless beaker and mesh attached using an elastic
band, retaining the beads on the mesh). They were then twice washed in D-MEM containing
10% FCS, to remove polymerisation buffer to prevent over polymerisation. A volume of 100ml
HepG2 cell and Alginate mix, typically provided 20ml of HepG2 encapsulated Alginate beads.
Subsequent solutions that come into contact with the beads were controlled for Ca2+.
2.1.3.6 Jetcutter encapsulation
This protocol was performed by other members of the Liver Group, and is detailed in Appendix
I.
Jetcutter® principle
The Jet Cutter encapsulation enables the production of large volumes of beads, and is currently
the method of choice for encapsulating cells for use with the full scale Bioartificial Liver
system.
The Jetcutter® system consists of a pressurised chamber, which forces the alginate/cell/media
mix through a nozzle at a controlled rate. The stream then passes through a cutting tool with
asymmetrically arranged wires, which are inclined relative to the vertical solid stream of liquid,
resulting in a horizontal cut as the tool passes through the liquid stream. The cylindrical
segment then forms a bead due to surface tension whilst descending to the polymerisation
buffer.
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2.2 DNA Detection Methods
The aim of detecting DNA within the BAL system is to ensure that contamination from the
HepG2 cells in this form is not transmitted to the patient. A number of approaches were tested
to establish a detection method for routine use with the BAL system. These focussed on
attaining a Limit of Detection (LoD) so that defined DNA concentrations and the cell numbers
relating to those DNA concentrations could be detected to sufficient sensitivity to detect small
changed in HepG2 viability (<1%).
2.2.1 DNA Extraction Methods
In order to measure DNA removal, and to test DNA detection methods, DNA was extracted
from different cells.
2.2.1.1 Qiagen® QIAamp® DNA Extraction Kit
This kit is based on DNA binding to the column with a number of wash steps and proteinase K
steps to remove contaminants.
Materials
 1ug/ml Proteinase K
 Qiagen® QIAamp® Columns
 PBS
 Qiagen® QIAamp® AL Lysis buffer
 Qiagen® QIAamp® AW1 wash buffer
 Qiagen® QIAamp® AW2 wash buffer
 100 % ethanol
 Qiagen® QIAamp® AE buffer
o 10 mM TrisHCl
o 0.5 mM EDTA
 Thermo-scientific® Nanodrop® ND1000™ spectrophotometer.
Qiagen® QIAamp® DNA Isolation Protocol
Each column is designed to extract DNA from 0.5 x 106 cells, therefore from a Nunc™ T25 flask
which can yield 5 x 106 cells, 10 columns were utilised simultaneously. To each 1.5 ml
Eppendorf® micro centrifuge tube, 20µl of Proteinase K was added followed by adding 200µl of
cell suspension at 2.5 x 106 million cells/ml. To this, 200 µl of AL lysis buffer was added,
incubating at 56 °C for 10 minutes. After briefly centrifuging at 1000g for 30 seconds to collect
the solution in the bottom, 200µl of ethanol was added and vortexed for 15 seconds. The entire
mixture was carefully pipetted into the column, and centrifuged at 6000g for 1 minute,
discarding the flow through. The DNA attached to the column was washed sequentially, by
initially adding 500µl of AW1 wash buffer, centrifuging at 6000g for 1 minute, followed by a
second wash with AW2 wash buffer, centrifuging as before. Again, the flow through was
discarded and a final centrifugation was performed at 20,000g for 3 minutes to remove any
residual liquid. Each column was then placed into a clean centrifuge tube, adding 50µl of AE
elution buffer and centrifuged at 6000g for 1 minute. The flow through was then analysed on the
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Nanodrop® spectrophotometer at 260ƞm and 280ƞm giving a measure of DNA concentration 
and purity.
2.2.2 Simplified Mammalian DNA isolation Procedure
This protocol was obtained from Laird et al.143 and was used to obtain high molecular weight
genomic DNA from cell culture.
Materials
 Lysis Buffer
o 100 mM TrisHCl
o 5 mM EDTA
o 0.2 % SDS
o 200 mM NaCl
o 100 µg Proteinase K (freshly added)
 100 % Isopropanol
DNA Isolation Protocol
Cells were cultured as in section 2.1.1, in a Nunc™ T80 flask to 80% confluency. The culture
medium removed and the cells washed 3 times with HBSS, to which 5 ml lysis buffer was
added and incubated for 4 hours at 37°C. To this, 5ml of isopropanol was added mixing gently
for 5 minutes, to allow the DNA to precipitate and aggregate, then transferring the entire
solution into a 50 ml Nunc™ tube. Using a clean pipette tip, the DNA aggregate was gently
moved to above the liquid to allow the isopropanol to dry for 10 minutes. The DNA aggregate
was then transferred to an Eppendorf® tube for re-suspension in DNAse-and-RNAse-free water.
2.2.3 Hoechst Dye Staining
Materials
 PBS
 0.1 M NaOH
 1 M TrisHCl pH 7
 1 mg/ml Hoechst Dye 33342 in water
 Applied Biosystems Cytofluor® Fluorescence plate reader
 TNE buffer
o 10 mM TrisHCl
o 200 mM NaCl,
o 1 mM EDTA,
Hoechst Dye Purpose
The bis-benzimide fluorophore Hoechst dye was used to quantify calculated DNA
concentrations in water compared to media and plasma to assess efficacy of the assay in
different environments, and to determine DNA concentration from lysing a pre-determined cell
number in 48 well plates.
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Determining Limit of Detection (LoD) with DNA Standards
A seven point DNA standard curve was prepared by serial dilution, with final concentrations
between 0.078µg/ml and 5µg/ml in 500µl TNE buffer, or plasma, respectively. To this 500µl of
1µg/ml Hoechst dye was added and immediately read on the Cytofluor® plate reader using
360ƞm excitation filter (bandwidth of 50) and 480ƞm emission filter (bandwidth of 20). An 
arbitrary fluorescence unit was converted to the known standard concentration, whilst ensuring
the gain was set so that the blank showed a signal in the order of 104 times greater than the
lowest sample signal, typically set at 90.
2.2.4 PCR and QPCR with Alu Repeats
Due to the proven sensitivity of QPCR, shown in other applications for detecting DNA in
plasma144-147, this was the natural progression from a chemical approach to DNA quantification
within a complex solution such as plasma. Initial optimisation and testing of primers was
performed by PCR amplification then analysis on a 2% agarose gel. Two sets of primers,
specific for the Alu repeat consensus sequence, were taken from Umetani et al.148, and utilised
in separate reactions to produce 115bp and 247bp Alu repeat amplicons.
2.2.4.1 Conventional PCR
Materials
 TBE Buffer
o 0.9 M Tris base
o 0.9 M Boric Acid
o 20 mM EDTA
 2 % Agarose Gel
o 2 g Agarose
o 100 ml TBE buffer
PCR Stock solutions
 2x Hot Star Taq® Polymerase (Qiagen®)
o 200 μM dNTP’s and  
o 1.25 units Taq Polymerase in
o 2x PCR Buffer.
o 1.5 mM MgCl2
 Certified DNase, RNase free PCR H2O (Bioline
®)
 28mM MgCl2 (Sigma-Aldrich
®)
 100µM 247bp primer (Sigma®)
o Forward: 5′-GTGGCTCACGCCTGTAATC-3
o Reverse: 5′-CAGGCTGGAGTGCAGTGG-3’
 100µM 115bp primer
o Forward: 5′-CCTGAGGTCAGGAGTTCGAG-3′
o Reverse: 5′-CCCGAGTAGCTGGGATTACA-3′
1x PCR mix
 10µl Hot Star Taq® Polymerase (concentration: 1x)
 1µl 10µM Forward Primer (concentration: 400 nM)
 1µl 10µM Forward Primer (concentration: 400 nM)
 3µl 23mM MgCl2 (concentration: 5 mM in total, 1.5 mM + 3.5 mM)
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 Total 15µl + 5µl sample
 iCycler 96 well PCR machine (BioRad®)
 0.5ml PCR tubes
PCR protocol
As a complement to QPCR described in section 2.2.4.3, optimisation and confirmation of the
amplicon size relative to the melt curve was undertaken using conventional PCRs, using the
iCycler® PCR machine.
Cycle:
95 °C 5 minutes
95 °C 15 seconds
64 °C 30 seconds
72 °C 30 seconds
72 °C 10 minutes
2.2.4.2 PCR Template Treatment for Sample Purification
Materials
 200 ng/µl stock Human Genomic DNA (Bioline®)
 TTE buffer for plasma sample purification
o 16 µg proteinase K (lyophilised into 0.2ml PCR tubes from 1mg/ml stock) (Sigma-
Aldrich®)
o 50 mM Tris Base
o 1 mM EDTA
 2.5% Tween-20
 Certified RNA, DNA, pyrogen, RNase and DNase free filtered Pipette tips (Starlabs®)
 Certified RNA, DNA, pyrogen, RNase and DNase free 2 ml, 0.5 ml and 0.2 ml tubes
 Certified RNA, DNA, pyrogen, RNase and DNase free 0.1 ml Rotorgene PCR tubes
(Corbette®, Qiagen®)
 Rotorgene 3000 (Corbette®, Qiagen®)
 Edwards® Lyophiliser
As a result of using plasma directly in the PCR reaction, interference from proteins and other
constituents of plasma was reduced using proteinase K treatment and dilution with TTE buffer.
Initially, 20μL of plasma was added to a 0.5ml PCR tube containing 16μL pre-lyophilised 
proteinase K and 20μL of TTE buffer, and then incubated at 50°C for 45 minutes. To this an 
extra 160µl of TTE buffer was added followed by deactivating proteinase K at 95°C for 10
minutes, producing a white precipitate removed by centrifugation at 13,000g for 10 minutes. A
volume of 5μL of this supernatant was added to the PCR mix being equivalent to 0.5μL of 
original sample.
2.2.4.3 Quantitative Real Time Genomic PCR
Material
30 Cycles
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PCR Stock solutions
 Same as 2.2.4.1, with the addition of
 10,000 x SybrGreen I (Biogene®)
1x PCR mix
 10 µl Hot Star Taq® Polymerase (concentration: 1x)
 0.5 µl 1/1000 SYBR Green I (concentration: 0.25 x)
 1 µl 10 µM Forward Primer (concentration: 400 nM)
 1 µl 10 µM Forward Primer (concentration: 400 nM)
 2.5 µl 28 mM MgCl2 (concentration: 5 mM)
 Total 15 µl + 5µl sample
Alu Repeat QPCR protocol
The absolute DNA concentration was determined using a five point standard curve, in triplicate,
from 0.01pg to 100pg DNA, giving a sample limit of detection (LoD) of 0.1pg/µl DNA.
Samples were run on the Rotor Gene™ 3000 PCR machine.
Cycle:
95 °C 5 minutes
95 °C 15 seconds
64 °C 30 seconds
72 °C 30 seconds
72 °C 10 minutes
Melt curve from 45 °C to 95 °C at 1 °C per minute.
40 Cycles
Page 62
Chapter 2 General Methods Small Scale BAL Experiment Setup
2.3 Small Scale BAL Experimental Setup
Principle of the Scale BAL
In order to provide a means to analyse specific parameters of the large scale BAL system with
sufficient replicates for statistical significance, a scale model of the BAL system was developed,
prior to implementation on a large scale system, which focussed on:
 DNA release in media, healthy human plasma, and acute liver failure plasma
 Bead integrity and debris release from fragmented beads,
Due to the flexibility of the model both the bioreactor growth phase and the treatment phase can
be modelled. For the bioreactor growth phase, media with FBS or media with FFP were used in
the columns, if modelling the BAL system FFP, acute liver failure plasma, renal failure plasma,
or pig plasma were used, depending on the large scale BAL system parameter being tested.
Materials
 Fresh Frozen Plasma from healthy patients (FFP)(Citrated)
o 1 M CaCl2
o 4 Units/ml plasma Sodium Heparin
o 100Uml/Penicillin/0.1mg/ml Streptomycin (Lonza®)
o 1.25g/ml Fungizone (Invitrogen™)
o 25mM Glucose
 Acute Liver Failure Plasma
o Obtained from acute liver failure patient plasma exchange using the Cobe Spectra®
Apheresis System
o Same additions as FFP, except no addition of CaCl2.
 Renal Failure Plasma
o Obtained from plasma exchange of renal failure patients using the Cobe Spectra®
Apheresis System
o Same additions as FFP
 Pig Plasma
o Obtained from BAL treatment of pig with a portal vein shunt to model acute liver
failure separated using the Cobe Spectra® Apheresis System.
o Heparinised during treatment at 20 Units/ml plasma Sodium Heparin
o Same additions as FFP
 Watson-Marlow 520Du peristaltic pump with a 10 channel pump head
 α-MEM with Ribonucleotides and Deoxyribonucleosides (Invitrogen™)
o Supplemented as of section 2.1.1.1
 Sterilised Column setup:
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o Glass column and fittings representing the chamber holding the beads (shown in
Figure 2-2.
Figure 2-2; the column set-up was used to provide a scale BAL chamber. A; tapered glass
fitting, was placed on the top of the glass column, with a 1.2mm rubber washer in between to
provide a seal between the column and the silicone tubing. B; polypropylene screw cap (with
an 8 mm hole), which holds the glass fitting, washer and column in place. The glass column
has on either end a thread, which enables the attachment of the cap. C; glass column. D Bead
filter to prevent bead escaping through the bottom when flow is off, comprising two rubber
O-rings and a 200µm nylon mesh secured with silicon glue.
Figure 2-3: Column setup for scale BAL system. A; the layout of a single column, in series with
the pump and the reservoir, tubing letters denote the differing length of tubing used (A, 75
cm; B, 50 cm; Pump tubing 45 cm). B; 8 columns in an incubator maintained at 37°C and 5%
CO2, using the Watson Marlow® Multichannel pump to perfuse beads with plasma/ and or
media, over 8 hours.
 Tubing between the pump and the reservoir. Figure 2-3 A shows the position of each length of
silicone tubing, also summarised below:
185 mm
15 mm
10 mm
15 mm
8 mm
12 mm
1 mm
Bottom
Filter
Silicone
glue
200 µm
Nylon
mesh
Rubber
Washer
Assembled
Tube B
Tube A
Pump
tubing
A
B
C
A B
D
B
A
C
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o Tube A: top of column to the reservoir; 75cm
o Tube B: from pump to the bottom of column; 50cm
o Pump tubing: attached to the reservoir then passes through the pump; 45cm (2.7mm bore
size, 0.5mm wall thickness)
 75ml polypropylene bottle
 9 column holder (shown in Figure 2-3 B)
 Watson Marlow multichannel pump
 Filter at bottom of column to retain beads when pump is off
o Two 1.2 mm x 0.5 mm rubber washer
o 200 µm nylon mesh
 Complete media with 24 mM D-Glucose
 2% Trypan blue in PBS
 FDA and PI staining
 Dry sterilised beaker (180 °C 3hours)
 PBS+ca (Lonza®)
 HBSS (Lonza®)
 100% ethanol
 70% IMS
 Sampling septum
 Serological pipette
 Sterile Steel spoon
 Sterile 10 ml syringe
2.3.1 Assembly of the Scale BAL Model
As illustrated in Figure 2-2, the column comprises a 15 ml glass tube with screw threads at each
end. A rubber washer was placed between this and a tapered glass fitting, held in place by
securing the polypropylene cap, also engineered with screw thread, so that the tapered glass
fitting can pass through the 8mm hole in the top of the cap, which is in turn attached to 2.7mm
internal diameter silicone tubing. At the bottom end of the column the washer is modified to
incorporate a 200µm nylon mesh, by cutting 6mm radius circular sections of nylon mesh, and
attaching two washers on either side of the mesh by silicone glue illustrated in Figure 2-2, to
form a liquid permeable, but bead impermeable membrane. The filter/washer are constructed 2
days prior to the experiment, allowing the silicone glue to set overnight, then sterilising for 1
hour by immersing in 70% IMS then washing with 100% ethanol, placing in a Class II
microbiological safety tissue cabinet, to dry for 30 minutes.
Columns were constructed on the bench as illustrated in Figure 2-3A with specific tube lengths
outlined below Figure 2-3, then placed in a sterilising bag for autoclaving at 121°C for 30
minutes (the cap on one end of each column was left loose to allow steam penetration). After
sterilisation, the bags containing the columns were placed in a Class II microbiological safety
tissue cabinet, where a sample port was added to a T-piece with luer fittings, fitted prior to
sterilisation. Whilst still in the tissue cabinet, the columns and tubing from the reservoir to the
Page 65
Chapter 2 General Methods A Model for Filtration of
Plasma in the BAL
System
column were placed on a multi-column rack able to hold 9 at one time (Figure 2-3B) and primed
with liquid (plasma or media depending on experiment) to just above the bottom filter using a
sterile syringe, to prevent bubbles passing through the beads. The columns were then ready to
add beads outlined in Section 2.3.2.
A day prior to commencing the experiment an incubator was set at 37°C and 5% CO2, to house
columns for the duration of the experiment commonly spanning between 5 and 12 hours.
Usually hourly samples of 300µl were taken through the septum attached to the reservoir for
later analysis. For some experiments, however, the frequency of sampling was reduced so that
no more than 10% of the original volume would be removed.
2.3.2 Preparation of Beads for Addition to the Scale Model
Cells were initially cultured as in section 2.1.1, then encapsulated either using the Inotech®
microencapsulator as outlined in section 2.1.3.5, and grown in static culture or encapsulated
using the Jetcutter microencapsulator outlined in section 2.1.3.6, and grown in the fluidised bed
bioreactor over 7 to 12 days allowing experimentation in plasma. Beads were extracted using a
serological pipette from either the bioreactor or static culture, and passed through a 200µm
mesh covering the underside of a bottomless beaker held over a sterile container, causing the
beads to be retained on the mesh.
The beads were then lowered into a second sterile beaker containing 500ml PBS+Ca, and agitated
briefly by swirling the beaker, leaving them for 5 minutes to allow the diffusion of PBS+Ca into
the beads. With a sterile steel spoon, the beads were gradually transferred into sterile 15ml
Nunc™ centrifuge tubes already containing 7ml of HBSS, plasma or media (depending on the
experiment), allowing the beads to settle. Thus enabling the measurement of bead volume with
the graduations on the exterior of the tube, each addition of beads required 3 minutes to settle.
With the desired bead volume, sufficient diluent was added to achieve a 15 ml total volume,
inverting the tube gently 5-10 times to completely re-suspend the beads, followed by un-
screwing the top of the column and pouring the content in the glass column.
2.3.3 Determination of Plasma / Media ratio
The ratio between media or plasma and beads related to whether the bioreactor growth phase or
the BAL system was being modelled. For example, modelling the full scale BAL with 500 ml
beads in 8L of plasma (4L in chamber, 1L reservoir, 1L in the circuit tubing, 0.5L in the Cobe
Spectra® Aphaeresis unit and 1.5L in the pig) was equivalent to a ratio of 16ml of plasma to 1ml
of beads in the scale column experiment. To provide adequate bead volume for fluidisation 5ml
beads with 80ml plasma would have been used (15ml in column, 3ml in tubing and 62ml in the
reservoir).
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2.3.4 Modelling Flow Rates between the Scale Model and BAL System
An essential condition the BAL scale model was to replicate the flow rate used to fluidise the
beads regardless of the experiment. An insufficient flow rate would cause inadequate
fluidisation, thereby inhibiting mass transfer between the cells and the surrounding
environment. Excessive flow rates may result in beads incurring shear stress damaged or
providing excessive upward force causing them to escape from the chamber. These parameters
have been established with the use of mathematical models and empirical observation. To
replicate a volumetric flow rate from the large BAL system to the scale BAL system, the
corresponding linear flow rate for the large system was calculated then replicated in the small
scale BAL system, back calculating the relevant volumetric flow rate for the scale BAL. As a
consequence, the linear flow rate in the large scale BAL would be identical to that of the scale
BAL model, resulting in the same fluid characteristics being encountered by the beads in the
large and small scale BAL model.
2.3.4.1 Calculating the Bioreactor and Large Scale BAL Volumetric and Linear Flow Rates
The linear flow rate describes the movement of liquid over a distance, and was calculated from
the volumetric flow rate, as follows:
The linear flow rate was determined for a given large scale BAL or bioreactor system that was
to be modelled using equation 2-4:
Equation 2-4: FL = Fv / D
Where Fv is the volumetric flow rate (m3sec-1), and D (m2) is the cross sectional area of the
bioreactor chamber and FL is the linear flow rate (ms-1).
Fv was converted from mlmin
-1 to m3sec-1, as follows:
 FV1 is in mlmin
-1 and is set on the peristaltic pump
 FV1 1x10
-6 (cm3min-1 to m3min-1) = F V2
 FV2 / 60 (m
3min-1to m3sec-1) = Fv
The cross sectional area, D, was calculated using equation 2-4:
Equation 2-4: D = πr2
Where r is the radius of the chamber or the column in m.
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Using this equation to establish the linear flow rate in the large scale model, the same linear
flow rate was implemented in the scale BAL model, by calculating the required volumetric flow
rate to achieve the given linear flow rate. The Watson-Marlow® peristaltic pump used for the
scale BAL system provided a single speed to drive a multichannel pump head.
For example, where the bioreactor utilised a 342 mlmin-1 volumetric flow rate to provide a 1.5
bead bed expansion in media (described in section 2.1.3) the linear flow rate was calculated as
3.23 x 10-4 ms-1; equation 2-5 provided the volumetric flow rate required to match the linear
flow rate, which was a re-arrangement of Equation 2-4, including the unit conversions.
Equation 2-5: FVs = 6
5FLD1
Where FVs (mlmin-1), is the volumetric flow rate for the small scale BAL model, FL is the linear
flow rate (ms-1) from equation 1, and D1 (m2) is the cross sectional area of the column.
Having established the volumetric flow rate required, the 2.74mm bore pump tubing was
calibrated for volumetric flow rate relative to RPM of the pump. To verify the correct flow rate
was being used, the bed expansion observed in the column should be identical to that of the
bioreactor using the same density of liquid, i.e. Media with 10% FFP, or media with 10% FBS.
2.3.5 “Worst Case Scenario” BAL Model
Materials
 Complete media as described in Section 2.1.1.1
 Plasma as in Section 2.3
 50 Nunc® tubes
 0.15 M HEPES (Lonza®)
End-Over-End Mixing Protocol
To trigger complete cell death, causing cell DNA and debris release, the relevant bead to
media/plasma ratio was calculated in the same manner as section 2.3.3. Beads encapsulated
using the Jetcutter® and cultured in the Bioreactor for 12 days were placed in a 50ml Nunc®
with 20ml of complete supplemented media or plasma with 0.15 M HEPES buffer, incubating at
37°C for 2 days, whilst mixing end-over-end on a cell mixer. The conditioned supernatant was
then removed and used as a “worst case scenario” of DNA and cell debris release.
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2.4 ELISA Protocols
All the ELISA protocols have been optimised to work with the same protocol, only differing in
the antibodies used.
2.4.1 AFP ELISA 10% FBS media
Alpha-fetoprotein (AFP) is thought to be a foetal counterpart to albumin and is generally used
as a biomarker for hepatic carcinoma149. We have harnessed this expression by HepG2 cells to
evaluate cellular synthetic performance in the presence of plasma, where excessive albumin
background would inhibit sensitivity and accuracy of the assay.
2.4.2 Albumin ELISA
Albumin quantification served as an indicator of cell function when cells were not in the
presence of human plasma, as the background albumin in plasma was too high to measure the
production from HepG2 cells. However, during filtration experiments albumin was measured in
plasma to establish whether the filter was removing albumin as a highly abundant protein,
merely requiring a change in concentration to be detected.
2.4.3 Fibrinogen ELISA
Fibrinogen whilst also being an indicator of cell function, at a size of 340kDa150 provided a
means of ensuring that proteins were not being excluded from alginate secretion nor filtered out
based on size.
2.4.4 Alpha-1-antitrypsin (AAT) ELISA
AAT provided another liver specific protein for assessment of HepG2 function.
Materials
 Nunc™ ELISA 96 well plate
 Primary antibody Table 2-2
 Secondary antibody Table 2-2
 ELISA 96 well immunosorbent plates (Nunc®)
 Coating Buffer
o 0.6 mM Na2CO3
o 1.4 mM NaHCO3
o pH 9.6 with 1 M NaOH
 PBS Tween-20
o PBS
o 0.05 % v/v Tween-20
 Blocking Buffer
o PBS
o 5% w/v powdered milk
 OPD (o-phenylenediamine dihydrochloride), H2O2 solution
o 6 µl/L H2O2
o 4 mg/L OPD
 1 M H2SO4
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2.4.5 ELISA Protocol
Primary Antibody Adsorption
In order to adsorb the primary antibody onto the immunosorbent 96 well plate, the stock
antibody was diluted as shown in Table 2-2 in coating buffer, adding 100µl to each well, and
then sealing the plate for overnight incubation at 4°C. The next day the plate was washed 3
times with PBS-Tween-20 and liquid flicked off; 100µl of blocking buffer was added to each
well and incubated for 1 hour at room temperature, to block any remaining antibody binding
sites on the plate.
Sample and Standard Preparation
Sufficient sample and standards were prepared to perform triplicate analysis, with a 5 point
standard curve starting from 200ng/ml prepared by serial dilution in supplemented culture
media or plasma. Samples were also diluted in media or plasma, using pre-determined dilution
factors in anticipation of obtaining optical densities equidistant from the top and bottom
standard (this was determined by using the same ELISA protocol with a matrix of sample
dilutions analysed relative to a standard curve). Finally, a pre-prepared QC control was used to
validate the ELISA, and was obtained by pooling media from 10 separate HepG2 cell cultures.
Following the addition of 100µl of standard and sample, the plate was incubated at 37ºC for at 2
hours.
Secondary Antibody Addition
To remove any unbound antigen, the plate was washed 3 times with PBS-Tween-20 and briefly
dried. Secondary antibody was diluted 1/2000 in blocking buffer, to block any remaining
primary antibody binding sites and therefore reducing false positives. To each well 100µl was
added, incubating for 1 hour on the bench, then washed 5 times.
Colorimetric Development
The secondary antibody used is conjugated with horseradish peroxidise (HRP), which catalyses
the oxidation of OPD with H2O2 to form 2, 3-diaminophenazine, producing an orange/brown
colour read spectrophotometrically at 492ηm. This change is directly proportional to antigen 
concentration, and varies with time up to a saturation point. Therefore, care was taken to ensure
each sample had identical development time. To each sample 100µl of OPD / H2O2 solution was
added at timed intervals, incubating in the dark for 5 minutes to allow colour development. The
reaction was stopped with the addition of 50µl 1M H2SO4 added at timed intervals.
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ELISA
Antigen
Primary
Antibody Source
and Catalogue
Number
Primary
Antibody
Dilution
Secondary Antibody
Source and
Catalogue Number
Secondary
Antibody
Dilution
Albumin DAKO (cat #
A0001)
1/1000 Abcam (cat # ab24458-
200)
1/1000
AFP cat # ab10071 1/1000 ab10072 1/3500
Fibrinogen
Alpha-1-
antitrypsin
Dako (cat #
A0012)
1/1000 Abcam (cat # ab7635-s) 1/2000
Prothrombin Abcam (cat #
ab9020-1 and).
1/10 Ab53597-200 1/3000
Table 2-2 Antibody and source dilution factors for ELISA protocol
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2.5 A Model for Filtration of Plasma in the BAL System
The filtration model assembly allowed the capacity and throughput of the filters to be tested and
scale up to remove DNA and endotoxin in the full scale BAL system.
Materials
 1.6 mm wall thickness thick, 4.6 mm bore size Watson-Marlow Silicone tubing from water
bath to the pump.
 1.6 mm wall thickness, 4.6 mm bore size Watson-Marlow PVC link tubing between the
pump and filter, as protection from possible increased pressure due to back pressure.
 1.6 mm wall thickness, 4.6 mm bore size Watson-Marlow Marprene™ peristaltic pump
tubing between the pump and filter, as protection from higher pressure.
 3M® Cuno® Zeta Plus™Maximiser™ Filters
o 60ZA50A dual layer filter
o 90ZA05A dual layer filter
 3M® Cuno® Plus EXP™ Filters
o 05SP (BC0030A - 05SP)
o 10SP (BC0030A - 10SP)
o 30SP (BC0030A - 30SP)
o 50SP (BC0030A - 50SP)
o 60SP (BC0030A - 60SP)
o 90SP (BC0030A - 90SP)
 Plasma
o FFP plasma
o Plasma from Cobe® Spectra® therapeutic plasma exchange
o Pig acute liver failure plasma from plasma exchange
 Pressure transducers assembly
o Smith Medical®Medex™ Optimax Medical Pressure transducers
o ADintruments® PowerLab® data acquisition system
o LabChart® 4 data acquisition software
o Modified data cables described in section 2.5.1
 Volume measurement Assembly
o A&D® GX 2000® Top plate balance
o Serial RS232 to USB converter
o RsWeight® version 100 Data acquisition software
 Other materials
 Water bath at 37°C
 4.6mm Watson Marlow® pump tubing
 Watson Marlow® 520 Du pump
 Sterile dry baked at 180 °C for 3 hours
 Certified sterile, DNA and pyrogen free 15ml Nunc® centrifuge tubes
 Certified sterile, DNA and pyrogen free 2 ml Eppendorf® tubes
 Sterile DNA and Endotoxin Free Filtered Pipette tips
 Timer
 25 g/L Virkon® disinfectant (containing potassium peroxymonosulphate, sodium
dodecylbenzenesulfonate, sulphamic acid; and inorganic buffers)
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Figure 2-4: Filtration model assembly. The Watson-Marlow® peristaltic pump forces
plasma/media from the water bath, at 37°C, to the filter where a pressure
transducer measures back pressure. The filtrate then passes to a collection vessel
on a top loading balance. The analogue signal from the pressure transducer is
converted to a digital signal using the PowerLab® data acquisition system, recording
reading on LabChart 4 program. The analogue signal from the A&D balance passes
through an analogue to digital converter into the A&D WinCT data logging program.
This provides real-time data acquisition to measure filtration function (capacity,
flux and volumetric throughput).
2.5.1 Construction of PowerLab and Pressure Gauge
In order to sufficiently model the filter system for the BAL, a series of data acquisition and fluid
systems were integrated to provide data for real time filter performance required to upscale for
the full scale BAL system.
PowerLab Data acquisition System
The PowerLab® Data Acquisition system is able to read most analogue signals with the relevant
conditioners and amplifiers to provide a real time digital signal, which is read by LabChart® 4
software.
Principle of the Transducer
The Medex® pressure transducers consisted of a strain gauge mounted on a thin diaphragm
wired to a Wheatstone bridge circuit, creating a load cell. To power the load cell, a regulated
DC voltage was provided by the PowerLab®. As a result of using specific medical grade
pressure transducers they required modification for integration with the PowerLab® system.
Figure 2-5 shows a circuit diagram of the connection between the pressure transducer and the
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PowerLab® data acquisition system, comprising the strain gauge, to the Wheatstone bridge, then
to the signal conditioner and finally the PowerLab®.
The strain gauge consisted of a stretched strip of metal, which under strain became thinner,
changing resistance between 30Ω to 300kΩ, end-to-end, proportionally to the strain applied. 
The degree of imbalance in resistance was measured between different arms of the Wheatstone
bridge circuit, providing a measure of the strain applied. This worked by the resistor R3 (Figure
2-5) and the strain gauge being set to an equal resistance with no force was applied; arms R1
and R2 were set at identical resistance to each other, so a symmetrical balance occurred and
output voltage was zero. When a strain was applied the resistance of the gauge changed causing
an imbalance in voltage, transmitting a micro voltage to the PowerLab® for signal conditioning,
amplifying the signal to 200mV.
Figure 2-5: A Wheatstone bridge circuit. This is the basis of Medex® pressure
transducer, consisting of four resistors that change resistance according to the
strain applied by the diaphragm of the transducer.
2.5.2 Preparation of the Filtration Assembly
All the tubing was pre-assembled, with the tubing length adjusted for the requirements of
specific experiments. Sterility was maintained in order to model the large scale BAL system and
to reduce any contamination, the tubing assembly and the filter were autoclaved for 20 minutes
at 121 °C. Prior to autoclaving the filter, 500 ml of MilliQ water passed through then purged
with air.
R1
R2R3
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Plasma was held in a baked sterile beaker, and covered with aluminium foil while pre-warming
to 37°C in the water bath; in the same water bath a sterile beaker of MilliQ water was also pre-
warmed for washing and calibration (Section 2.5.3). Meanwhile the tubing assembly was put in
place as shown in Figure 2-4, again passing 500ml of MilliQ water through the filter, then
purging with air.
2.5.3 Initial Filter Model Protocol
The pump was calibrated with the pre-warmed MilliQ water, to relate RPM to the volumetric
flow rate, then purging the whole system with air, before priming with Plasma. To prime the
filter with plasma, the air vent on the upside of the filter was opened to fill the top layer of the
filter capsule. Once full, both the pressure transducer and the tube between the filter and the
pressure transducer were primed with plasma, taking care to remove any air bubbles.
With the whole system primed, with exception of the filter membrane itself and the bottom end
of the filter capsule, the data acquisition systems were started and the pump turned on to the
required RPM for the given flow rate. It took a few moments to prime bottom end of the filter
and the tubing below it, however, this provided sufficient time for the pump to reach speed.
2.5.4 Sampling and Data Acquisition during Filter Model Protocol
At regular intervals 1ml samples were taken from the collection vessel and immediately
aliquoted into 2ml Eppendorf® tubes and frozen to -20°C. As a result of this, temporary
reduction in the mass of the vessel was observed which was later accounted for when analysing
data. During the course of the filtration experiment the progressive pressure increase determined
the end of the experiment, and the frequency of sample taking. According to 3M® Cuno® the
filters are designed to withstand a differential pressure up to 40psig (equivalent to 2.7 bar or
2026 mmHg). Considering atmospheric pressure at 1 atmosphere equivalent to 1.01295 Bar or
760 mmHg, the maximal differential pressure for the filter model was set at 1200mmHg (2026
mmHg – 760 mmHg = 1266 mmHg). If the pressure increased quickly then the samples were
taken with greater frequency to ensure that any point of contaminant breakthrough in the form
of DNA or endotoxin could be recorded.
2.5.5 Termination of Filter Model Experiment and Data Analysis
At the end of the experiment, the entire system, including the filter, was purged with 2L MilliQ
water, whilst measuring the pressure to determine the extent of the pressure attributable to the
plasma, and the amount of pressure remaining due to blockage of the filter. Finally, the entire
system excluding the filter was washed with 2L of 25g/L Virkon® then washed again with 5 L
of MilliQ water. .
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2.6 Testing Endotoxin in Plasma by Fluorometric Limulus Amoebocyte Lysate
Assay
Materials
 All materials were from Lonza® unless otherwise stated
 Fluorescence buffer
o 1 part Fluorescence Enzyme Solution,
o 4 parts Assay Buffer, B50-658, 5.0 ml/vial
o 5 parts Fluorogenic Substrate,
 20 EU/ml E. coli Endotoxin, O55:B5, E50-643,
 LAL Reagent Water, 30 ml/vial.
 1 ml endotoxin free glass tubes, baked for 3 hours at 250 °C
 Endotoxin free, sterile filtered pipette tips (Starlab®)
 Endotoxin free, sterile 96 well plate (Nunc®)
 LAL certified endotoxin free water
Principle of Fluorometric Endotoxin Assay
Endotoxin testing is based upon a Gram-negative bacterial infection of Limulus polyphemus, the
horseshoe crab, resulting in a potentially fatal intravascular151,152 . At the molecular level, a
serine protease catalytic coagulation cascade results in the gelation of Limulus blood. This
cascade is used in the Limulus Amebocyte Lysate Assay (LAL)153.
Chromogenic assays developed from utilising the enzymatic cascade, shown in Figure 2-6A,
where the protease cascade activates a chromogenic change. However, due to the possibility that
glucans in the solution may activate this cascade, producing false positives, another option was
used. The recombinant Factor C (Figure 2-6B) directly interacts with the endotoxin, causing a
fluorometeric change proportional to the level of endotoxin, which is more sensitive and robust
compared with the chromogenic assay.
Figure 2-6: LAL assay enzyme cascade A; The enzyme cascade found in the Limulus
polyphemus when in the presence of gram-negative bacteria, modified in the form of
an assay utilising a chromogenic substrate or turbidity testing to relate amount of
endotoxin proportionately to colour of turbidity change. B; The recombinant Factor
C which only binds endotoxin to cause a fluorescent change, by passing the
possibility of false negatives from the presence of Glucan. Obtained from Lonza®154,
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Preparation of the Endotoxin facilities
Environmental endotoxin contamination was averted by following a number of procedural and
technical protocols. A dedicated room was used for analysis, using a dedicated category 3
biological safety tissue cabinet to provide a sterile environment. The room was maintained as a
clean room, using separate robes, wearing hair nets and face mask to reduce the probability of
bacterial and endotoxin contamination into the room. All glassware was baked at 250°C for 3
hours and only certified endotoxin free sterile plastic ware in the form of pipette tips were used.
To decontaminate the room and the tissue hood after sterilisation using UV light, Virkon® and
70% IMS, the surfaces were exposed to 0.1M NaOH in 60% Ethanol for at least 6 hours, which
promoted endotoxin hydrolysis followed by dissolution, finally wiping surfaces with endotoxin
free water.
Endotoxin Assay Protocol
To a 96-well plate, 100µl of sample was added in triplicate, either a standard curve, water
blanks, a quality control sample, or unknown test samples, incubating at 37°C for 10 minutes.
Meanwhile the stock fluorescence buffer was mixed, in the following ratio:
 1 x fluorescence buffer:
 1 x fluorescence enzyme
 4 x assay buffer
 5 x fluorogenic substrate
Sufficient stock was made to accommodate 100µl for all samples, standards, and blanks. At
timed intervals, 100µl of fluorescence buffer was added to each well and the fluorescence read
at 380ƞm excitation and 440ƞm emission wavelengths; this constituted the blank fluorescence. 
The plate was then incubated for 1 hour at 37°C and read again at the same wavelengths,
subtracting the blank reading from the 1 hour reading.
Preparation of Standards and samples
Endotoxin standards were prepared from the lyophilized E. coli O55:B5 endotoxin reconstituted
with LAL Reagent water to yield a 20EU/ml stock solution, agitating vigorously for at least 15
minutes at high speed on a vortex mixer (This was of particular importance, for standards and
samples stored in glass containers, which endotoxin readily binds to). Immediately prior to
administering standards or samples, each was agitated again for 20 seconds by vortexing. A four
point logarithmic standard curve was prepared from 0.1EU/ml to 10EU/ml by serial dilution and
analysis in quadruplicate.
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Inhibition from components of the plasma samples were reduced by diluting to 0.5% with in
endotoxin free water, then heating samples at 70°C for 20 minutes. A positive control was
included in each sample preparation, where a 1EU/ml plasma sample was prepared, and treated
in an identical manner, to ensure that reduction in inhibition was confirmed.
2.6.1 Preparing and Extraction of Lipopolysaccharides to Spike Plasma for Filtration
The aim was to produce at least 500 mg of dry cell mass, for extraction of lipopolysaccharides
2.6.1.1 Materials
 E.Coli with DR7 vector containing XL -1 blue and Kanamycin resistance
 35g/L L Broth, autoclaved
 Kanamycin 1/1000 dilution of 50 mg/ml stock solution
 200 µg/ml Proteinase K (1 mg/ml stock)
 TM buffer, with added DNase and RNAse Buffer
o 10mM TrisHCl
o 2mM MgCl2
o 200 µg/ml DNAse (10mg/ml stock)
o 50 µg/ml RNAse (10mg/ml stock)
 TSE Buffer at pH 7
o 0.1M EDTA (Ethylenediaminetetraacetic acid)
o 10mM TrisHCl
o 2 %SDS (sodium dodecyl sulphate)
 95% Ethanol in 0.375 M MgC2 at 0 °C
 2 %SDS in 0.1 M EDTA
 25mM MgCl2
 Sterile (by autoclaving at 121 °C) glass 500ml, 1 L and 5 L conical flask
 Sterile 50ml Nunc® centrifuge tube
 Beckman- Coulter® J6-MI floor centrifuge
o JS-4.2A Aries™ series rotor
 Beckman- Coulter® 80K LE floor centrifuge
o 70 Ti rotor
 Edwards Lyophiliser
 Pestle and mortar at -20 °C
Preparation of E.Coli Cells for LPS Extraction
A 2ml solution of L broth was added to a 50 ml Nunc™ centrifuge tube, with 1/1000 dilution of
50ug/ml Kanamycin then inoculated with 50µl of E. coli Glycerol Stock and incubated
overnight at 37°C, with constant circular agitation. The following day the 2ml inoculum was
added to 200 ml L Broth (with Kanamycin) in a 500ml sterile conical flask, incubating for 8
hours at 37°C, with constant circular agitation. This inoculum was added to 2 x 1L L broth (with
Kanamycin) contained in 2 x 5L Conical flasks incubated overnight at 37°C, with constant
circular agitation.
To isolate the E.Coli, the 2 x 1L broths were centrifuged at 8000g for 10 minutes at 4°C in
sterile 1L Beckman- Coulter® centrifuge tubes in the J6-MI floor centrifuge using the JS-4.2A
Aries™ series rotor. Discarding the supernatant, each of the 2 pellets were re-suspended in the
50ml TM buffer, with no DNAse or RNAse added, and separated into 4 sterile 50ml Nunc®
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tubes, freezing at -80°C overnight. In order to gather dry homogenised cell mass, the frozen
samples were lyophilised for 32 hours then ground into a fine powder in a pestle and mortar,
(previously incubated at -20°C).
Extracting Lipopolysaccharides from the Dry Cell Mass
The remainder of the protocol is designed for 500mg of dry weight, greater or less than this
quantity would have necessitated a proportional alteration in the amount of each solution used.
In addition to this, any centrifugation step above 4000g was performed in sterile 100ml
Beckman-Coulter® centrifuge tubes in the Beckmann-Coulter ® 80K LE floor centrifuge using
the 70Ti rotor; otherwise a conventional bench top centrifuge was used .
500mg of dry E.Coli cell powder was re-suspended in 15ml TM buffer contained in a 50ml
Nunc® tube and vortexed thoroughly; adding 150µl of 10mg/ml DNAse and 37.5µl of 10mg/ml
RNAse, giving 200µg/ml and 50µg/ml final concentrations, respectively, incubating at 37°C for
4 hours. The first step of protein removal was initiated with the addition of 10ml of TSE buffer,
vortexing for 5 minutes to mix and then centrifuging at 50,000g for 30 minutes at 20°C.
Decanting the supernatant into 50ml Nunc® tubes, 200µg/ml of proteinase K was added and
incubated overnight at 37°C with constant rotary agitation. A white precipitate appeared at this
stage, which was removed by centrifugation at 1000g for 10 minutes. The supernatant was
decanted and allowed to cool for 30 minutes, followed by adding two volumes of 0.375 M
MgCl2 in 95% ethanol at 0°C, finally centrifuging at 12,000 g for 15 minutes at 2–4 °C.
A second protein removal step was performed by re-suspending the pellet in 25ml TSE buffer,
and sonicated for 15 minutes to dislodge the pellet and all residual lipopolysaccharides from the
centrifuge tube. This time a lower concentration of 25ug/ml proteinase K was added (due to
lower contaminant levels), again incubating overnight at 37°C with rotary agitation, and
centrifuging at 1000g to remove any precipitate. Two volumes of 0.375M MgCl2 in 95 %
ethanol at 0 °C were again added, centrifuging at 12,000 g for 30 minutes at 2 -4°C.
A final wash step consisted of re-suspending the pellet in 15mM TrisHCl and sonicating for 15
minutes. The solution was finally centrifuged at 200,000 g for 2 hours at 12 °C, re-suspended in
sterile MilliQ water.
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2.8 PMAS SBSS Liquid Particulate Counter
Materials
 PMASS GmbH SBSS Particulate counter with the HCB-LD-50/50 sensor provided by PMT Ltd.
 diH2O treated with the MilliQ System
Principle of Particulate Counting using the PMAS System
The PMAS particulate counter detects light scattering due to the presence of particulates in a
sample. A laser light was passed through the sample, where any loss in light was detected by
sensor attributing loss in signal proportionately to size and frequency of particulates. As a result,
a fully quantitative measure of particulates was provided, giving both a size distribution and
total particulate count per ml of sample.
Particulate Counting Protocol
The Particulate counter was first calibrated by passing through a solution, which contained
defined size and concentration of latex beads at 10ml/min, assigning an mV change in signal to
a particulate size illustrated in Table 2-3. Prior to sample analysis, the instrument was flushed
with 500ml of MilliQ treated diH2O. The parameters for analysis were set at 10ml/min,
measuring 0 to 20 particulate sizes with 50ml sample volumes. In order to reduce the effect of
superimposing particulates introducing inaccuracy into the measurement, samples were diluted
in MilliQ treated RO water. The effect of superimposition was evaluated by incrementally
testing diluted samples until the particulate measurement showed a linear distribution in line
with the dilution, i.e. a samples serially diluted ½ must show a ½ in particulate number between
dilutions.
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Particulate
size (µm)
Change in
signal (mV)
Particulate size
(µm)
Change in signal (mV)
1 101 11 1771.3
2 321 12 1835.9
3 513 13 1892
4 714 14 1944.3
5 1030.9 15 1992.1
6 1259.5 16 2037.7
7 1399.7 17 2081.9
8 1512.2 18 2167.2
9 1611 19 2209
10 1697 20 2250.5
Table 2-3: Calibration values for the particulate counter. Values obtained by passing defined
sizes of 1,000 beads/ml solutions of latex beads through the PAMAS GmbH SBSS particulate
counter to determine the mV change, which is then entered into the software to determine
sample particulate size and frequency.
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This Chapter details experiments to remove particulates
from alginate using different filtration methods,
measuring efficacy by rheometry, bead sphericity and
encapsulated HepG2 cell growth and function. The sand
filtration was performed in partnership with Timea Grego
as part of her MSc project, as the UCL Department of Civil
Engineering
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3. Alginate Purification
3.1 Introduction
For encapsulation of HepG2 cells, analytical grade sodium alginate powder is currently used
and is perfectly adequate for research purposes, but falls short of meeting some of the standards
attributed to medical grade alginate (Table 3). Medical grade alginate has been used in small
quantities, mainly as a scaffold for cell implantation155, 156, but has two drawbacks for use within
the BAL system; firstly it is prohibitively expensive at the necessary BAL scale, and the
properties of alginate are not necessarily appropriate for encapsulation in a fluidised bed system,
over 8-10days.
One aspect of attaining medical grade alginate is purity as a starting material157-160, which will
be tackled in this chapter. The main focus will be the level of particulates between 1 and 20µm
in diameter that remains in the alginate supplied by Sigma-Aldrich™ that is visible under a phase
contrast microscope. Other groups have purified alginate for biotechnology application, often
using lengthy extraction and filtration processes161-163 that often adds to the cost of supplying
alginate and affects the final properties. Therefore, an in-house method is required, starting with
the removal of particulates, whilst maintaining alginate properties.
Control of alginate as a starting material can be distinguished from controlling particulates
entering the patient during alginate bead fluidisation, as particulates trapped within alginate
beads may not escape to enter the patient, although this cannot be relied upon. Furthermore, the
basis of many regulations regarding particulates is derived from possible immunogenic
reactions166. One such example is the development of phlebitis from particulate exposure with
intravenous therapies167. As a consequence, compliant intravenous therapies must control and
eliminate particulates within regulatory limits for the specific markets, as illustrated Table 3-1.
These particulate levels relate to fluid directly infused into patients, so may not directly relate to
the BAL system; however, it could be argued that plasma from the patient will be in direct
contact with the alginate beads in the BAL circuit and therefore is analogous to direct infusion.
As a result, the particulate levels in Table 3-1 were used as a guide.
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Pharmacopeia source Particle size (µm) Particle limit in 1cm3
USA,UK,Australia
25102025
10001005055
Table 3-1: Particulate size and frequency admissible in water for parenteral medicines
within specified regulatory jurisdiction.
Other regulatory considerations relating to alginate during the treatment phase have been tested
in vitro and in vivo to meet fundamental requirements such as: immunogenicity, integrity as a
cell support and reactivity with human, pig and rabbit74,75,168,169. Although controlling
particulates in the starting material will be the focus, a quality management strategy, where
particulates will be removed directly from the plasma upon re-entry into the patient is another
possible approach.
Any alginate purification technique must maintain alginate properties outlined in the Thesis
Introduction. These include: the ability to encapsulate cells, promote cell growth, cell function,
and maintenance of viability for 8 – 12 days in fluidised bed 3D culture, as well as preserve
bead integrity throughout the growth and treatment phase.
3.2 Summary of Chapter
Several different principles of purification will be tested to remove particulates whilst
maintaining the required alginate properties for use within the entire BAL system. In brief the
three approaches are:
 Filtration through depth charged filter
 Sand Filtration
 Gas Solid Cyclonic Filtration .
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3.3 Methods
3.3.1 Characterising Particulate Contamination in Analytical Grade Alginate
3.3.1.1 Particulates Measurement in 2% Alginate using Phase Contrast Microscopy
Materials
 Phase contrast microscope.
 Lucia G Software.
 Glass slide.
 Glass Cover slip.
 Calibration graticule.
Particulate Measurement
Alginate was prepared as detailed in Methods Section 2.1.3.2, carefully adding 250µl to a glass
slide, then protecting the sample with a glass cover slip, analysing at 160x magnification on a
phase contrast microscope, calibrated using a calibration graticule. Particulate size and
frequency were evaluated using a function in the Lucia G® software, enabling lines to be drawn
across the diameter of the particulates in a given field. Different fields across the slide were
randomly chosen counting a total of 100 particulates across each slide. This provided a
distribution of sizes reflecting the population distribution of particulates.
This method was semi-quantitative as total particulate numbers could not be determined,
although it did provide a measurement of particulates in alginate for preliminary sample
analysis.
3.3.1.2 PMAS SBSS Liquid Particulate Counter
Materials
 PMASS GmbH SBSS Particulate counter with the HCB-LD-50/50 sensor provided by PMT Ltd.
 MilliQ treated RO H2O.
 Clean glass 250ml beaker.
Principle of Particulate Counting using the PMAS System
The PMAS particulate counter detects the extent of light scattered by particulates in a solution.
Laser light was passed through the sample, where any loss in light transmission was detected by
a sensor calibrated to attribute loss in signal proportionately to size and frequency of
particulates. As a result, this provided an objective and quantitative measure of particulates,
giving both a size distribution and total particulate count per ml of sample. However, to
maintain accurate particulate measurement the samples required dilution to between 0.01% and
0.001% to prevent particulate agglomeration or overlapping interference, which may distort
detection.
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Particulate Counting Protocol
Calibration of the particulate counter used a solution containing defined size and concentration
of latex beads at 10ml/min, assigning an mV change in signal to particulate sizes, as illustrated
in Figure 3-1. Prior to sample analysis, the instrument was washed with 500ml of MilliQ treated
RO H2O. The parameters for analysis were set at 10ml/min, measuring 0µm to 20µm particulate
size with 10ml sample volume.
Figure 3-1: Calibration curve for the particulate counting. The curve was obtained by passing
defined sizes of 1,000 beads/ml solutions of latex beads through the PAMAS GmbH SBSS
particulate counter to determine the mV change, which was then entered into the software
to determine sample particulate size and frequency.
3.3.2 Alginate Lyophilisation and Reconstitution
Materials
 Sodium Alginate (Sigma-Aldrich®)
 Dry ice
 Acetone (Sigma-Aldrich®)
 Round bottomed Winchester flask
 Edwards lyophiliser
For encapsulation, as described in Methods Section 2.3, 2% alginate was diluted to 1% by
adding cell and media mix to a 1:1 ratio. For filtration, however, the relatively high the viscosity
of 1% alginate (0.25Pas, equivalent to 250cPois) required dilution to 0.2%. Consequently, after
filtration, the alginate solution was lyophilised and reconstitution in preparation for
encapsulation, as illustrated in Figure 3-2.
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.
Figure 3-2: Alginate filtration process. This included alginate dilution, filtration and
reconstitution: 0.2% alginate solution was diluted in HEPES buffered 0.15M NaCl, pH 7.4;
stage I consisted of a filtration step; stage II involved shell freezing the alginate filtrate in
round bottomed flasks using dry ice acetone bath, followed by lyophilisation over 3-5 days;
stage III entailed reconstituting the alginate with sterile MilliQ treated RO diH2O, to the
desired alginate concentration; stage IV used the alginate initially to encapsulate empty
beads to verify bead integrity then proceeding with HepG2 cells.
Processing of Alginate from Filtration to Encapsulation
A volume of 2% alginate was diluted to 0.2% with MilliQ treated RO H2O for filtration in stage
I. Stage II commenced by adding 200ml of filtrate to a round bottomed Winchester flask for
shell freezing, by adding dry ice to an acetone bath, whilst rotating the bottom of a 1L
Winchester flask in the bath (this was performed in a fume cupboard). The alginate gradually
froze in increasing layers on the inside of the Winchester flask. Once complete, the flasks were
stored at -80°C for lyophilisation over 2-3 days to leave a shell of dry alginate. The dry alginate
was reconstituted in MilliQ treated RO H2O to get 2% alginate solution, for particulate analysis
or encapsulation.
3.3.3 Rheometry of Alginate
Materials
 Bohlin® CVO automated dynamic shear rheometer
 Graduated cone upper spinning plate
 Na alginate
Rheometry Principle
Changes to alginate molecular composition, attributable to filtration, were determined by
rheometry. This provided a numeric comparison of shear stress (which is related to viscosity
and in turn related to the size and distribution of polymer components) between filtered and
unfiltered alginate solutions, based on the way the solution behaves when increased shear
stresses were applied. The alginate solution was placed between two adjacent surfaces, where
the upper surface rotated and the lower surface remained stationary. As the shear rate of the
upper surface was incrementally increased, the resistance in the fluid was evaluated by a sensor
attached to the axle of the upper surface, which was expressed as shear stress. Viscosity was
then directly calculated from shear stress using Equation 3-1:
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Equation 3-1: Viscosity (Pas) = Shear Stress (Pa)
Shear rate (s-1)
Where viscosity (Pas) is equal to the detected shear stress (Pa) divided by the shear rate
applied (s-1).
The way a solution responds to shear rate can be placed into two broad catagories; Newtonian
and non-Newtonian fluids. Newtonian fluids do not change viscosity with increased shear stress
as shown in Figure 3-3; these include fluids such as water and human plasma. Non-Newtonian
fluids do change viscosity when shear is applied and are further subdivided depending on the
response to the applied shear.
Figure 3-3: Flow curves representing Newtonian and non-Newtonian fluids. Non-Newtonian
fluids change shear stress with changes to shear rate; as shear rate increases pseudoplastics
show a concave downward curve for shear stress, whereas dilatants fluids show an upwards
concave curve for shear stress. Newtonian fluids do not change shear stress as shear rate
increases. This provides an indication of intermolecular interactions within the solution.
Rheometry Protocol
Prior to sample analysis the plates were cleaned with MilliQ treated RO H2O followed by
adding 1ml of 2% alginate sample to the center of the bottom plate. The top plate was then
lowered to leave a 500µm gap between the center of the plates. An initial high shear of 250RPS
was imposed for 5 seconds to remove air bubbles and ensure uniform distribution of alginate
across the plate. After this, the shear measurement began at 0 shear rate, increasing in velocity
by 10 RPS every 30 seconds. A sensor measuring resistance from the alginate solution provided
a real time shear stress output on the Malvern® software.
Alginate viscosity was determined by measuring the mean viscosity over the range of shear
rates, with the variance expressing the non-Newtonian change in viscosity over shear rate. To
ShearS
tress(P
a) DilatantNewtonian
Pseudoplastic
Shear Rate (s-1)
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measure mean viscosity for both Newtonian and non-Newtonian fluids a representative shear
rate can be chosen for the given set of samples, so that the variance illustrates the spread of
results at a particular shear rate. For the purposes of alginate purification, measuring alginate
viscosity across shear rates and deriving a variance provided an indication of Newtonian vs.
non-Newtonian fluid characteristics.
3.3.4. Filtration of Alginate using Cuno® Filters.
Materials
 3M Cuno® filters
 Watson-Marlow® D510U pump
Principle of Depth Charged Filtration for Alginate
As described in Section 1.6.2 in the Introduction, depth charged filters work on two
principles: the physical porosity of the filters, and the charge of the filter media. Due to
the nature of the particulates, the charge cannot be easily determined, instead relying on
the porosity of the filter to remove particulates.
Filtration Protocol
Filters were autoclaved to gain sterility, which would be essential if used for large scale
alginate production. The filters were prepared for this by being flushed with 500ml of
MilliQ treated RO H2O, at 25ml/min, discarding the flow through then purging with air
to leave the filter media moist. Following autoclaving at 121°C for 20 minutes, another
500ml water flush and air purge was performed. Samples of 0.2% alginate were passed
through the filter at 10 ml/min, taking 1ml samples every 30 seconds for particulate
analysis (Methods Section 3.3.1).
3.3.5. Sand Filtration
Sand filtration was performed by the UCL Civil Engineering Department, for full
protocol, please refer to Appendix II.
Sand Filtration Principle
Fine sand filtration more conventionally serves as a means of removing particulates in
industrial water purification and many bioengineering processes170. As Figure 3-4
illustrates, granular media filtration (e.g. sand) can retain particulates from 1µm to
1000µm, depending on sand sizes used.
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Figure 3-4: Different filtration approaches for purification of solutions. Granular media
filtration (sand) can remove particulates of between 1µm to 1mm171.
3.3.6 Measurement of Bead Size and Sphericity after Filtration Processes
Materials
 Phase contrast microscope
 Lucia G software
 Calibration graticule
Bead Size and Sphericity Protocol
Measurement of bead size and sphericity provided a means of assessing the effects of different
purification protocols on the integrity of beads, for cell growth and to prevent inhibition to bead
fluidisation through deformation.
Initially, a calibration graticule was used to measure a defined length for each magnification.
Images of alginate beads taken, using the Lucia G microscope, were analysed for bead size and
sphericity, by drawing two perpendicular lines across the diameter, incorporating the longest
diameter of a given bead. This was repeated 100 times to provide a statistically representative
analysis of the beads. One of the diameters was used to evaluate bead size and the combination
of the two perpendicular diameters were used to evaluate sphericity as expressed by Equation 3-
2. Accordingly, a figure closer to 0 depicts greater sphericity, whereas a higher figure indicates
greater deformation.
Equation 3-2: S= 1 – (d2 /d1)
Where the sphericity, S (dimensionless) is equal to the longest diameter, d1 (µm) divided by the
perpendicular diameter, d2 (µm).
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Visualisation of Particulates in an Alginate Bead
In order to visualise the particulates in the alginate, beads were encapsulated and
analysed under a phase contrast microscope, Figure 3-5.
Figure 3-5: Particulates visible in an encapsulated alginate bead. This used 160 x
magnification.
100µm
Particulates inalginate
Fragment ofalginate in solution
Out of focusbubble in thesolution
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3.4 Results
For the purposes of clarity, this chapter will present each set of relevant results with a short
introduction and discussion, as many of the experiments performed were relatively disparate.
3.4.1 Changes in Alginate Property due to Sterilisation
3.4.1.1 Introduction to Alginate Sterilisation
Sterility is of vital importance to any intravenous medical device. Alginate is highly heat
labile78, alginate sterilisation (121°C for 10 minutes), causes a reduction in alginate viscosity
crucial for cell growth and function whilst maintaining bead integrity (data not shown).
Conventional autoclaving protocols often use 121°C for 20 minutes to provide sterility, which
causes alginate viscosity to reduce to an extent which compromises bead integrity. To
distinguish between autoclaving for different times, in the remainder of the chapter, sterilised
alginate will refer to 10 minutes at 121°C, whereas autoclaving will refer to 20 minutes at
121°C. The change in viscosity between sterilised and autoclaved alginate were evaluated by
rheometry, arring at the ideal viscosity for successful encapsulation. The sterility of the alginate
sterilised for 10 minutes at 121°C was emperically assessed due to the lack of infection over 8-
10 days of culture.
3.4.1.2 Results from Rheometric Analysis of Alginate
Autoclaving alginate (20 minutes at 121°C) caused a 6-fold decrease in mean viscosity
compared with unautoclaved alginate, as illustrated in Figure 3-6A and Figure 3-6C. A 2.25 fold
reduction in viscosity, was observed between unautoclaved and sterilised alginate (Figure 3-
6B). This clearly illustrates the highly heat labile nature of alginate polymeric chains. For all
subsequent experiments, alginate was sterilised in an autoclave for 10 minutes at 121°C, as is
currently the practice for the large scale BAL growth phase in our group.
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Figure 3-6: Rheometric analysis of sterilising alginate. The viscosity of 2% alginate changes
significantly between 10 and 20 minutes at 121°C. A; 2% unautoclaved, unsterilized alginate
solution, mean viscosity of 0.9±0.12Pas. B; 2% alginate sterilised at 121°C for 10 minutes,
mean viscosity of 0.4±7x10-3Pas. C; 2% alginate autoclaved for 20 minutes at 121°C, mean
viscosity of 0.14±1x10-3Pas.
3.4.1.3 Discussion of Alginate Sterilisation
Clearly, the exposure of a 2% alginate solution to heat treatment decreases viscosity of the
solution, which has been shown by others172. As mentioned in the General Methods Section
2.1.3, sterilisation of alginate is controlled by using specific vessels for certain alginate volumes
(100ml in a 250ml glass bottle) to ensure uniform bulk density between experiments, as well as
replicating the time the alginate is at 121°C (10 minutes). As a result, a 2% solution of alginate
should maintain a viscosity of 0.4±7x10-3 Pas to maintain the required encapsulation properties
for the BAL system. .
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3.4.2 Effect of Lyophilisation on Alginate Properties
To confirm that filtration was the primary cause of any alteration in alginate properties, any
changes as a result of dissolution, freezing, lyophilisation, and reconstitution were assessed
(described in Section 3.3.2). As part of the development of the BAL system, the dissolution of
alginic acid salt powder has become standardised to prevent any changes in alginate properties.
The effects of freezing alginate have also been previously established as having no effect on
alginate properties. Therefore, the viscosities of unfiltered, un-lyophilised, and lyophilised
alginate (both un-sterilised) were determined to ensure the lyophilisation had no effect on
alginate properties. The mean viscosity of un-lyophilised alginate sample was 0.9±0.12Pas, as
compared with 0.9±0.11Pas for lyophilised alginate sample. This was further illustrated in
Figure 3-7 where change in shear stress and viscosity with increased shear rate show almost
identical curves.
Figure 3-7: The process of shell freezing, lyophilisation, and reconstitution did not change
alginate properties. Un-lyophilised, unfiltered and unautoclaved alginate showed a mean
viscosity of 0.9±1.2Pas (Figure 3-6A), compared with a mean of 0.9±0.11PAS for Lyophilised,
unautoclaved and unfiltered alginate. .
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3.4.3 Depth Charge Filtration
3.4.3.1 Introduction
As described in Section 1.6.2.3 of the Introduction, Cuno® SP filters are designed for
downstream bioprocessing clarification. To make a preliminary assessment of particulate
retention capability of depth charged filters, the filtered alginate solution was analysed under
phase contrast microscope, as mentioned in Methods Section 3.3.1. With the filtered alginate,
cells were encapsulated as described in General Methods Section 2.1.3.2.
3.4.3.2 Results of Alginate Filtration using Cuno® Depth Charged Filters
Alginate filtered through both 10SP filter media (1 – 4.5µm nominal porosity) and 05SP filter
media (1.5 – 10µm nominal porosity), showed a modest decrease in particulate size distribution,
using a phase contrast microscope (data not shown). Despite this, the properties of alginate were
compromised; inhibiting encapsulation as illustrated in Figure 3-8 and Table 3-2 with reduced
sphericity. After 2 days of cell culture, beads made with filtered alginate lost integrity and began
to dissolve.
Alginate type Bead Size (µm) SphericityUnfiltered Alginate 494±27 0.25±0.02605SP Filtered Alginate 475±41 0.80±0. 1410SP Filtered Alginate 432±87 0.92±0.25
Table 3-2: Sphericity and bead size of encapsulated alginate beads filtered with Cuno®
Filters. Bead size and sphericity were altered as a result of filtration.
Figure 3-8: HepG2 cells encapsulated with alginate filtered through depth charged filters. A;
un-filtered alginate. B; alginate filtered through a 05SP filter. C; alginate filtered through a
10SP filter.
3.4.3.3. Discussion of Cuno® Depth Charged Filtration
As a result of the beads dissolving after only 2 days, possibly due to a drastic alteration in
alginate composition, no further experiments were performed with depth charged filters.
A B
500µm 500µm 500µm
C
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3.4.4. Preliminary Sand Filtration
3.4.4.1. Introduction to Preliminary Sand Filtration
In order to assess the ability for sand filtration to remove particulates from alginate, a set of
preliminary experiments were performed, by measuring change in sand particulate distribution
by phase contrast microscopy, as detailed in Methods Section 3.3.1. Prior to this, size of sand
grains used in the filter measured, again using phase contrast microscopy, to ascertain the
correct flow rate and sand bed height for filtration, (detailed in Appendix II). Measurements of
sand size distribution were made using a standard phase contrast microscope.
Following this, bead integrity was determined by encapsulating alginate without cells and
measuring bead size and sphericity. Finally, HepG2 cells were encapsulated in alginate to
measure cell function and growth over 12 days.
3.4.4.2. Results of Preliminary Sand Filtration
Measurement of Sand Size
Sand size was measured to determine correct flow rate for filtration. Sand at 129±31µm was
categorised as fine sand, whereas sand at 523±114µm was categorised as coarse sand.
Figure 3-9: Fine and coarse sand sizes, for alginate filtration, were measured using phase
contrast microscopy. A; Fine sand size distribution with a mean size of 129±31µm. B; Coarse
sand size distribution with a mean size of 523±114µm. C; phase contrast image of 129±31µm
sand grains at 40 x magnification. D; phase contrast image of 523±114µm at 20x
magnification.
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Preliminary Particulate Analysis
Unfiltered alginate showed a mean particulate size of 5±2µm, whereas alginate filtered through
coarse sand bed (523±114µm) showed a reduction in particular size distribution to 4±1.5µm.
Filtration through a fine sand bed (129±31µm) further decreased particulate size distribution to
3±1µm. This confirmed that particulates were being retained by the sand bed, thereby reducing
the larger sized particulates, as illustrated in Figure 3-10.
Figure 3-10: Larger particulates were removed from sand filtration, increasing in efficiency
with smaller sand size. Unfiltered alginate (Black) was compared with alginate filtered
through a fine sand bed (129±31µm) (Red), and alginate filtered through a coarse sand bed
(526±114µm) (Green) and unfiltered alginate. Each distribution represents 100 particulates
on a single slide. The particulate size distributions were; 5±2µm (unfiltered alginate),
4±1.5µm (526±114µm sand), and 3±1µm (129±31µm Sand). No stats available due to semi
quantitative nature of analysis.
Alginate encapsulation without cells
Bead size showed no significant change between unfiltered and filtered alginate (n=100,
p=0.1927), as shown in Figure 3-11. However, bead shape was significantly compromised as
measured by bead sphericity (p=0.0059, n=100, Figure 3-11).
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Figure 3-11: Preliminary experiments by encapsulating sand filtered alginate. Encapsulation
was successful with all samples, although some changes in bead shape were observed. A; 1%
unfiltered alginate. B; 1% alginate filtered through coarse sand bead (526±31µm). C; 1 %
alginate filtered through sand bed (129±31µm). Green lines show measurement of diameter
to determine bead size and sphericity.Alginate type Bead Size (µm) SphericityUnfiltered 492±17 0.12±0.0012Coarse sand filtered(526±31µm) 489±28 0.84±0.04Fine sand filtered(129±31µm) 478±25 0.90±0.12
Table 3-3: Bead size shows no significant change due to filtration(n=100, p=0.1927),
whereas sphericity as measured by perpendicular diameter measurement shows significant
change (n=100 for each sample, ANOVA showed: bead size P=0.0059, bead sphericity p=0.1).
The sphericity of beads showed a significant change with filtered alginate, but no change in
bead size, as can be seen with the formation of tails illustrated in Figure 3-11 B and C. Despite
this, the bead shape was deemed sufficient to assess any changes in cell proliferation and
function, as measured by viable cell growth and albumin production, respectively.
Alginate Encapsulation with Cells
HepG2 cells encapsulated in sand filtered alginate and cultured in a static environment over 12
days (Methods 2.1.3), showed no significant difference in viable cell numbers and albumin
production (Figure 3-12A and B, ANOVA on viable cell growth n=5, P=0.54; ANOVA on
albumin production n=5, P=0.058).
500µm 500µm 500µm
A B C
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Figure 3-12: Viable cell growth and albumin production were not significantly affected by
filtration (ANOVA on viable cell growth n=5, P0.54) (ANOVA on albumin production n=5,
P=0.058). Cells were grown over 12 days in static cell culture using Alpha-MEM
supplemented media (Methods Section 2.1.3). A; Viable cell number per ml of beads over 12
days B; Albumin production over 24 hours on day 9 and 12.
3.4.4.3 Discussion of Prelimenary Sand Filtration
Preliminary sand filtration experiments showed encouraging results with a reduction in
alginate particulate size distribution, with only a modest change in bead integrity and no
effect in cell growth or cell function. To increase the efficiency of filtration, the sand
size was reduced then the particulate numbers and size were more accurately measured,
as detailed in Methods Section 3.3.1.2.
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3.4.5 Alginate Filtration with Reduced Sand Size
3.4.5.1 Introduction for Alginate Filtration with Reduced Sand Size
Despite some changes in bead morphology, viable cell number and function showed no
significant differences. Therefore, to increase particulate removal efficiency whilst maintaining
acceptable bead morphology, smaller sizes of sand were obtained from Sebelco® who provided
sand size distribution, as illustrated in Figure 3-13. This data originated from experiments using
a series of sieves to trap sand of a particular size range, denoted by “particulate size”, also
showing the defined blend prepared by Sebelco®.
Three types of sand filtration media were prepared from the sand size analysis in Figure 3-13:
RH70, RH110 and a 50:50 mix of RH70 and RH110. The mixed sand was referred to as dual
layered filter media and was backwashed a number of times to produce a gradient of sand sizes
from larger particulates at the bottom, to smaller at the top of the filtration column. This was
performed by the collaborators at the UCL department of Civil Engineering.
Particulates within alginate were then measured by laser light obscuration as detailed in
Methods Section 3.3.1.2. Compared to a light microscope, laser light obscuration provided two
important improvements: a value of total alginate particulates per ml of sample; as well as a true
evaluation of the number smaller alginate particulates, being greater in number than larger
particulates (Figure 3-14).
To assess integrity prior to a full cellular encapsulation the filtered alginate was used for
encapsulation without cells. However, filtered alginate exhibited extensive bead deformation as
shown in Figure 3-15. One possible way to correct for poor bead morphology using filtered
alginate could be to increase the concentration of filtered alginate during polymerisation and
encapsulation. Ordinarily a 2% concentration was mixed with media/cells to give a 1% final
concentration, as described in General Methods Section 2.1.3.2. Alginate concentration was
increased prior to encapsulation with RH110 and RH70 sand filtered alginate (Figure 3-16).
Optimal alginate concentration was determined by observing restored alginate bead integrity in
terms of sphericity and bead diameter, alginate was filtered through the dual layered filter
consisting of both RH110 and RH70 sand, (described in Methods Section 3.3.5). By combining
Sibelco® RH70 and RH110, filter media the particulate retention may be further optimised as
described in Section 3.3.5. Both the RH110 and RH70 were mixed at a ratio of 50:50 to form a
single new sand blend, for alginate filtration as before.
Alginate filtered with RH110 and dual layered reduced particulate levels with the greatest
efficiency (Figure 3-19 and 3-20). Therefore, this alginate was used to encapsulate HepG2 cells
to measure growth and function.
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Finally, rheometric analysis of the three sand filtered alginate types was used to
determine the changes in bead integrity in terms of viscosity as a measure of the extent
of alginate compositional change (Figure 3-21).
Results Alginate Filtration with Reduced Sand SizeThe RH110 sand showed a mean sand size distribution of 102 ±30µm, whereas RH70 Sandshowed a mean size distribution of 149±56µm, when analysed by Sibelco®
Figure 3-13: Sibelco® provided defined sand blends by using a series of sieves to trap the
sand as denoted by particulate size. A; RH110 sand with a mean size distribution of
149±56µm. B; RH70 Sand with a mean size distribution of 102±30µm.
Particulate Analysis by Light Obscuration
Particulate analysis of alginate filtered with Sibelco® sand showed a reduction in particulate
number with both RH70 and RH110 sand, with the finer RH110 showing the greatest particulate
removal efficiency, as illustrated in Figure 3-14.
010
2030
4050
60
pan 63 125 250 500 1000 2000 4000 8000
Fr
eq
ue
nc
y
Sand Particulate Size (µm)
Smaller Sibelco® RH110
Sand
01020
304050
607080
pan 63 125 250 500 1000 2000 4000 8000
Fr
eq
ue
nc
y
Sand Particulate Size (µm)
Larger Sibelco® RH70 Sand
102±30µm 149±56µm
A B
Page 101
Chapter 3 Alginate Purification Results - Air Filtration
of Dry Alginate
Figure 3-14: Particulate size and frequency in RH70 and RH110 sand filtered alginate.
Particulate numbers reduced in sand filtered alginate compared with unfiltered alginate, as
measured by the GmbH PMAS SBSS particulate counter by laser light obscuration. RH110
sand composed by larger grains showed a lower level of reduction compared with the finer
RH70 sand. Numbers on the figure represent the numbers of particulates x105 for clarity.
Filtered Alginate Encapsulation without Cells
As a result of deformation to alginate beads illustrated in Figure 3-15, sphericity and bead size
were not measured. Unfortunately, the beads in Figure 3-15 B and C were deemed unsuitable
for cellular encapsulation.
Figure 3-15: Bead integrity with RH70 and RH110 sand filtered alginate. Bead integrity was
significantly reduced with RH70 and RH110 sand filtration. Beads were encapsulated
without cells to assess integrity prior to full cellular encapsulation. Unfortunately, beads
were deemed unsuitable for cellular encapsulation. A; Unfiltered alginate. B; RH70 sand. C;
RH110 sand.
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Increasing Alginate Concentration to Restore Bead Morphology
Increasing alginate concentration increases the viscosity of the solution as illustrated in Figure
3-16, using unfiltered alginate.
Figure 3-16: Change in alginate viscosity with increased concentration. As alginate
concentration was increased, viscosity increases in a non-linear manner, as measured by
rheometry (detailed in Methods Section 3.3.3), with increasing unfiltered alginate
concentration. This used unfiltered alginate.
A series of increased alginate concentrations were used to encapsulate alginate without cells;
analysing bead size and sphericity (Table 3-4), until at 1.875% final concentration (3.75% prior
to encapsulation), bead morphology was restored (Figure 3-17). Bead size and sphericity
showed no significant difference, analysing by ANOVA, n=100 p=0.25 with bead size, and
sphericity of n=100 p=0.084.
After encapsulation, the viscosity of 3.75% filtered alginate was 0.98±0.147Pa (RH110) and
1.12±0.26Pa (RH70) filtered alginate.
Figure 3-17: Bead morphology after increasing alginate concentration. Alginate
encapsulated at 1.875% final concentrations (normally 1%), reconstituting dry alginate to
3.75% alginate for encapsulation.
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Alginate type Bead Size (µm) Sphericity
Unfiltered 498±26 0.12±1.2x10-3
Smaller RH110 Sand 481±13 0.22±0.011
Larger RH70 Sand 485±10 0.36±0.04
Table 3-4: Bead morphology was restored by increasing alginate concentration to 1.875%
alginate, as measured by bead size and sphericity (n=100 for each sample, ANOVA showed:
bead size P=0.25, bead sphericity p=0.084).
Dual Layered Sand Filtration
Particulates and Bead Integrity
Filtration with the dual media reduced particulate levels, compared with unfiltered alginate, and
further improved removal efficiency relative to RH110 sand, as illustrated in Figure 3-19.
However, bead integrity was compromised as a result of filtration through the dual layered sand
(Figure 3-18A). Despite this, increasing the alginate concentration to 1.875% (final
concentration, from 3.75% reconstitution) restored bead morphology, similarly to RH70 and
RH110 alginate filtrates. Mean bead size was restored to 479±17µm and sphericity to
0.22±4.2x10-3, showing no significant difference with unfiltered beads (t-test, bead size n=100,
p=0. 32).
Figure 3-18: Bead integrity was again compromised by encapsulating without cells at 1%
final alginate concentration (reconstituted to 2%), but restored after increasing alginate
concentration to 1.875% (reconstituted at 3.75%). A; Alginate filtered through the dual
media filter. B; Dual media filtered alginate shows no significant difference in bead size or
sphericity compared to unfiltered alginate (n=100, p=0.32 bead size; n=100, p=0.12 for P
sphericity).
500µm 500µm
A B
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Figure 3-19: Alginate particulate content was reduced by dual sand media filtration,
compared with unfiltered and RH70 filtered sand. Numbers above the x-axis were included
for clarity, reflecting particulate numbers x105 for different alginate filtration states.
Numbers above bars were added for clarity, signifying the particulate number x105/ml.
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Cell Number and Function
Encapsulation of HepG2 cells in alginate filtered with RH70 and dual media showed a
significant difference in viable cell growth, shown in Figure 3-20A (ANOVA n=5, p=0.0012),
despite no significant difference in albumin production, as illustrated in Figure 3-20 B
(ANOVA n=5, p=0.38). Having restored bead morphology by increasing alginate concentration,
cell growth was inhibited.
Figure 3-20: HepG2 growth and Cell function in sand filtered alginate encapsulated at
1.875%. Cell growth was significantly affected by alginate filtration (ANOVA n=5, p=0.0012),
whereas albumin production was unaffected by alginate filtration (ANOVA n=5, p=0.38). A;
Viable cell growth over 14 days of static culture in Alpha MEM media. . B; Albumin
production n days 4, 9, and 12.
Rheometric Analysis of Sand Filtered Alginate.
Rheometry of Alginate Filtered with RH110 and RH70
Comparing viscosity of unfiltered alginate with filtered alginates showed differing viscosities,
possibly resulting from compositional changes. Filtered alginate exhibited more Newtonian
fluid characteristics, where shear rate had little effect on viscosity, as illustrated in Figure 3-21.
Alginate filtered through the smaller RH110 sand showed a mean viscosity of 3.6x10-2± 9.1x10-
6Pas, similar to alginate filtered through the larger RH70 sand with mean viscosity of
0.0492±7.3x10-4Pas. Unfiltered alginate showed a viscosity of 0.4±0.007Pas, exhibiting non-
Newtonian fluid characteristics as shown in Figure 3-6B.
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Figure 3-21: Filtered alginate had reduced viscosity exhibiting Newtonian fluid
characteristics compared with unfiltered alginate (Figure 3-6B). A; 2% alginate filtered with
RH110 sand, mean viscosity 3.6x10-2 ± 9.6x10-6Pas. B; 2% alginate filtered with RH70 sand
mean viscosity of 3.78±4.7x10-5Pas.
Rheometry of Dual layered samples
The viscosity of 2% alginate filtered through the dual layered filter media was reduced from
0.4±0.007Pas for unfiltered sterilised alginate to 0.05±1.3x10-4Pas for dual layered filtered
alginate, shown in Figure 3-22. This demonstrated both lower mean viscosity as well as a
reduced variance, indicating reduction in non-Newtonian fluid characteristics due to lower
viscosity. By increasing the alginate concentration, the viscosity of dual sand layered alginate
was increased from 0.05±1.3x10-4Pas to 0.5±0.009Pas.
Figure 3-22: Filtration through the dual layered media caused a reduction in viscosity to
exhibit Newtonian fluid characteristics. Mean viscosity of 0.05±1.3x10-4Pas excluding the
first 10 RPS increase in shear rate.
3.4.5.3 Discussion of Alginate Filtration by Reduced Sand Size
Increasing the filtration efficiency by reducing sand size or using the dual layered sand
filter resulted in bead integrity being severely compromised (Figure 3-15 and Figure 3-
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18). A reduction in alginate viscosity confirmed this, with an 8-fold and an 11-fold
reduction, from 0.4±0.007Pas (ideal alginate viscosity) to 0.05±1.3x10-4 and
0.036±9.1x10-6Pas, for dual layered and RH110 sand filtration, respectively. This
reduction in viscosity probably did not affect the bead formation during transit between
the encapsulator nozzle and the polymerisation buffer, but distorting upon impact with
the surface tension of the polymerisation buffer, despite pluronic acid being added to
reduce this effect.
Mitigating the loss in viscosity by increasing alginate concentration to1.875% (3.75%
alginate concentration for reconstitution) during encapsulation restored bead integrity,
as measured by bead morphology (sphericity and size). Although, the limitations of
viscosity and beads morphology analyses were revealed when the perceived bead
integrity was improved, but the alginate viscosity increased from 0.4±0.007Pa to
0.5±0.009Pa, 0.98±0.147Pa, and 1.12±0.26Pa for dual sand, RH110 sand and RH70
sand filtered alginate, respectively. As a result, cell growth was compromised as
illustrated in Figure 3-17 and Figure 3-20; if the alginate encapsulation concentration was
reduced to below 1.875% significant bead deformation would occur. Consequently, a
balance could not be reached between sufficient bead integrity, to withstand fluidisation
in a BAL growth and treatment phase, and achieving the required viscosity of
0.4±0.007Pa. Potential causes of the reduction in cell growth as a result of higher
alginate concentration could have been an increase in internal alginate cross-linking
physically inhibiting cell growth. Alternatively, alginate bead porosity has been shown
to decrease with increased alginate concentration, therefore inhibiting mass transfer and
indirectly reducing cell growth173, although with protein levels unaffected by increasing
alginate concentration, this seems unlikely.
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3.4.6 Gas Solid Cyclonic Filtration of Dry Alginate
3.4.6.1 Introduction
Filtering alginate whilst in solution caused changes in viscosity coupled with reduction in cell
growth. Therefore, another approach was taken in the form of filtering alginate in dry state by
gas solid cyclonic filtration. This approach can be visualised as akin to the ancient process of
“winnowing” to purify wheat grains by removing soil particles and other debris. Powder in dry
state is passed into the top of a cylinder contained within it an upward cyclonic air flow.
Depending on the speed of the flow and height of the cylinder, smaller particles would escape at
the top quicker than larger particles (otherwise drop out of the bottom) as illustrated in Figure 3-
23. It has been extensively used in many industrial applications from plastic fragment separation
to dust removal from gaslines and could provide a means of fractionating alginate particles from
pure alginate powder; as a result, they are often industrial sized machines with a high
throughput capability174. The Air filtration was performed by The Department of Civil
Engineering at the University of Miskolc, Hungary.
Figure 3-23: Gas solid cyclonic filtration unit. An upward cyclone separates dry particle
travelling in a downward direction by size according to the upward thrust of the air and the
weight of the particulates.
With the alginate obtained from this type of filtration, the same rheometric, and cell
encapsulation studies were performed to determine effect of bead integrity, composition of
alginate and effect of growth and function of the beads.
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3.4.6.2 Results of Particulates Removal by Gas solid Cyclonic Filtration of Alginate
Gas solid cyclonic filtration reduced particulates within alginate to approximately the same
levels as dual layered media filtration as illustrated in Figure 3-24.
Figure 3-24: Gas solid cyclonic filtration of alginate reduced particulates to similar levels as
dual media sand filtration, compared with unfiltered alginate. Values were included on the
graph to represent particulate numbers x105, for clarity.
Rheometry of Air filtered samples
Unlike alginate filtered after reconstitution, gas solid cyclonic filtration did not change the
viscosity of reconstituted alginate compared with unfiltered alginate, shown in Figure 3-25
(mean unfiltered at 0.291±8.6x10-4Pas, vs. air filtered at 0.288±2.6x10-3Pas).
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Figure 3-25: Gas solid cyclonic filtered and unfiltered alginate, reconstituted to 2% Viscosity
maintained the same viscosity. A: mean unfiltered alginate viscosity at 0.291±8.6x10-4Pas.
B; air filtered viscosity at 0.222±2.6x10-3Pas.
Encapsulation with HepG2 Cells of Air Filtered Alginate
Viable Cell Growth
Viable cell numbers were unaffected by gas solid cyclonic filtration of alginate, (two tailed t-
test n=5, p=0.57).
Figure 3-26: No significant difference in viable HepG2 cells numbers between unfiltered and
gas solid cyclonic filtered alginate. (2 tailed t-test n=5, P=0.57)
Function of Cells Encapsulated
Cell function was also unaffected by alginate filtration as shown in Figure 3-27; four HepG2
specific proteins, albumin, AFP (α-Fetoprotein) and α-1-antitrypsin, and fibrinogen assayed by 
ELISA, showed no significant changes to protein production between samples on each day.
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Figure 3-27: Gas solid cyclonic filtration did not significantly affect production of four
proteins expressed in encapsulated HepG2 cells, over 24 hours, in static culture on days 8,
12 and 15 (Methods Section 2.1.2) as measured by ELISA (Methods Section 2.5). A; Alpha
fetoprotein production (n=5, P=0.47). B; Albumin Production (n= 5, p=0.14). C; Fibrinogen
Production (n=5, p=0.42). D; Alpha 1 Anti Trypsin (n=5, p=0.095).
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3.3.4 Comparison of Alginate Particulates in Injectables and Air Filtered Alginate
As illustrated in Table 3-5, the reduction of particulate levels had been achieved by gas solid
cyclonic filtration in comparison to unfiltered alginate. However, particulate levels still remain
higher than the acceptable range for parenterals.
Pharmacopeiasource Particle size(µm) Particle limitin (105/ml) Particulates inAir filteredalginate (105/ml)
ParticulatesinUnfilteredalginate(105/ml)
USA
UK
Australia
25102025
0.10.010.0050.00050.0005
16.471.060.3200
72.413.710.760.010.01
Table 3-5: Alginate particulates are compliant for injectables for particulates of 10, 20 and
25µm, but approximately 10 times the acceptable levels for 2 and 5 µm particulate sizes.
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3.5 Conclusions of Alginate Filtration Findings
The development of a standardised HepG2 cell encapsulation protocol, with analytical grade
alginate, has produced robust alginate beads capable of withstanding 12 days of cell culture
(BAL growth Phase), and 8 hours of perfusion with plasma from an ALF patient (BAL
treatment phase). A central feature of the protocol is the sterilisation step (sterilised by
autoclaving for 10 minutes) causing a 2.25-fold reduction in alginate viscosity, producing
alginate with 0.4±0.007Pas mean viscosity (with the variance illustrating the change in viscosity
with increased shear stress). For particulate reduction and other future purification methods, the
central tenet will be the maintenance of these alginate bead properties.
Throughout the numerous steps of alginate reconstitution and lyophilisation only direct filtration
introduced a change in viscosity, suggesting either a decrease in overall alginate polymer
concentration or the selective retention of G uronic acid chains over M and MG by the sand, that
have been shown to be important in alginate viscosity162. If a reduction in alginate concentration
was the cause, increasing alginate concentration at encapsulation should have reversed the
reduction in bead integrity. Alternatively, modification of alginate polymer chain length has
been attributed to changes in alginate viscosity during purification87.These purification
protocols, often lengthy; involve a series of acetic acid and ethanol extraction and dialysis steps,
which bring about in changes to alginate chain lengths86,175-178. The stability of alginate solutions
(not cross-linked) over much longer periods than the 2-4 days taken for sand filtration has been
established in diH2O at pH 7-9 for more than 1 month
179. Furthermore, the inert nature of sand is
important for the more common application in water purification128, so it is unlikely to have
catalysed the shortening of alginate polymer chains. Chain shortening has only been reported
when storing in diH2O at pH 4.5 as a consequence of acid hydrolysis, the pH during alginate
filtration was always maintained at pH 7.4 with HEPES buffer. Others have attributed changes
to alginate viscosity when purifying pharmaceutical grade alginate to the removal of constituent
contaminants, specifically protein (COOH group of particular importance), showing an inverse
relationship between viscosity and protein content87,175,180,181. The nominal porosity of the sand
filter media would be too large to prevent protein transit, as illustrated in Figure 3-4, therefore
supporting the original idea that preferential removal of M and MG over G uronic acid chains
caused the changes to viscosity.
Regardless of gas solid cyclonic filtration being at the preliminary stages of development, a
clear potential for removing particulates was shown. For the study to be widened, analytical
methods to measure and standardise alginate contamination levels and M/G composition need to
be incorporated for the current analytical grade alginate. In addition to this extraction and
chemical analysis of particulates may aid the air filtration optimisation. The most likely origin
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of the alginate particulates is residual fibrous cellulose from extraction182, which can be
confirmed using the Updegraff acetic acid colorimetric assay181.
In addition to characterising alginate particulates, other contaminants could be analysed using
X-ray photoelectronic spectroscopy providing all alginate molecular components including
elemental composition and electronic state of the surface 1-10nm of an alginate sample87. This
would include evaluation of heavy metal content. In addition to this, others have accurately
measured total residual protein contamination derived from the source, using fluorescent
compounds, which bind amine groups in the primary structure of the protein, such as the amine
group at the end175. An optimised version of the Pierce BCA (bicinchoninic acid) protein assay,
named the Micro BCA, has been used to measure protein contaminants, but is less sensitive183.
The bulk properties of the alginate, against which all purification protocols should be measured,
could use two central techniques: measurement of viscosity to provide a valuable quality control
tool for final bead shape87; C13-NMR to accurately quantify specific M, G and MG composition
in filtered alginate177. The cumulative information of these techniques will evaluate the
composition of analytical grade alginate in terms of both particulate and molecular scale
contaminants, as well as vital compositional information.
Most groups who have in-house alginate purification methods require improvement in
biocompatibility for encapsulated cell transplantation, often reporting changes to alginate
properties as a consequence of lengthy complicated purification techniques86,175-178. The Liver
Group BAL has two distinct advantages over alginate transplantation: the BAL is not directly in
contact with cellular components of the immune system, so some of the biocompatibility issues
may be alleviated; the treatment time is for 8 hours, as opposed to up to 12 months for some
alginate encapsulated cell transplantations176. As a result, if the composition and contaminants
of alginate can be controlled and shown to be biocompatible, regulatory compliance may be
attainable despite the presence of higher contaminants compared with other biomedical
applications.
The Next Chapter will focus on detection methods for DNA and endotoxin in the context of the
BAL system, with specific attention to validating the protocols where appropriate for future use
for as analytical methods.
Page 115
Chapter 4Quantification ofBAL BiologicalContaminants
This Chapter details different methods for DNA
and Endotoxin detection in human plasma, for
use with the Liver Group BAL system.
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4. Quantification of BAL Biological Contaminants
4.1 Introduction
Biological contaminants within the BAL system, will originate primarily from the biomass in
the form of cell debris DNA and endotoxin from the system. Although much more of the
endotoxin is likely to originate from the patient119,184. In order to develop methods of removing
such contaminants methods were developed to quantify them in the BAL context.
4.1.1 Detection of Cell Debris
The importance of preventing foreign cell fragments from passing into a patient has been
clearly defined, cellular debris in the form of cell membranes as well as fractions of cell
organelles, have been shown to cause an immune response185. Therefore, avoiding HepG2 cell
debris from entering the patient during BAL treatment has become an important stipulation, in
terms of asserting the safety and efficacy of the system and in gaining regulatory market
approval77,186. Currently the large scale BAL system utilises a 200µm meshes prevents transit of
alginate bead and large alginate and cellular fragments from the fluidised bed to the patient.
With the use of charged depth filters described in later chapters, cell fragments down to 0.3µm
should be retained by the filter187,188.
4.1.2 DNA Contamination
4.1.2.1. Detecting DNA in BAL Plasma
For the purposes of detecting DNA in the BAL system, QPCR can be used to determine total
DNA levels. Two potential approaches for quantitative polymerase chain reaction of genomic
DNA (qPCR) analysis in human plasma could be used: detecting DNA based on primers
specific for a gene locus, as used to detect Tuberculosis by primers specific for the
MBP62107,189; or targeting primers for repeating genetic elements such as Alu repeats148. If the
principle of QPCR using a primer specific to a particular gene locus is applied to measuring
total DNA, sensitivity may be compromised as only DNA with the specific gene will be
amplified. Alternatively, detecting repeating genetic elements are found in large numbers across
the genome increasing the probability of a DNA fragment containing the element, such as Alu
repeats.
Another approach could utilise the ability for fluorescent molecules such as Hoechst dye or
Picogreen, to indiscriminately bind DNA <200bp and <500bp, respectively. It may provide
greater accuracy, as DNA amplification by QPCR requires the presence of a consensus
sequence94,148,190.
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4.1.2.2. Alu Repeat QPCR to Determine DNA Integrity
A way of quantifying DNA in plasma for diagnostic purposes was developed by Umetani et al.
who measured cfcDNA (cell free circulating DNA) for diagnosis of Colorectal or Periampullary
Cancers, both associated with necrotic cell death148. The concentration of cfcDNA from
apoptotic and necrotic cell death were determined in separate reactions, to provide a measure of
necrosis from the carcinoma. The ratio between background apoptotic cfcDNA and carcinoma
necrotic cfcDNA was referred to as DNA integrity reflecting the ratio between the two and was
calculated using Equation 4-1:
Equation 4-1: DNA integrity = Q247/ Q115
Where DNA integrity (dimensionless) is equal to DNA concentration of DNA from necrotic cell
death, Q247 (ng/ml) divided by total DNA, Q115 (ng/ml).
Total DNA was determined using a primer set specific for a 115bp stretch of the Alu repeat
consensus sequence, amplifying DNA from apoptotic cell death containing the 115bp sequence
(apoptosis truncating DNA to 180-200bp in length). DNA from necrotic cell death (truncated to
>300bp in length) was amplified using a primer set specific for a 247bp stretch of the Alu
consensus sequence, only binding to DNA containing the entire sequence. Equation 4-1 reflects
the ratio between these concentrations.
The Alu repeat Gene
The primers were based on Alu tandem repeated genetic elements, making up around 10.8% of
the human genome numbering over 1,179,211 copies in total. Alu repeats are found
ubiquitously across the primate genomes as illustrated in Figure 4-1A191. Alu genetic elements
comprise three evolutionarily based subunits all with a 282bp conserved consensus sequence,
although 6 other abundant subfamilies also exist191-197.
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4.1.2.3 QPCR method Validation
Choosing the appropriate validation methods for an analytical method depends upon the specific
requirements of the situation. Further discussion regarding the wider implications of specific
validation criteria and requirements for regulatory compliance will be made in the Discussion
Chapters. For the purposes of creating a QPCR method, which is fit for purpose, reliable and
robust in detecting DNA in human plasma for pre-clinical and clinical trials, the focus was on
precision, DNA recovery, robustness, linearity, and sensitivity.
Precision is defined as being the closeness of agreement between independent measurements,
obtained under stipulated conditions198. It is important that the samples go through the entire
testing procedure (from collection, purification, and analysis) performed on identical samples,
providing measure of sample spread and the highest and lowest points. Crucially the precision
of data does not reflect trueness, which is the closeness of data in relation to a reference
standard. Measurement of precision relies on the coefficient of variance (CV), defined by the
standard deviation divided by the mean of the results expressed as a percentage. The greater the
CV figure is, the lower the constitutive precision of the results are199.
A measure of precision utilises repeatability analysis, which uses the same analyst, instrument
laboratory, over a short period to show the constitutive error within the method, expressing as
precision. As a result a measure of random variability in the more specific manner is obtained.
Figure 4-1: Alu repeat repetitive
elements are found ubiquitously
across the primate genome
originating from three main
evolutionary subfamilies. A;
Analysis of the human genome
project sequence by bioinformatics
PERL programme showed Alu
repeat sequences ubiquitously
across the genome. B; Analysis
using the same program revealed
the three main subfamilies and
further subdivisions of Alu repeat
family. Obtained from Grover
et.al191.
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A measure of precision (used in this chapter) was reproducibility that reflects variation using the
identical method and samples under different conditions. This measure of precision was
evaluated for two reasons: to confirm the effects of changing the QPCR conditions; to provide
information for further validation if the method is transferred to a certified analytical laboratory.
Recovery was one of the most important parameters measured due to the relatively low levels of
DNA in large volumes of plasma. If DNA loss was incurred from purification or extraction of
the sample, then the method may not provide the sensitivity necessary for regulatory
compliance103. Recovery analysis usually involves the addition of an analyte to a representative
sample put through the purification and analytical process, for evaluation against the original
amount added, expressed as a percentage.
Sensitivity is usually defined as the lowest level of analyte that can be measured, but can vary
depending on the field in which the term is applied199. In the context of the QPCR, the
sensitivity is defined as the lowest quantifiable DNA concentration or the limit of quantification
(LoQ). Therefore the lowest DNA concentration that could yield a meaningful repeatable result
was used.
4.1.3 Endotoxin Contamination
Quantification of endotoxin in plasma provides many challenges; many of the components of
plasma will inhibit the reaction, including heparin, divalent cationic proteins, Penicillin.
Dilution of plasma has been shown to reduce the interference of the substances mentioned,
followed by heating which also causes release of protein bound endotoxin increasing the
sensitivity of the endotoxin assay200.
4.1.3.1 Determination of Endotoxin
In order to determine the level of Endotoxin removal by any quality system, an appropriate
endotoxin assay was developed as described in Methods Section 2.6 and tested in Section 0. The
sensitivity of the endotoxin assay was determined by using a zero calibrator, where a negative
sample was repeated, calculating the mean and standard deviation of the fluorescence unit. The
LoQ was established as the mean value + 10 x the standard deviation, using the lowest
quantifiable endotoxin level that is above this figure199.
4.1.4. Small BAL Scale Model
The scale BAL model detailed in Methods Section 2.3 served as a means of establishing
contaminant levels in sufficient numbers to gain statistical power. During the large scale BAL
treatment phase, the chamber (which holds the biomass) and tubing are primed with plasma,
from healthy patients. Accordingly, during the first part of treatment, plasma from healthy
patients will be continually diluted with plasma from the ALF patient. Therefore, testing
alginate encapsulated HepG2 cells over 8 hours in undiluted plasma from an ALF patient,
presents a worst case scenario for the large scale BAL system.
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The plasma used in the scale model was tested by the Royal Free Clinical Biochemistry
laboratory to confirm the characteristic ALF and healthy plasma markers, shown in Figure 4-3.
4.1.5 Defining Characteristic Plasma Markers and Parameters
4.1.5.1 Plasma from Patients with Liver Failure
One treatment for ALF patients is therapeutic plasma exchange126., where the patient’s plasma is
replaced with healthy plasma. We have exploited this opportunity to acquire large volumes of
human ALF plasma by storing the “waste” plasma at -20°C until required. To confirm the
extent of ALF diagnostic markers, described below, for liver failure, were measured by the
clinical biochemistry department at the Royal Free Hospital.
Alkaline Phosphatase
Alkaline phosphatases are a group of enzymes found in a wide variety of tissue, particularly
concentrated in Liver, bile duct, kidney and bone. They hydrolyse a number of organic
phosphate esters into inorganic phosphates and organic radicals. A low level of alkaline
phosphatase is an indicator of fulminant Wilkinson’s disease or severe liver disease where liver
function is severely comprised32,203.
Alanine transaminase
Amino transaminases are a group of enzymes involved with amino acid synthesis by
transferring amine groups. Alanine transaminase is a cytosolic enzyme predominantly found in
the liver. Hepatotoxicity leads to release into the blood and elevated levels, and due to the
relative localisation in the liver, it is a good indicator of liver damage32,203.
Albumin
Albumin is an important protein synthesised by the liver, a decreased level indicates failure in
liver synthetic function often associated with chronic liver disease. Due to the 20 day half-life of
albumin, validity of this test is reliant on the speed of liver failure onset32.
C - reactive protein
Acute phase proteins are a class of proteins mainly synthesised in the liver in response to
inflammation including: coagulation proteins (fibrinogen, prothrombin), transport proteins
(heptoglobin), complement proteins and C-reactive protein204. The extent of inflammation can
be determined by testing for C-reactive protein providing a measure of systemic inflammation32.
4.1.5.2 Fresh Frozen Plasma (FFP)
Fresh frozen plasma (FFP) is collected from blood donations under strict guidelines as to the
processing of the samples. Whole blood is routinely processed either by centrifuged at between
1000-2000rcf for 15 minutes or filtration to provide specified plasma parameters205:
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 Leukocyte depletion more than 99% with fewer than 5 x 106 with a 95%
confidence interval
 0.8% haemolysis as measured at the end of shelf life of plasma as part of
process validation
 Total protein >50g/L
 Platelet content < 30 x 109/L
 Red Cells < 6 x 109/L
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4.2 Methods
4.2.1 Small Scale BAL Models
Detail of the scale BAL model assembly was described in Methods Section 2.3.
Materials
 All materials, other than those stated below, are detailed in Methods Section 2.3, 2.3.1, 2.3.2,
2.3.3 and 2.3.4.
4.2.1.1 Small Scale BAL Model with Plasma from Healthy and ALF Patients
Materials
 Healthy plasma in the form of pooled FFP (Fresh Frozen Plasma)
o Same addition as in Methods Section 2.3
o Four units of Rhesus negative blood group B plasma were pooled totalling 1072ml
 ALF Plasma from TPE (therapeutic plasma exchange)
o Same addition as detailed in Methods Section 2.3
o Rhesus positive, blood group A
The viability and function of alginate encapsulated HepG2 cells were tested in both plasma from
healthy and ALF patients. Prior to addition to the scale BAL system, characteristic markers for
ALF, as outlined in Section 4.1.5, were tested in both types of plasma by the Clinical
Biochemistry laboratory at the Royal Free Hospital (Appendix V). After which, 50ml plasma
aliquots were made of both plasma types for immediate freezing at -80°C, in order to use the
same plasma conditions across experiments.
HepG2 cells were encapsulated using the large scale JetCutter® encapsulation system, and
cultured in the large scale bioreactor as described in Methods Section 2.1.3. To each column
5ml of beads was added to a total plasma volume of 80ml held in the column and reservoir, for
8 hours of perfusion. Each plasma condition was in duplicate (four columns in total) for each
large scale encapsulation, repeating with five sets of beads. Total viable cell numbers were
determined using FDA and PI staining (Methods Section 2.1.3.4) and total cell number using a
Nucleocounter (Methods Section 2.1.3.3) at the beginning and end of each 8 hours experiment.
4.2.1.2. Small Scale BAL with Different Flow Velocities
Materials
 Volumetric Flask
 10 Channel Watson-Marlow® pump
 Plasma
 Silicone tubing
 Greater details in Methods Section 2.3
HepG2 cells were encapsulated using the Inotech® microencapsulator and placed in static
cultured over 14 days, as described in Methods Section 2.1.2.5. With each encapsulation, six
columns were assembled with duplicates for each of the three flow velocities created, using
three different bore sizes of pump tubing, 2.79mm, 1.52mm and 1.14mm.
Page 123
Chapter 4 Quantification of BAL Biological Contaminants Discussion
Initially, the ten-channel pump was calibrated with plasma from healthy patients using the
2.79mm bore size tube to convert pump RPM to volumetric flow rate (mlmin-1). The volumetric
output was measured by disassembling the lower end of the column, in a sterile tissue cabinet,
and measuring the flow over time, using a volumetric flask. Following this, the volumetric flow
rate at a fixed RPM for the 1.52mm and 1.14mm bore size tubing were measured in the same
way, giving a flow rate ratio between the 2.79mm and 1.52 and 1.14mm tubing. Whilst
reassembling the columns, 5ml of beads were added to each column making up to a total
volume of 80ml in the system by supplementing the reservoir as described in Methods Section
2.3.
The large scale BAL system uses a volumetric flow rate (mlmin-1) that propagates a 2-fold bead
bed height. The flow velocity (linear flow rate) was determined for the large scale BAL using
the calculations in Methods Section 2.3.4. The volumetric flow rate (mlmin-1) for the columns
fed by the 2.79mm pump tubing was set to produce a 2-fold bed height, then the corresponding
flow velocity (ms-1) was calculated, illustrated in Table 4-4. The ratio calculated for the
different volumetric flow rates between the 2.79mm and the 1.52mm and 1.14mm bore size
tubing, was used to calculate the flow velocity (ms-1) for the smaller pump tubing (Table 4-12).
4.2.1.3 Scale BAL Experiment for Cell debris
Materials
 Acute Liver Failure Plasma
 Phase Contrast Microscope
 PBS (Methods Section 2.1.1.1)
 16mM EDTA
HepG2 cells encapsulated using the Jetcutter® system then grown in a fluidised bed for 12 days,
was tested in the small scale BAL system (Methods Sections 2.3). Plasma from an acute liver
failure patient was used to perfuse beads over 8 hours, taking samples from the bottom of the
reservoir for analysis using FDA and PI staining (Methods Section 2.1.3.4) to determine cell
viability of any intact cells which may have escaped from the biomass.
Sample Preparation to Visualise Intact Cells
Each plasma sample was placed in a 2ml microfuge tube for centrifuged at 1200g at 4°C for 6
minutes. Discarding the plasma, 1.5 ml of PBS was added to the microfuge tube, then pulse
vortexed for 15 second to re-suspend the pellet. Following this, the solution was centrifuged as
before, discarding the supernatant and replacing with 1.5ml of 16mM EDTA, again pulse
vortexed to re-suspend the pellet and incubated at room temperature for 10 minutes, finally
centrifuging as before and re-suspending in 1ml PBS. A volume of 250µl cell suspension was
then ready for analysis using FDA and PI staining as detailed in Methods Section 2.1.2.4.
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4.2.2. Encapsulated HepG2 Cell Number
The total cell number in the reservoir of the BAL scale model after 8 hours of perfusion with
plasma from an ALF patient was determined using a haemocytometer as described in Methods
Section 2.1.1.1.
4.2.3. QCPR Validation
The QPCR protocol described in the Methods Section 2.2.4 was used to determine total DNA in
media and plasma samples as well as evaluating DNA integrity. Aspects of method validation
were performed to ensure that the protocol could be utilised for pre-clinical and clinical testing.
4.2.3.1 Recovery Analysis
Recovery analysis involved spiking representative plasma or media samples with DNA, then
determining concentration by Alu repeat QPCR after purification (as detailed in Methods
Section 2.3.3) to ensure DNA recovery was not significantly affected. Untreated samples were
concurrently analysed by QPCR to quantify the extent of inhibition or enhancement from
components within the sample.
4.2.3.2. QPCR for Recovery Analysis with Spiked Media and Plasma Samples
Materials
 100 µg/ml DNAse
 Alpha MEM media (PAA)
 Certified Human Genomic DNA (Bioline®)
Protocol
FFP Plasma or Media supplemented with 10% FFP (made as detailed in Methods Section
2.1.1.1), were made into 2ml aliquots for storage at -80°C. To remove background DNA, media
and plasma aliquots were treated with a final concentration of 100µg/ml of DNAse I at 37°C for
4 hours, then to deactivate DNAse, heated at 70°C for 10 minutes. Following this, top DNA
standards of 20pg/µl in media or plasma made by adding 20µl of 2ng/µl (1/100 dilution of the
certified DNA stock certified in PCR water, appendix III), then serially diluting the top media or
plasma standard with the same batch of media or plasma, to create identical final DNA
concentrations to the DNA standards in water. A 20µl sample from each media or plasma
standard concentration was treated using the purification protocol (outlined in Methods Section
2.2.4), also taking a corresponding set of samples to store on ice as the untreated samples. After
treatment, DNA standards (in water), treated and untreated samples were analysed by QPCR as
outlined in Methods Section 2.2.4.3.
Each sample was analysed in triplicate, with a total of five standard curves in media or plasma
and water in separate QPCR runs, with both primers specific for 247bp and 115bp replicons.
The data for the standard curves in water and media were pooled to provide a measure of
variance, for comparison of recovery.
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4.2.3.3. DNA Extraction from Apoptotic and Necrotic Cell Death
Materials
 Supplemented Alpha MEM media, Methods Section 2.1.1.1.
 6 well culture plates (Falcon™).
 T80 Cell Culture flask (Thermo® Nunc®)
 1µM staurosporine (Sigma-Aldrich®)
 HepG2 Cells
Cell culture
HepG2 cells were cultured in an 80cm2 flask as described in Methods Section 2.1.1.1 over 7
days, then harvested by trypsinisation and re-suspended in media at a seeding density of 5.0 x
105cells/ml with supplemented media. Two Falcon™ 6-well plates were used adding 2ml of the
cell suspension to each 9.6cm2 well, totalling 1x106 cells in each well. The plates were cultured
for 2 days; on the second day the media on one plate was replaced with 1ml fresh media
containing 1µm staurosporine, cultured for a further 18 hours, after which cells were harvested
and passed through a 27 gauge syringe to break up the cell clumps. The second plate was
replenished with 1 ml fresh media, immediately transferred to a -80°C freezer overnight,
removed and allowed to thaw at room temperature for 2 hours; these steps were repeated three
time to encourage apoptotic cell death. The media was then removed and treated as part of the
PCR purification protocol (Methods Section 2.2.4) for direct addition as a template to QPCR.
4.2.4 Caspase-GLO® Assay
Materials:
 Caspase 3/7 GLO kit (Promega G8091)
 Serum- and phenol red-free media
 White-walled plates
 Luminometer
Apoptosis is a tightly controlled process, occurring in response to environmental stresses via the
intrinsic pathway, or activation of external cell receptors through the extrinsic pathway. Both
the intrinsic and extrinsic pathways activate Caspase 3/7, which then go on to cleave other
proteins with the DEVD amino acid sequence (Aspartic acid (D), Glutamic acid (E), Valine
(V)). The activation of apoptosis can be quantified using the DEVD sequence engineered to
instigate a luminescent signal when cleaved by Caspase 3/7, as shown in Figure 4-2.
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Protocol
Sufficient reagent was made for the assay by adding equal volumes of the Caspase-GLO®
Buffer to the Caspase-GLO® Substrate to make the Caspase-GLO® reagent, allowing it to
equilibrate to room temperature. A volume of 100µl of Staurosporine-treated cell suspension
was added to a 96- well plate and again allowed to equilibrate to room temperature, to providing
2.0 x 105 cells per well. To this 100µl of Caspase-GLO® reagent was added and mixed on a
shaker at 300-500rpm for 30seconds, followed by incubating at 37°C for 1 hour. A 100µl
sample from each well was transferred to a white walled 96-well plate and analysed using the
luminometer.
4.2.5 Glucose and Lactate Quantification by Analox®
Material
 Analox® GM7 Direct Glucose and lactate analyser
 MilliQ treated RO H2O
 Glucose oxidase reagent (Annalox®)
 Lactate oxidase reagent (Annalox®)
 8mM Glucose Standard (Annalox®)
 8mM Lactate standard (Annalox®)
The Analox® GM7 analyser works by exposing the sample to glucose or lactate oxidase, which
consumes oxygen at a rate that is proportional to the concentration of analyte. Initially, all
reagents were allowed to warm to room temperature. The glucose-oxidase reagent was added to
the reagent reservoir, priming the system with reagent by running 6-8 analytical cycles. Using a
positive displacement pipette 10µl of 8mM glucose standard was analysed, and repeated until
the reading was ± 0.2mM of the 8mM standard. Prior to each sample addition, the positive
displacement pipette and the Analox® system were flushed with MilliQ treated H2O.
Figure 4-2: Caspase-3/7 cleavage of the luminogenic substrate containing the DEVD
sequence. Following Caspase cleavage, a substrate for luciferase (aminoluciferin) is
released, resulting in the luciferase reaction and the production of light monitored on a
luminometer206.
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The same protocol was used for lactate analysis, using lactate-oxidase reagent and an 8mM
lactate standard.
4.2.6. Preparation of Fresh ALF Plasma.
Materials
 Citrated blood collection vials
The tubes containing whole blood from normal and ALF patients were centrifuged at 1200g for
10 minutes at 4°C. The plasma supernatant was removed and carefully aliquoted into 2ml
microfuge tubes for immediate freezing at -80°C. The blood cells were also frozen for DNA
extraction as in Methods Section 2.2.1.
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4.3. Results
4.3.1. Determination of Liver failure and Healthy Plasma
Both Plasma from acute liver failure (ALF) and healthy patients, used in subsequent
experiments, were tested by the Royal Free Hospital Clinical Biochemistry Diagnostic
laboratory to confirm characteristic parameters associated with ALF and healthy patients.
Alkaline phosphatase (ALP) and aspartate transaminase (AST) at the levels shown in Figure 4-
5A and C were indicative of liver damage, being associated with Hepatic cells. Low levels of
ALP suggested a breakdown of liver function causing a reduction in synthesis, whereas high
levels of AST were suggestive of Hepatotoxicity, causing release from the intracellular
environment of the hepatocyte into the blood. Both these proteins are indicative of ALF but not
definitive, as AST is also found in skeletal muscle, and ALP is present more ubiquitously32.
High alanine transaminase (ALT), shown in Figure 4-5B, provided definitive evidence of
supporting ALF, due to exclusively being an intracellular hepatic transaminase, uniquely
synthesised by hepatic cells, therefore release into the blood stream only occurs during liver
damage. Along with ALP and AST concentrations, ALF was confirmed.
Further confirmation of ALF was provided by low albumin in Figure 4-3D suggesting inhibition
of synthesis due to liver damage. Systemic inflammation due to liver failure as illustrated by
elevated C-reactive protein shown in Figure 3-5E. Plasma from healthy patients were all within
normal levels.
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patients. A; Alkaline phosphatase, normal
physiological range is between 35-129U/L. B;
Alanine Transaminase (ALT), normal
physiological range is 5-31U/L. C; Aspartate
Transaminase (AST), normal physiological
range 5-31U/L. D; Albumin, normal
physiological range is 35-129 g/L. D;
phosphate, normal physiological range is 0.87-
1.45mM. E; C-reactive protein, normal
physiological range is between 0 – 5mg/ml.
Plasma pooled from 3 patients.
A B
C D
E
Page 130
Chapter 4 Quantification of BAL Biological Contaminants Discussion
4.3.2 Cell Debris in the BAL System
Cellular contamination from the biomass, as a direct result of fluidisation in plasma, was
quantified by fluidising beads with healthy human plasma as part of a scale BAL model. The
beads contained 56 x 106 ±11x6 cell/ml, giving a total cell number of 280 x 106 cell/ml. Plasma
samples taken from the bottom of the scale BAL system reservoir, after 8 hours of perfusion,
were analysed using FDA PI staining, (described in Section 0,) showing intact viable and non-
viable cells ( ).
Size of cell fragment 10µm± 4µm
Viable Cell
Concentration
4 x 103± 3x102cells/ml
Non-viable cell
concentration
6.2 x 103± 1.2 x 103/ml
The cell numbers above, form part of the contamination risk to the patient, it does not account
for cells having already undergone apoptosis or necrosis and released DNA into solution, as
plasma samples are taken from a sample port attached to the inlet of the reservoir.
4.3.3. Detection of DNA in Plasma
4.3.3.1 Theoretical calculations for expected DNA Concentration
A theoretical calculation was made to assess the potential DNA release from the BAL treatment
phase, using the assumption that cell death is proportional to DNA release. This provided
information for the DNA quantity the quality system may encounter and the potential LoQ
necessary for the associated detection system; calculating according to mass of DNA in a single
cell207 and predicted cell number given in Table 4-1.
 6.64 x 10-12g ± 0.43 DNA in a Diploid cell207
 Proposed BAL cell number between:
 7 x 1010 and 1 x 1011 HepG2 cells,
Table 4-1: Cells escaping the beads in the small scale BAL model. Both viable
and non-viable cells escaped from the fluidised bed and were detected in
samples taken from the reservoir of the column experiment after 8 hours
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BAL Condition BAL with 7x1010 cells BAL with 1 x 1011 cells
Total DNA contained in
Biomass (µg)
4.6 x 105 6.6 x 105
DNA concentration in 3.5L
Human Plasma (µg/ml)
133 190
DNA concentration in 7L
Human Plasma (µg/ml)
66 95
DNA concentration in 10L
Human Plasma (µg/ml)
47 66
DNA concentration with 10%
cell death in 7L Human Plasma
(µg/ml)
7 10
DNA concentration with 1% cell
death in 7L (µg/ml)
0.7 0.9
According to the calculations of cell death and DNA release, (assuming cell death is
proportionate to DNA release) illustrated in Table 4-2, a 1% reduction in cell viability would
release 0.7µg/ml DNA. Furthermore, to detect DNA from greater cell death, samples may need
to be diluted to be within the standard curve range.
4.3.4. Fluorescence DNA Quantification by Hoechst Dye
Assessment of fluorescent DNA staining by Hoechst dye, utilised a nine point standard curve in
water (Figure 4-4A), then comparing increased plasma dilutions to minimise any interfrence
from plasma componnents, such as proteins. At 1% plasma concentration and below, a standard
curve comparable to water was produced in terms of linear regression, although at lower DNA
concentrations signal enhancement was observed (Figure 4-4B).
Table4-2: Theoretical calculations of DNA concentration within the BAL treatment
phase with different cell numbers and total BAL volume, using the assumption that 1
cell contains 6.64 x 10-12 ± 0.43g DNA207 and that cell death is proportional to DNA
release.
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Calculating Hoechst Dye performance for a Large Scale BAL
By diluting plasma to 1%, the LoQ was 0.078µg/ml DNA. This is equivalent to 7.8µg/ml LoQ
in 100% plasma. A BAL system with 7 x 1010 cells would contain a total DNA content of 4.6 x
105µg, with a DNA concentration of 46µg/ml in 10L plasma, requiring a reduction of 17%
viability before reaching the LoQ of 0.078µg/ml. Table 4-3 illustrates the theoretical change in
viability neccessary to provide sufficient DNA to meet the LoQ in different BAL sizes.
Cell Number
in BAL
Total Cellular
DNA (µg)
DNA in
3.5L
Plasma
(µg/ml)
% Cell
Death
Detectable
DNA in 10L
plasma (µg/ml)
% Cell
Death
Detectable
7 x 1010 4.6 x 105 133 6 46 17
1 x 1011 6.6 x 105 190 4 66 12
y = 5.7424xR² = 0.9988
0510
152025
3035
0 1 2 3 4 5Fluore
scence
Units(
x104 )
DNA Concentration (µg/ml)
Hoechst Dye DNA
Analysis in water y = 9.5557xR² = 0.9789
01020
304050
60
0 1 2 3 4 5Fluore
scence
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x104 )
DNA concentration (µg/ml)
Hoechst Dye DNA Analysis
in 1% plasma
Figure 4-4: Plasma proteins caused inhibition of Hoechst dye DNA analysis,
despite substantial dilution to improve linearity using a nine point DNA standard
curve between 0 – 5µg/ml, analysed by Hoechst dye. A; Standard curve in water.
B; standard curve in 1% Plasma. (N=5 for each point, error=standard deviation ).
Table 4-3: Assuming that cell death causes complete DNA release, the viability of DNA would
have to drop between 4 - 17% to reach the LoQ of Hoechst dye assay, dependent on the
plasma volume and cell number. These figures were based on 6.64 x 10-12 ± 0.43g DNA207 .
A B
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4.3.5. DNA Quantification by QPCR
4.3.5.1 PCR Analysis by Gel Electrophoresis for Primer Optimisation
Initial PCR optimisation involved confirming the expected 115 nucleic acid base pairs (bp) and
247bp amplicon size at decreasing DNA template concentrations, by gel electrophoresis
(Methods Section 2.2.4).
4.3.5.2 QPCR Method Development
Standard Curve
For both the 115bp and 247bp replicon primer sets, a 5 point Real Time Quantitative PCR
standard curve was optimised for the conditions stated in the Methods Section 2.2. This
included optimisation of primer and MgCl2 concentration as well as establishing the limit of
quantification (LoQ), producing the standard curves illustrated in Figure 4-6A and B.
Figure 4-5: Reducing template concentration caused a reduction in non-specific PCR
amplification, using primers specific to 115bp and 247bp Alu repeats consensus
sequence Methods 2.2.3. A; 115bp Alu repeat amplicon, with decreasing DNA
concentration. B; 247bp Alu repeat amplicon, with decreasing DNA concentration.
A B4,500 450 45 4.5 0.45 0.045 H2O 4,500 450 45 4.5 0.45 0.045 H2O
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4.3.5.3. Confirmation of Melt curve
Initial confirmation that the QPCR melt curve corresponded to the correct product size, analysis
of the QPCR product was analysed on a 1% electrophoresis gel as illustrated in Figure 4-7. The
QPCR melt curve reflects the unique temperature that the QPCR amplicons dissociate into
single stranded DNA. This was used to confirm the correct replicon amplification, removing the
necessity to analyse each QPCR by electrophoresis. A melt curve peaking at 90.5°C melting
temperature matched with the 115bp amplicon size (Figure 4-7A and B) and the 87°C melt
curve matched with the 247bp amplicon (Figure 4-7C and D). In addition, some non-specific
DNA amplification was seen, especially in Figure 4-7 A, reflecting the numerous subfamilies of
Alu repeats in the human genome.
Figure 4-6: Optimised QPCR standard curves using Alu repeat primers. Amplifying from
human genomic DNA samples from 0.01pg to 100pg total DNA per reaction; DNA was
quantified using the threshold line providing a calculated measure of the most linear region of
amplification. Each sample was performed in triplicate A; primer set specific for the 115bp
Alu replicon. B; primer set specific for the 247bp Alu replicon.
A
B
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4.3.5.4. Efficiency of the PCR reaction
The efficiency and linearity of each DNA standard curve provided crucial information
confirming successful amplification. Equation 4.2 shows the method of calculating the
efficiency, from the gradient of the regression line presented Figure 4-8, comparing the result
with the ideal -3.32 to provide a percentage measure of efficiency.
Equation 4.2: Efficiency = 10(–1/slope) -1.
Figure 4-7: The QPCR DNA standards shown in Figure 4-6 also produced melt curves
as outlined in Methods Section 2.2.4, analysing the QPCR product on a 1% agarose gel
by electrophoresis, confirmed the amplicon size and the corresponding melting
temperature for each primer set. A; Agarose gel electrophoresis analysis of the 100pg
DNA standard, amplified by the 115bp Alu primer, showing some non-specific
amplification as expected. B; melt curve peaking at 90.5°C, of the 100pg DNA standard
amplified by the 115bp Alu primer C; Agarose gel electrophoresis analysis of the
100pg DNA standard amplified by the 247bp Alu primer. D; melt curve peaking at
87°C, of the 100pg DNA standard amplified by the 247bp Alu primer.
A
C D
B
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4.3.6. QPCR Validation
4.3.6.1. Repeatability
Repeatability provides a measure of constitutive variation to be expected within the protocol by
amplifying a single set of PCR standard concentrations, using identical: PCR machine, reagents,
consumables and location, all performed on the same day. The standard DNA template was also
kept constant using Human genomic DNA, certified both in purity and concentration (see
appendix IV). Table 4-4 shows the variation between standard curves using the mean value and
the standard deviation on 20 samples for each concentration performed over five runs.
y = -1.466ln(x) + 14.732R² = 0.999905
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y = -1.521ln(x) + 15.436R² = 0.999805
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Figure 4-8: The mean linearity and efficiency of the QPCR reaction was determined by
plotting the log of DNA template concentration vs. cT values, for each primer set. The
efficiency was determined from the gradient of the line using equation 4.2. Linearity was
evaluated using regression with n=20 for each sample. A; Regression line for the 115bp
replicon primer, with a linearity of 0.9999 and efficiency of 106±1.2%. B; Regression line for
the247bp replicon primer, with a linearity of 0.9998 and efficiency of 101±0.9%
A B
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DNA Template (pg)
Final DNA amount
in PCR reaction (pg)
100 10 1 0.1 0.01
cT for 115bp
amplicon
8.0±0.2 11.4±0.3 14.62±0.2 18.12±0.4 21.52±0.6
CV value (%) 2.5 2.6 1.4 2.2 2.8
cT for 247bp
amplicon
8.47±0.4 11.9±0.4 15.46±0.4 18.83±0.5 22.52±1.1
CV value (%) 4.7 3.4 2.6 2.7 4.9
4.3.6.2. Reproducibility
Reproducibility provides a measure of the extremes in precision when transferring the technique
between PCR thermocyclers, analysts, PCR facilities, and over time. Consequently, the identical
protocol and PCR samples were used with three PCR thermocyclers (including the in house
Liver Group RotorGene® 3000 thermocycler used for all subsequent experiments) with different
analysts, performing the analysis over the course of a year. Each standard sample was
performed in triplicate as part of a 5 point standard curve, performed four times on three
separate PCR machines then a year later the protocol was repeated with the same samples, kept
at -80°C.
The standard curves produced on a single thermocycler (Rotorgene® 3000) in Table 4-4 were
compared with the mean of standard curves produced by multiple analysts, on different
thermocyclers, as illustrated in Table 4-5. A paired student’s t-test was used to compare
standard curves for each primer set. The primer set for the 115bp replicon performed on
different thermocyclers showed a significant difference (p= 0.04, n=60). Whereas, when
comparing standard curves using the primer set for the 247bp replicon performed on different
thermocyclers, there was no significance between the means (p=0.99, n=60).
Both Repeatability and reproducibility analysis used the same standard curve DNA samples,
incorporating the results from that experiment with those obtained from the two other PCR
Table 4-4: The repeatability of the DNA standard curves, performed using identical DNA
standards samples (diluted from certified DNA stock, shown in appendix IV), on the same
PCR machine, with identical reagents and consumables, analysed on the same day. Four
standard curves, with triplicate samples, were performed simultaneously in one run, with
five runs in total (n=60 for each standard reaction). For each DNA concentration the % CV
value illustrated the indicated the level of constitutive error.
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machines, analysts, and laboratories. In total 180 samples were performed for each standard
concentration. With Thanks to Dr Amy Thomas and Dr Miguel Centelles for providing the
“other” analysts.
DNA Template (pg)
Final DNA amount
in PCR reaction
(pg)
100 10 1 0.1 0.01
cT for 115bp
amplicon
8.1±0.4 11.62±1.0 14.8±0.9 18.7±1.2 22.2±2.2
CV Value (%) 4.9 8.6 6.1 6.4 9.9
cT for 247bp
amplicon
CV Value (%)
8.1±1.2
14.8
11.5±1.5
13.0
15.48±1.3
8.4
19.3±1.1
5.7
22.7±1.1
4.8
4.3.6.3. Effect of Changing the PCR Thermocycler
The data from Table 4-5 was further reanalysed to focus on the change in PCR thermocycler
using the same analyst. Therefore, for both 115bp and 247bp standard curves, the three PCR
thermocyclers were compared and analysed using a paired, two tailed student’s t-test as detailed
in Table 4-6.
Each standard sample was performed in triplicate as part of a 5 point standard curve, with four
standard curves performed on a single PCR run. The same standard concentration template was
used for five separate PCR runs totalling n=60 for each sample. In all cases there was a
significant difference between standards performed on different PCR thermocyclers, as shown
in Table 4-6.
Table 4-5: The same standard template samples were tested on different PCR
machines, by different operators in different laboratories, calculating the mean
and standard deviation between all standard curves. Each standard sample was
in triplicate, with each 5 point standard curve performed four times on three
separate PCR machines over a year. Four standard curves were performed
simultaneously on one machine at a time, with each machine being used twice
(n=180 for each standard concentration). The CV value reflects the level of error
from changing the PCR machine.
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DNA RG3000 RG6000 RG3000 RG6000
(pg) 115bp 247bp
100 8.0±0.2 8.6±0.4 8.5±0.4 9.1±0.4
10 11.4±0.3 12.3±0.3 11.9±0.4 12.8±0.5
1 14.6±0.2 15.7±0.7 15.5±0.4 16.7±0.7
0.1 18.1±0.4 20.1±0.8 18.8±0.5 20.6±0.4
0.01 21.5±0.6 24.6±0.9 22.5±1.1 24.0±1.0
P Value 0.0288 P Value 0.0035
The % CV value was calculated for each primer set on separate PCR machines, as illustrated in
Table 4-7. For each specific PCR machine the %CV was relatively low for both primer sets,
whereas when transferring the protocol between PCR machines there was a significant
difference in cT value as illustrated in Table 4-6.
DNA RG3000 Biorad® RG3000 Biorad®
(pg) 115bp 247bp
100 8.0±0.2 7.7±0.3 8.5±0.4 6.8±0.3
10 11.4±0.3 10.4±0.4 11.9±0.4 9.9±0.4
1 14.6±0.2 14.0±0.6 15.5±0.4 14.2±0.7
0.1 18.1±0.4 17.8±0.8 18.8±0.5 18.5±0.6
0.01 21.5±0.6 20.5±0.9 22.5±1.1 21.7±1.1
P Value 0.0165 P Value 0.0151
DNA RG6000 Biorad RG6000 Biorad
(pg) 115bp 247bp
100 8.6±0.4 7.7±0.3 9.1±0.4 6.8±0.3
10 12.3±0.3 10.4±0.4 12.8±0.5 9.9±0.4
1 15.7±0.7 14.0±0.6 16.7±0.7 14.2±0.7
0.1 20.1±0.8 17.8±0.8 20.6±0.4 18.5±0.6
0.01 24.6±0.9 20.5±0.9 24.0±1.0 21.7±1.1
P Value 0.0158 P Value 0.001
Table4-6: QPCR amplification for primers
specific to the 115bp and 247bp replicon
show significant difference at 95%, between
the Liver Group Rotorgene 3000 and the
other PCR machines tested. All standard
curves were performed by the same analyst,
with 4 standard curve on each PCR run,
repeating the run 5 times with the same
original DNA standard template (n= 60).
A B
C
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RG3000® RG6000® Biorad®
DNA standard
(pg)
CV 115bp
(%)
CV 247bp
(%)
CV 115bp
(%)
CV 247bp
(%)
CV 115bp
(%)
CV 247bp
(%)
100 2.5 4.7 4.6 4.4 3.4 4.4
10 2.6 3.4 2.4 3.9 3.8 4.0
1 1.4 2.6 4.6 4.2 4.3 4.9
0.1 2.2 2.7 3.9 1.9 4.5 3.2
0.01 2.8 4.9 3.6 4.2 5.1 5.1
4.3.7 Recovery of DNA from Spiked Media and Human Plasma Samples
4.3.7.1. DNA Recovery from Media
DNA recovery was measured to evaluate the level of inhibition or enhancement incurred by
addition of raw media to the PCR reaction, and to determine the difference between standards in
water and treated samples, prepared as outlined in Section 4.2.3. For primers specific to the
115bp amplicon, the mean DNA recovery of treated samples was 98.8±2.4%, whereas untreated
samples showed an average DNA recovery of 62.8±36.2%, shown in Table 4-8. DNA recovery
for the primer specific to the 247bp replicon showed a mean 101±3.55% recovery after
treatment, with a 58±41.85% recovery before treatment.
Table 4-7: CV values for both 115bp and 247bp replicon primers performed on different
PCR machines.
Page 141
Chapter 4 Quantification of BAL Biological Contaminants Discussion
Standards
(pg)
Treated Media (pg) %
recovery
Un-treatment
Media (pg)
%
Recovery
100 101±4 101 89±10 89
10 9.88±1 99 6.7±2 67
1 0.96±0.3 96 0.85±0.2 85
0.1 0.102±0.06 102 0.073±0.003 73
0.01 0.0101±0.003 101 0 0
Standards
(pg)
Treated Media (pg) % recovery Un-treatment
Media (pg)
%
Recovery
100 99±3 99 78±11 78
10 10.2±1 102 15±4 15
1 1.06±0.7 106 0.3±0.1 30
0.1 0.97±0.1 0.97 0.047±0.01 47
0.01 0.0103 ± 0.002 103 0.12±0.1 120
As illustrated in Figure 4-9, media added raw to the PCR reaction caused a mean inhibition of
21.5±10.2% across the standard curve. After medium samples were treated using the
purification protocol outline in the Methods Section 2.4 of the media, inhibition was reduced to
a mean 0.2±1.2%.
Table 4-8: Using the Primers specific for the 115bp replicon, treatment of media removed
inhibition and enhancement of the fluorescent signal as well as significantly reducing the
standard deviation of samples. Each sample was performed in triplicate over five PCR runs
alongside a standard curve (n=5).
Table 4-9: Using the Primers specific for the 247bp replicon, treatment of media
removed inhibition and enhancement of the fluorescent signal as well as
significantly reducing the standard deviation of samples. Each sample was
performed in triplicate over five PCR runs alongside a standard curve (n=5).
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4.3.7.2. DNA Recovery from Human Plasma
The same recovery protocol used with media was applied to human plasma for both primers
specific to 115bp and 247bp replicon. The application of untreated human plasma directly to the
PCR reaction showed greater inhibition than addition of untreated media, as illustrated in Table
4-10 and Table 10-11. Despite this, by treating plasma the mean recovery was restored to
98.8±3.27% for the 115bp replicon primer, and 101.5± 3.5% for the 247bp replicon primer
(Table 4-10 and 4-11).
Figure 4-9: Un-treated media containing 10% FFP added to the PCR caused 21±10.2%
inhibition. Treatment of the media prior to addition reduced inhibition to
0.2%±1.2%. Media samples were spiked to give the media and standards identical
final DNA final concentration (each sample n=3). Only the media samples spiked with
100pg DNA is shown above for clarity.
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Standards
(pg)
Treated Plasma (pg) % Recovery Un-treatment Plasma (pg) % Recovery
100 101±3 101 74±15 74
10 9.4±2 94 6.9±4 69
1 1±0.7 100 0 0
0.1 0.097±0.05 97 0 0
0.01 0.0102 ±0.009 102 0 0
Untreated plasma samples spiked with 1pg of DNA showed a lower cT value than treated
plasma with a 1pg DNA, producing the same cT value as 1pg DNA in water, illustrated in
Figure 4-10. In addition, untreated plasma with no DNA spike showed enhancement of DNA
signal showing DNA concentration of 1.2±0.98pg/µl compared with no DNA levels below the
LoD for treated plasma with no DNA spike.
Table 4-10: Using the Primers specific for the 115bp replicon, treatment of plasma
removed inhibition and enhancement of the fluorescent signal as well as significantly
reducing the standard deviation of samples. Untreated samples with 1, 0.1 and 0.01pg
DNA spike were inhibited to below the LoQ of the assay. Each sample was performed in
triplicate over five PCR runs alongside a standard curve (n=5).
Standards
(pg)
Treated Media (pg) % recovery Un-treatment Media
(pg)
%
Recovery
100 99±3 99 78±11 89.00
10 10.2±1 102 15±4 67.00
1 1.06±0.7 106 0.3±0.1 85.00
0.1 0.97±0.1 97 0 73.00
0.01 0.0.103 ± 0.02 103 0 0.00
Table 4-11: Using the Primers specific for the 247bp replicon, treatment of plasma
removed inhibition and enhancement of the fluorescent signal as well as significantly
reducing the standard deviation of samples. Untreated samples spiked with 0.1 and
0.01pg DNA spike were inhibited to below the LoQ of the assay. Each sample was
performed in triplicate over five PCR runs alongside a standard curve (n=5).
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4.3.8 DNA Integrity
DNA integrity provided a means of measuring the ratio of DNA from apoptotic and necrotic
cell death. Cells cultured in 6-well plates were treated with 1µM Staurosporine over 18 hours to
induce apoptosis or subjected to 4 freeze/thaw cycles between -80°C and 37°C to induce
necrosis. Then DNA was tested using the QPCR with the 115bp and 247bp Alu replicon
primers to assess the validity of the DNA integrity ratio.
4.3.8.1. Inducing Apoptosis and Necrosis
To ensure the cells had undergone apoptosis, pictures were taken under a phase microscope, as
illustrated in Figure 4-11, confirming using the Caspase GLO® assay on a sample of cells
treated with Staurosporine, shown in Figure 4-12.
Figure 4-10: Untreated plasma added to the PCR caused inhibition. Treatment of the
plasma prior to addition significantly reduced inhibition (as illustrated in Table 4-10
and Table 4-11). Plasma samples were spiked with DNA to give identical final
concentrations (each sample n=3). Error! Reference source not found.Only the plasma
samples spiked with 1pg DNA are shown above, for clarity.
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Figure 4-11: Inducing HepG2 apoptosis HepG2 cells cultured in monolayer were
treated with 1µM Staurosporine for 18 hours, showing apoptotic cell morphology. A;
HepG2 cells prior to addition of Staurosporine. B; HepG2 cells after 18 hours of
treatment with Staurosporine.
Figure 4-12: Caspase GLO® assay for apoptosis. Cells treated with Staurosporine showed a
significant increase in Caspase 3/7 activation, the negative control represents background
apoptosis of untreated HepG2 cells (n=5, unpaired t-test p<0.994).
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DNA Integrity from Apoptosis and Necrosis
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N.S P=0.7157egrity was determined in media (after purification) using the 115bp and 247bp replicon
to evaluate necrotic and total DNA concentration, as illustrated in Figure 4-7A. From
A integrity was calculated as described in Equation 4-1. The DNA integrity when
:1 DNA from necrotic and apoptotic cell death, increased from 1.7 x 10-3± 8.0 x 10-4 to
7, as shown in Figure 4-7A. There was no significant difference in total DNA
ation for DNA from both necrotic and apoptotic cell death (Figure 4-7B).
orst Case Scenario” Model to Confirm Upper Limit of DNA Standard Curve
for “worst case scenario” was developed to condition plasma by simulating complete
h, using the same beads to plasma ratio as the large scale BAL system, as outlined
Section 2.3.5. DNA concentration in the conditioned plasma was used to determine the
ndard curve for the Alu repeat QPCR.
lated HepG2 cell viability, was 95.6±2% immediately after harvesting (Figure 4-8A and
lume of 2ml beads in 40ml of plasma from healthy patients was incubated for 48 hours
under constant vigorous agitation, to achieve mechanical cell damage, causing a
n in viability to 26±6% (Figure 4-8C and D). The initial DNA integrity measured
tely after bead harvesting was 0.34±0.05 increasing to 0.48±0.07 after 48 hours
ning. This confirmed that DNA release from cells that underwent mechanical stress was
crotic cell death. In addition, total DNA concentration increased by 62.2ng/ml
ng that a loss in viability causes DNA release.
-13: Validation of DNA integrity. DNA integrity was calculated on DNA
d from apoptotic cell death with a mean DNA integrity of 1.7 x 10-3± 8.0 x 10-4.
grity of necrotic cell death showed a mean DNA integrity of 0.90±0.036. A 1:1
of DNA from apoptotic cell Death: DNA from necrotic cell death showed a
A integrity of 0.45±0.07. All conditions at n=5.
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DNA Integrity of Beads Before and After
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4.3.10. Determination of DNA Release using the Small Scale BAL Model
The small scale BAL system was used to measure the potential DNA release in the large scale
BAL treatment phase, indicating the amount of DNA a filter must remove. Plasma from both
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Figure 4-14: Mechanical damage of cell to induce necrosis. Encapsulated HepG2 Cells
incubated at 37°C for 48 hours in HEPES buffered plasma from healthy patients, under
constant agitation, showed decreased viability from 95.6±2% immediately after harvesting
to 26±6%. A; FDA stained beads immediately after harvest from the BAL growth phase. B;
pI Stained cells immediately after harvest from the BAL growth phase. C; FDA staining of
beads after incubation. D; pI staining of beads after incubation.
Figure 4-16: DNA integrity and total DNA for beads under mechanical stress (i.e. increased
DNA from necrotic cell death) concentration increased by incubating 2ml of encapsulated
HepG2 cells in human 40ml of plasma from healthy patients, over 48 hours, as outlined in.
A; mean DNA integrity of 0.34±0.05 with beads incubated in human plasma and 0.48±0.07
with beads freshly harvested from the BAL growth phase (n=5). B; Total DNA concentration
in plasma sampled at the end of 48 hours incubation compared with DNA in the plasma
immediately after adding the beads (n=5).
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ALF and healthy patients were used in the scale BAL system to show changes in viability and
DNA release. From this, DNA integrity was determined to assess the nature of DNA release
over treatment time. In addition, other parameters, such as glucose consumption and protein
synthesis, were determined to indicate the cause of cell death.
Five separate sets of encapsulated HepG2 cells and scale BAL models were used to gain
statistical power, making beads using the Jetcutter® encapsulator system and culturing beads in
the large scale growth phase. The mean cell density between experiments was 51.9 x 106 ± 1.12
x 106 cells/ml of beads (FBB 22, 26, 27, 30 and 32), where a volume of 5ml from each
encapsulation was used in each scale BAL model experiment, testing each plasma condition in
duplicate.
4.3.10.1. Perfusion of Beads in Plasma from Healthy and ALF Patients
Viable cell numbers were significantly reduced when perfused with plasma from the ALF
patients, from 51.9 x 106 ± 1.12 x 106 cells/ml of beads to 37.9 x 106 ± 2.2 x 106cells/ml of
beads (Figure 4-17). A two-tailed t-test showed a significant difference with p<0.0001 with
n=10 (error bars representing standard deviation). However, perfusion with plasma from healthy
patients showed no significant difference in viable cell number, (using a two tailed t-test
p=0.3674, n= 10, error bars representing standard deviation).
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Figure 4-17: viable cell number for encapsulated HepG2 cells, perfused with plasma from
ALF patients, reduced from 51.7x106 ± 2.2x106cells/ml beads to 37.9x106± 1.5x106cells/ml
beads. Perfusion with healthy plasma had no significant effect. A; ALF plasma caused a
significant reduction in viable cell number, paired t-test, n=10, P<0.0001, error bars
represent standard deviation. B; Plasma from healthy patients had no significant effect of
viable cell numbers, paired t-test, n=10, p=0.367, error bars represent standard deviation.
P<0.0001 P=0.367
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4.3.10.2. Glucose and Lactate Consumption as a Measure of Metabolic Activity
Glucose consumption by encapsulated HepG2 cells perfused with either plasma from healthy or
ALF patients showed no significant difference as illustrated in Figure 11A and B (Paired two
tailed t- test, p=0.1079, n=10). However, lactate levels in the same experiment were different
between plasma from healthy and ALF patients (paired two tailed t-test p=0.0058, n=10). This
result may be due to higher lactate levels in liver failure patients, causing the difference to be
attributable to higher background levels. The rate of lactate increase during the experiment was
not significantly different (regression analysis p=0.5914) Figure 4-11B.
4.3.10.3. AFP Production
Encapsulated HepG2 AFP production showed no significant difference between beads perfused
with either plasma from healthy or liver failure plasma, shown in Figure 4-12 (regression
analysis p=0.7633 n=10).
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Figure 4-11: Glucose consumption and lactate accumulation. No significant difference in
glucose metabolism was observed in beads perfused for 8 hours with either plasma from
ALF or healthy patients, (Paired, two way t-test, n=10, p=0.1079, error bars representing
standard deviation). Lactate levels were significantly higher in plasma from liver failure
patient compared plasma from healthy patient, (paired two way t-test, with n=10 giving,
p=0.0558, error bars representing standard deviation). The rate of lactate increase was
not significantly different (regression analysis, p=0.05914). A; change in glucose and
lactate concentration in plasma from ALF patients. B; change in glucose and lactate
concentration in plasma from healthy patients.
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4.3.10.4. DNA Integrity of Beads Perfused with Liver Failure Plasma
DNA integrity showed no significant difference before and after 8 hours of perfusion with
plasma from the ALF patient (Figure 4-2, p=0.7221). However, DNA concentration increased
4-fold every hour during the perfusion with liver failure plasma, with a background DNA level
of 11±2ng/ml measured at time 0. This was coupled with a 13.8 x 106cell/ml beads reduction in
cell viability as illustrated in Figure 4-2, totalling 69.0 x 106cells death from 5 ml of beads over
the 8 hours.
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Figure 0-1: encapsulated HepG2 cells were perfused for 8 hours with either plasma
from healthy or liver failure patients. AFP production was not significantly different in
these conditions (regression analysis p=0.7633). A; AFP production in plasma from
liver failure patient. B; AFP production in plasma from healthy patients.
Figure 4-2: Encapsulated HepG2 cells perfused with plasma from an ALF patient over 8
hours. A; no significant difference in DNA integrity before and after perfusion (n=10
p=0.7221 two tailed t-test). B; an increase in DNA concentration over 8 hours, with a 3-fold
increase in DNA concentration every hour, (n=10, error bar show standard deviation).
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4.3.10.5. DNA Integrity between Plasma from Healthy and Acute Liver Failure Patients
A fresh sample of plasma, obtained from a patient suffering from ALF, was obtained for method
validation, and analysed for DNA integrity and total DNA concentration. DNA integrity in
plasma from the patient with ALF was significantly higher (0.72±1.7) than plasma from healthy
patients (0.336±15) (p=0.006, two tailed t test), demonstrating an increased level of DNA from
necrotic cell death, Figure 4-21A. In addition, total DNA concentration in plasma increased
from a mean of 0.23±0.0012ng/ml in healthy patients to 86±4ng/ml in patients with ALF,
further confirming the increased DNA release from patients with acute liver failure due to
hepatic cell death by necrosis, Figure 22B.
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4.3.10.6. Changes in DNA as a function of Flow Velocity in the BAL model System
Despite a reduction in viable cell numbers, no significant changes in metabolic activity were
found with plasma from ALF patients. Another parameter that may cause changes in viability is
flow rate in the BAL system; there are two ways in which this could occur: an alteration in bead
bed height causing reduction in mass transfer, or shear stress from the laminar flow. Therefore,
healthy plasma was perfused at different flow rates measuring DNA integrity and cell viability.
As outlined in Section 4.1, flow velocities (ms-1) in the scale BAL system were selected to fall
either side of the large scale BAL flow velocity (Methods Section 2.3.4). The flow velocities of
the scale BAL were 510mlmin-1, 191mlmin-1, and 101 mlmin-1 for the 2.79mm, 1.52mm and
1.14mm bore size tubing respectively, compared with 3.8 x 10-4 in the large scale BAL, as
listed Table 4-12Table 4-1.
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Figure 0-3: DNA in healthy and ALF plasma. A; DNA integrity significantly increases in
plasma from a patient with ALF (0.72±1.7) compared with plasma from healthy patients
(0.33±0.15), indicating an increased level of necrotic DNA. B; Total DNA concentration
significantly increased between from 0.23±0.012ng/ml to 86±7ng/ml.
A BP=0.006 P<0.001
Page 152
Chapter 4 Quantification of BAL Biological Contaminants Discussion
BAL Type Chamber
height
(m)
Chamber
internal
diameter
(m)
Total
volume
(m3)
Volumetri
c flow rate
(mlmin-1)
Linear flow
rate (ms-1)
Large scale BAL
Chamber
0.24 0.15 4.2 x 10-3 400 3.8 x 10-4
Small scale with
2.79mm pump tubing
0.18 0.01 1.4 x 10-5 2.25 4.8 x 10-4
Small scale with
1.52mm pump tubing
0.18 0.01 1.4 x 10-5 0.837 1.8 x 10-4
Small scale with
1.14mm pump tubing
0.18 0.01 1.4 x 10-5 0.45 9.5 x 10-5
4.3.10.7. DNA Release from Beads in Plasma
Although no significant change in viability was detected after perfusion with healthy plasma
over 8 hours, using FDA and PI staining (Figure 4-15C), some DNA release was detected
(Figure 4-15A). As a result, some cell death, undetectable by fluorescent staining, produced an
increase in DNA integrity from 0.081 ± 0.082, to 0.56 ± 0.15 (Figure 4-15C). This suggests that
DNA in the plasma was from predominantly apoptotic origin, and over the 8 hours, any cell
death that did occur was necrotic, possibly due to the laminar flow of the plasma causing low
levels of cellular disruption.
An increase in necrotic DNA during the first two hours of perfusion followed by stabilisation,
illustrated in Figure 4-15B, suggests that some cell death occurred during this time. It also
became clear that, increased flow rates did not contribute to cell death as there was no
significant difference in DNA release over the 8 hours, as illustrated in Figure 4-15C (paired t-
tests with n=10, 2.79mm vs. 1.52 with P=0.2984, 1.52mm vs. 1.14mm with P= 0.0560 and
2.79mm vs. 1.14 with P=0.1605).
Table 4-1: Chamber and flow characteristics in the large scale BAL chamber to achieve a 2-
fold bead bed height, compared with the small scale BAL. At 400mlmin-1 the large scale BAL
system shows a 2-fold bed height with a linear flow rate of 3.8 x 10-4ms-1. The small scale
BAL with 2.79mm bore size tubing, at 2.25mlmin-1, showed a two-fold bed height; where
1.52mm and 1.14mm bore tubing showed lower bed heights of 1.5-and 1.2-fold,
respectively. The linear flow rate was used to provide flow conditions comparable to that
of the large scale BAL.
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Figure 4-15: DNA release from a scale BAL system. Total DNA concentration was
measured in samples taken every hour, over 8 hours perfusion with plasma from healthy
patients, using the 115bp replicon primer. Amplification with the 247bp replicon primer
provided DNA integrity (methods Section 2.2.3). A; total DNA concentration showed no
significant difference with increased flow velocity, (t-test with n=10, 2.79mm vs. 1.52
with P=0.2984, 1.52mm vs. 1.14mm with P= 0.0560 and 2.79mm vs. 1.14 with P=0.1605,
all error bars represent standard deviation). One way ANOVA analysis on all samples vs.
no beads showed a significant difference in DNA level (P=0.0083, n=10). B; DNA integrity
of beads perfused using the 2.79mm bore size tubing, showing an initial increase in DNA
integrity up to 2 hours where there was no significant difference thereafter, (ANOVA,
n=10, P=0.00062, error bars represent standard deviation). C; change in DNA integrity
with perfusion using 2.79mm bore size tubing from initial DNA integrity to that after 8
hours, illustrating the change from mainly apoptotic DNA (0.081 ± 0.082, to 0.56 ± 0.15)
to necrotic. D; Viable cell number before and after perfusion with healthy plasma for 8
hours showed no significant decrease viability for all tubing size (one tailed paired t-test
p<0.0001).
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4.3.11. Calculating Total DNA Release during a BAL Experiment
In the small scale BAL with 5ml beads and a starting HepG2 cell density of 51.7 x 106cells/ml,
showed a 22ng/ml DNA release into 80ml from 69.0 x 106 dead cells over 8 hours, giving
1.76µg total DNA.
A large scale system of 7L of plasma with a bead cell density of 51.7x106cells/ml beads requires
1353ml of beads to provide the 7.0 x 1010cells/ml predicted to be sufficient for treatment.
Therefore, if 5ml of beads at this density released 1.76µg, 1353ml beads at the same cell density
would release a total of 476.6µg of DNA in 7L, assuming a 23% drop in viability shown in the
scale BAL. A final DNA concentration of 68ng/ml DNA would be expected after 8 hours of
perfusion, in the large scale BAL. According to the theoretical calculation in Table 4-2, a 27%
drop in viability with 7x1010 cells would release 19µg/ml DNA, over 200-fold greater than the
amount measured in the scale BAL. DNA concentrations with a final BAL design of different
volumes and total cell numbers are outlined in Table 4-13 as calculated from the scale BAL.
BAL Condition Volume of
beads with
7x1010 cells (ml)
Volume of
Beads with
1x1011 cells (ml)
DNA
concentration
with BAL with
7x1010 cells
(µg/ml)
DNA
concentration
with 1 x 1011
cells (µg/ml)
3.5L Plasma 1353 1934 136 195
7L Plasma 1353 1934 68 97
10L Plasma 1353 1934 48 68
4.3.12. Endotoxin
As previously mentioned, endotoxin contamination may originate from the BAL system, but
may be eclipsed by the amount originating from a patient suffering from ALF. In order to
reduce or remove endotoxin levels for both therapeutic and regulatory reasons, an endotoxin
assay was optimised for use in human plasma.
4.3.12.1. Endotoxin Standard Curve
The LoQ of endotoxin in water was established by initially using a zero calibrator, and serial
endotoxin dilutions. The zero calibrator involved repeating negative endotoxin free sample with
n=20 which gave a mean value of 64±2.4 Fluorescence units (FU). According to accepted
models154,208, the limit of detection (LoD) should be set at two standard deviations above the
Table 0-2: potential DNA concentration in large scale BALs with increasing total plasma
from liver failure patient volume, with a bead density of 51.7 x 106cells/ml beads and a
mean 19 ±3.7% reduction in cell viability.
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zero calibrator, giving 68.4FU. The limit of detection should be set at ten-fold the standard
deviation above the zero calibrator, at 88 FU. As a result, any endotoxin reading below 88FU
was disregarded, and so the LoQ for this assay was set at 0.01pg, showing a mean 112±7
fluorescence units (n=20), shown in Figure 0-4.
Removal of inhibition from plasma was achieved using two approaches: reduction in protein
inhibition through dilution; heat treatment causing inactivation of proteins and endotoxin release
from other proteins (Methods Section 2.7). Dilution of plasma down to 0.5% and heat treatment
removed inhibition from plasma to an insignificant level, shown in Figure 4-17 (paired two way
t-test with P=0.68, n=5).
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Figure 0-4: Endotoxin standard curve with LoQ of 0.01EU/ml, in water. Each sample n=5
using certified Endotoxin standard extracted from Escherichia coli O55:B5.
P=0.68
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Figure 4-17: Endotoxin levels in plasma. Plasma samples were spiked with 1EU/ml of
endotoxin for fluorescence analysis, requiring a 0.5% dilution and heat treatment to
remove inhibition (n=5, p=0.68, two tailed). Raw samples denote untreated plasma spiked
with 1EU/ml endotoxin, followed by the dilution. Treated samples denote samples heated
as outline in Methods Section 2.6.5 followed by dilution. The same undiluted, untreated
plasma used for other samples was added to the endotoxin assay.
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4.4. Discussion
This chapter involved establishing detection methods for contaminants, including, cell debris
and endotoxin, but mainly focusing on DNA detection. Development of a DNA detection
system was initially based on predicted release, (particularly QPCR) to be optimised in a plasma
environment. Thereafter, the scale BAL model enabled the refinement of the detection methods
by demonstrating realistic levels to be expected in the large scale BAL. Those DNA levels also
provided information regarding the necessary capacity of a filtration system, which was tested
in later chapters.
In addition to DNA release, the Scale BAL model also provided an indicator of cellular
response to plasma from one ALF patient. As previously mentioned, during the priming process
healthy plasma would be used to prime the system. Therefore, at the beginning of the
experiment, healthy plasma is constantly diluted by ALF plasma from the patient.
Consequently, the scale BAL model provides an environment, reflecting extreme conditions, in
the absence of this dilution effect.
4.4.1. Method Validation
To fulfil the criteria for regulatory market approval for manufacture of a medical device, each
contaminant measurement within the BAL system will require validation77,117,118,209-211. The
process of validating an analytical assay for use with a medical device requires a process of
testing a wide variety of parameters, which include the analyst, the instruments and the
preparation environment77,209. For a research laboratory, many of the processes necessary are
hugely impractical without substantial investment that is inappropriate for a research laboratory.
These considerations will be discussed in more detail in later chapters.
As a result, an approach was used to validate methods to a stage that were deemed adequate for
pre-clinical trials, with the view that extending the methodology for incorporation into a
manufacturing quality control mechanism would require minimal added development. The
QPCR methodology was validated to provide a robust, precise and reliable analytical method in
the Liver Group laboratory, using the Rotorgene 3000 thermocycler. Extending this into a GLP
quality control laboratory would require further developments including validation of new
thermocyclers and an expansion of the quality manual and related SOPs to incorporate
regulatory compliant and standardised training documents, detailed in later Chapters.
4.4.2. Alu Repeat QPCR Development
A key aspect towards eventual Alu repeat QPCR validation was to determine the reliability of
the reaction, for both standards and the samples treatment process. Attaining efficiency values
between 80% and 110% have been shown to be sufficient for accurate DNA quantification, if
the sensitivity of the PCR is adequate for the application212,213. An efficiency less than 100%
suggests PCR reaction inhibition, whereas greater than 100% is indicative of non-specific
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amplification, enhancement of fluorescent signal or DNA contamination214-216. Ultimately, the
efficiency values obtained provide a measure of proportionality217. Despite clear non-specific
amplification (illustrated in Figure 4-5A and C) by smearing above the band of interest, both
replicon primers proved to amplify template concentration proportionately, confirmed by high
R2 values for standard amplification (in Figure 4-9A and B), with amplification efficiencies
close to the desired 100%, at 106±1.2% and 101±0.9%, for the 115bp and 247bp replicon
primers, respectively.
To substantiate the efficiency, the melt curve analysis illustrated that a single product was being
amplified although some background was clearly evident (Figure 4-8). For most QPCR
applications, a set of primers for a specific gene is used, producing a much more distinct peak
for the melt curve, essential in ensuring that the primers do not cross amplify other genes and
the PCR product is not contaminated107,145,218. The non-specific amplification alluded to here
was attributable to the Alu primers being specifically designed to amplify as many of the Alu
repeat subfamilies as possible to increase sensitivity, reflected in melt curve and electrophoresis
analysis showing non-specific amplification. Others using Alu repeat primers and other tandem
repeat sequences have observed the same phenomenon, coming to the conclusion that a melt
curve with background is inevitable as long as linearity and efficiency are proven219,220.
4.4.3. QPCR Validation
Different aspects of QPCR validation provide information to support the reliability of the results
by establishing the limits and ensuring the method was fit for purpose. Furthermore, as
discussed in later chapters, legal requirements for work to be carried out in certified
laboratories, such as GLP compliance, rely not only on the quality of method development,
initiated in this chapter, but also on the quality of the supporting documentation and
management systems199.
Important validation parameters outlined in Section 4.1.2 were: precision (as measured by
repeatability and reproducibility), recovery, linearity, and sensitivity. As part of defining
precision, repeatability analysis determined the constitutive error within the protocol by
calculating the % CV values, to provide values reflecting the tightest form of precision
measurement. In all cases, the % CV value was between 2.5% and 4.9%, showing the low level
of constitutive error achieved. Two QPCR methods passed by the FDA for detecting the H1N1
RNA in human plasma between them showed %CV values spanning 0.6% - 4.6%221,222.
Therefore, the values obtained for Alu repeat QPCR for total blood would be within these
limits, if performed on a single thermocycler.
Using identical samples reproducibility analysis provided a less robust measure of precision by
incorporating changes to analyst and QPCR thermocycler over time. As a result, the data was
grouped for different analysts, PCR thermocyclers and tests performed over a year, showing a
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significant increase in %CV values ranging from 8.1% to 14.8%. This clearly demonstrated that
the QPCR method loses precision when incorporating changes in analyst, PCR machine, and
increased time between analyses.
Another important indicator for the reduction in precision was the significant difference
between the cT values obtained from different PCR thermocyclers, as illustrated in Table 4-6.
The %CV figures for each primer set on individual PCR machine were within acceptable limits,
albeit the %CV increased slightly for the RG6000® and BioRad® thermocyclers, due to initial
PCR optimisation being performed on the RG3000®. It was clear, therefore, that changing the
QPCR thermocycler had a significant effect on cT values, but results performed on specific
thermocyclers maintained reliability, consequently requiring re-validation only if changing
between thermocyclers.
Conventionally, an analytical method as part of a GLP laboratory involved with quality control
of a manufacturing process would be validated on a single PCR thermocycler. Other variables,
such as changing an analyst, would be addressed in a GLP Laboratory through formal training
on a specified instrument, with extra analysis during changeover of analysts, to ensure the
reliability of the results223.
4.4.3.1. Recovery Analysis
Spiking plasma and media samples with a known concentration of DNA, then purifying and
analysing samples, as described in Section 4.1.2, provided a measure of DNA recovery. The
purification protocol (Methods Section 2.2.3.2) improved recovery in both plasma and media
from between 58.0±41.85% - 62.8±36.2% to 98.8±2.4% - 101.5± 3.5%, quantifiable down to
the LoQ of 0.01ng/ml. These figures are within acceptable limits for recovery analysis, for
validated QPCR methodology217,224,225 enabling the accurate analysis of DNA in media and
human plasma for reliable total DNA quantification and DNA integrity analysis.
4.4.3.2. DNA Integrity
The concept of DNA integrity was used to establish DNA from apoptotic and necrotic cell death
in differing BAL treatment states. Apoptosis was induced by Staurosporine treatment, which
was confirmed by the Caspase 3/7 GLO® assay (Figure 4-6 and Figure 4-7A) typically yields a
low DNA integrity (1.7 x 10-3± 8.0 x 10-4). Conversely, necrotic DNA from multiple freeze
thaw cycles, at -80°C, showed a significantly higher DNA integrity at 0.90±0.036. Finally,
mixing the apoptotic and necrotic DNA to a 1:1 ratio was reflected in the DNA integrity of
0.45±0.07 (Figure 4-7A). Importantly, the DNA concentration of both remained unchanged;
confirming that the DNA integrity reflected the induction of apoptosis or necrosis in HepG2
cells in culture. The utilisation of this technique has been demonstrated as providing a potential
cancer diagnostic tool, with an increase in DNA integrity representing necrotic cell
death115,147,148,225.
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Expanding the use of DNA integrity to the “worst case scenario” BAL model of cell death
provided an indication of DNA concentration if cells died in large numbers. Over 48 hours of
incubation in healthy plasma, 69% reduction in viability produced a 62.2ng/ml increase in DNA
concentration, as well as an increase in DNA integrity from 0.34±0.05 to 0.48±0.07. The
increase in DNA integrity illustrated that DNA release from HepG2 cells under mechanical and
environmental stress underwent necrotic cell death (Figure 4-9). In addition to this, a
background level of cfcDNA was detected in plasma with no beads, although predominantly
apoptotic, some DNA from necrosis was detected. A similar observation was made with cancer
diagnostics using Alu QPCR, where a background of cfcDNA from necrotic origin was
represented in the DNA integrity which showed a predominantly apoptotic DNA origin99,148,
unlike tested DNA integrity from induced cell necrosis by freeze thawing in Figure4-6.
4.4.3.3. DNA integrity in ALF plasma
The background DNA level in plasma from the ALF patients used in the small scale BAL was
11±2ng/ml. Analysis of DNA integrity showed DNA predominantly from necrotic cell death.
As a result, when perfusing alginate encapsulated HepG2 cells with plasma from the ALF
patient, in the small scale BAL experiment, the DNA integrity was not significantly different
(Figure 4-13), due to the background necrotic DNA being too great for the QPCR protocol to
detect any changes.
Although no significant change in DNA integrity was observed, a trend towards a higher DNA
integrity could be seen, with a possible addition of DNA from HepG2 necrosis (Figure 4-10). In
addition to this, perfused with plasma from ALF patients, HepG2 cells showed a 27% reduction
in viability, releasing 22ng/ml or 1.76µg total DNA, which is over 200-fold less than the
19µg/ml calculated using the theoretical calculation shown in Table 4-2. Therefore, cell death
does not correspond to DNA release with the same efficiency that was assumed for the
theoretical calculation. Despite this, a lower DNA concentration will place a lesser burden on a
filtration system.
4.4.4. DNA Integrity as a Diagnostic Tool
In the same way that DNA integrity may be used for cancer diagnostics, the technique could be
applied to changes in cfcDNA in ALF patients. Some interest has been has been reported on this
topic, where a recent conference proceeding at The American Association for the Study of Liver
Disease (AASLD) reported using primers specific for the β-actin gene, showing a significant 
difference in cfcDNA concentration in sera of chronic liver failure patients compared with
healthy patients226. This method goes further in being able to distinguish between background
apoptotic DNA and necrotic DNA, as well as potentially improving sensitivity by virtue of
amplifying Alu repeats, which are ubiquitously found across the genome. Furthermore, the
DNA concentration in a fresh plasma sample collected from a patient and frozen at -80°C within
6 hours showed a DNA concentration of 86±7ng/ml as opposed to 11±2ng/ml, which could
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have been due to variation between patients, as a result of storing the plasma used to perfuse
cells at -20°C, or a difference in the method of collection, namely direct phlebotomy vs. plasma
exchange where the plasma is lymphocyte and platelet depleted.
To fulfil the potential as a diagnostic tool, a trial should include patients suffering from ALF
and healthy patients with sufficient replicates for statistical power. In addition to this, variations
in state of liver disease including chronic liver diseases, could be investigated to confirm
whether cell death by necrosis can be correlated with either the extent of liver damage, the rate
of liver damage and the cause of damage31,227,228.
A background level of cfcDNA was detected in plasma without beads; although predominantly
apoptotic, some DNA from necrotic origin was detected. A similar observation was made with
cancer diagnostics using Alu QPCR, where a background of DNA from necrotic origin was
represented in the DNA integrity otherwise reflecting a predominantly apoptotic origin99,148.
4.4.4.1. Cell Debris
The largest contaminant within the plasma will be from cell and alginate debris. Conventionally
in process manufacturing, these would be removed through filtration or centrifugation. To
analyse the effectiveness of the method, electron microscopy or nucleic magnetic resonance
imagery would show the presence of cell debris on the filter membrane, or in the centrifuged
pellet, as well as particulate analysis by laser light obscuration to confirm absence in the
clarified liquid188,229,230.
Particulate analysis of filtered plasma to remove cell debris will be discussed in later chapters.
In this chapter, viable and non-viable whole cells were detected in the reservoir of the scale
BAL system. Currently a 200µm physical barrier prevents large particulates entering the patient,
if the alginate/cell fragments are smaller than 200µm they would pass into the patient. The most
efficient way of preventing cells from entering the patient would be to introduce a filter with a
nominal porosity sufficient to retain hepatocytes, typically between 10-40µm in diameter231.
The porosity of charged depth filters discussed in later chapters were all below 10µm nominal
porosity, being ideal for cell retention.
4.4.4.2. Endotoxin Analysis
As previously mentioned, the main source of endotoxins within the BAL system will originate
from the patient, the control of which is necessary mainly for clinical benefit. Initial validation
of the endotoxin standard curve showed a LoQ of 0.01pg using a zero calibrator. However, to
remove plasma inhibition, samples were diluted to 0.5% followed by heat treatment (Methods
Section 2.7). As a result, the LoQ of the endotoxin assay was 2EU/ml or 200pg/ml of endotoxin.
For parenterals 25EU/ml is the limit required201; but for further method development and
validation a more accurate method of analysis may be required, to determine reduction in
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endotoxin concentration in ALF patients, previously shown to be 58.2±12.3pg/ml232 or
0.582±0.123EU/ml, below the current LoQ. The use of kinetic end point chromogenic LAL
assay has been reported to have sufficient sensitivity to measure endotoxin in healthy donor’s
blood223.
The validation process for endotoxin removal was not as extensive as the QPCR methodology
for two reasons; the LoQ would be insufficient for a valid analytical method223, and for research
purposes the assay was sufficient in showing the endotoxin removal capabilities of a quality
system. A kinetic fluorogenic approach may be more appropriate which has a lower LoQ of
0.005EU/ml in water, performed in a facility that is dedicated to endotoxin analysis.
The next chapter will seek to remove the DNA and endotoxin, which were shown to be present
in the scale BAL models, by filtration. Initially a scale filtration model was developed to test the
efficacy of the filtration system for removal of DNA from the BAL system.
4.5. Conclusions
For the Purposes of measuring reduction in DNA or endotoxin in the full scale BAL system,
QPCR was validated in human plasma to show reduction or even absence by a removal system.
Endotoxin analysis although not validated to the same extent as QPCR, was sufficiently
sensitive to show endotoxin removal down to 2EU/ml. DNA and endotoxin removal was then
tested in the small scale BAL detailed in the next chapter.
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This Chapter details filtration of plasma
using 3M Cuno Filters to remove DNA,
endotoxin, and particulates, with a scaled
down model of the BAL system.
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5. Scaled Down Model for Filtration
5.1. Introduction
Selection of an appropriate filter membrane is central to the BAL quality management
scheme and relies on measuring two main parameters: volumetric capacity (volume
throughput before filter blocks) and breakthrough capacity (volume throughput before
selected impurity is found in filtrate). It is essential to have this information before
embarking on pre-clinical trials, because problems of inadequate filtration would be difficult
to correct once a BAL run has started.
5.1.1.1. Filtration Principles
Filtration of blood and plasma has been used in many medical contexts as described in
Introduction Section 1.6.2. To establish the required efficacy of a filtration system, three
equally important and interrelated principles need to be considered: the sieve capacity, total
volumetric capacity and molecular binding capacity.
Sieve capacity relates to the physical retention of macromolecules and particulates on/in the
membrane, such as proteins and platelets, respectively. Depending on the porosity of the
filter, macromolecules and particulates retention by size exclusion may lead to filter fouling,
resulting in a reduction in total volumetric capacity and abnormal pressure build up in the
circuit. In addition to this, molecular interactions in the form of hydrophobic, ionic or charge
based adsorption can add to retention of substrates needed to be retained in the circulating
fluids of the BAL234,235. In many cases, retention of certain macromolecules or particulates
may be desirable, for example in the BAL retention of particulates over 1µm, constituting
mainly cell debris and potentially particulates from the alginate236.
Retention of macromolecules and particulates, however desirable or unwanted, strongly
influence the volumetric capacity of the filter. Some of the ways particulates may settle onto
a filter are illustrated in Figure 5-1, showing effect of filter porosity and the size distribution
of particulates. Mathematical models, detailed in Sections 5.1.2, describe the way
particulates block filters, to allow us to predict the volumetric capacity of the full-size BAL
using a scaled down circuit, small filter and where volume throughput can be measured.
The filter binding capacity reflects the number of molecular binding sites available for
interaction between molecular compounds dissolved in the plasma, such as DNA and
endotoxins, and the filter membrane236. Retention of larger particulates and macromolecules
may reduce the number of binding sites; simply by impeding access, but molecular binding
capacity does not ordinarily impact on total volumetric capacity236,237. All three filter
principles, sieve capacity, volumetric capacity and binding capacity, were quantified using
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the small scale filter model, which I designed for the BAL treatment phase. The
methodology followed the following process:
 The scaled down filtration model was used to pass plasma through selected filter
media, as described in Methods Section 2.5.
 During the filtration, pressure and volumetric throughput were measured in real time.
 The filtration experiment was stopped if the differential transmembrane pressure
reached 1.6bar, or supply of plasma was exhausted (based on information supplied
by 3M Cuno® engineers).
 Membrane resistance over time was plotted to provide the data to model kinetics of
filter blockage.
 Using mathematical models for filter blockage, the volume throughput for the filter
media were calculated (Lm-2).
 The volumetric flow through the filter media was applied to specific filter
sizes as defined in the Introduction Section 1.6.2.3.
5.1.1.1. Estimation of DNA capacity
The DNA capacity of the 3M® Cuno® EXP® filters, including the capacities of the ZA, LP
and S series filters, have not previously been determined in plasma, due to the predominant
use for purification and clarification of bioprocessing fluids188,230. Previous studies
determined DNA removal using a 3M® Cuno® 90SP single layered charged depth filters
(nominal porosity of 0.1µm) with 10µg/ml calf thymus DNA in culture broth at pH 7.4,
measuring circulating DNA in the presence of Hoechst dye. The filter continually removed
10µg/ml of DNA, with DNA breakthrough eventually occurring at 53.8L/m2 of filter media.
Using a filter with a 25cm2 (0.0025m2) filter media area (utilised in the scale filtration
model), the following DNA capacity was calculated:
 53.8Lm-2 x 0.0025m2 = 0.1345L capacity before breakthrough with 10µgml-1 dose.
 134ml x 10µgml-1 = 1345µg = 1.35mg of DNA capacity in a 25cm2 filter.
 In Chapter 4, the DNA concentration in a 7L BAL, with 1353ml of beads, at 5.7 x
10cellsml-1 beads was expected to release 68ngml-1, totalling 0.476mg DNA over 8
hours.
With an entire large scale BAL treatment phase predicted to release 0.476mg total DNA over
8 hours, theoretically a 25cm2 3M® Cuno® 90LP filter, with a filter capacity of 1.35mg DNA,
has sufficient capacity. Even if the extra cfcDNA (cell free circulating DNA) from the
patient is included, at 78µg total DNA over 8 hours, totalling 0.553mg, the 25cm2 filter
would still be sufficient. However, the calculations are based on two assumptions: the filter
will remove DNA from culture broth with same efficiency as human plasma, and the 25cm2
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filter capacity would provide sufficient volumetric capacity for the entire BAL treatment
phase.
5.1.1.2. Principle of Particulate Adsorption
To model the ability for a 25cm2 filter to provide sufficient capacity for 8 hours of plasma
perfusion, the plasma constituents contributing to filter blockage were investigated. Plasma
constituents that may cause physical filtration blockage could range from protein aggregates,
lipids, cell debris, platelets, and whole cells. These constituents will be collectively referred
to as particles for simplicity. Two factors govern the adsorption of particles onto a filter
membrane are: hydrodynamic forces, which are the opposing forces to an object in the liquid
flow and body forces that affect the entire body of the fluid such as gravity and electrostatic
forces. Body forces do not significantly affect filtration capacity of depth charged filters and
will not be included in calculations238.
5.1.1.3. Hydrodynamic Forces
Different hydrodynamic forces affect the movement of particles in a liquid with competing
influence, dependant on the size of the particulate and viscosity of the solution. Competing
hydrodynamic forces are expressed as particulate velocities, with the highest velocity having
the overriding influence on particulate behaviour. Characteristic velocities associated with
the specific hydrodynamic forces are outlined in Table 5-1. The dominant force for
macromolecules of around 100Å (proteins, Figure 5-3) is Brownian diffusion, so that
adsorption onto the filter membrane is dictated by intermolecular equilibrium. As the
particles radius increases, the effect of Brownian diffusive velocity decreases in influence at
a ratio of 1/rs2 (where rs is equal to particle radius). At an rs of 1µm, random particle motion,
particle-particle interactions, and inter-particle collisions become the dominant forces,
collectively named shear induced diffusion239,240. For larger particles, the inertial lift velocity
becomes the overriding force, caused by the viscous flow of liquid against the particles to
cause movement238.
Characteristic Velocity (m/sec)
Force Velocity equation rs = 100Å rs = 1µm rs = 10µm
Viscous Drag Uvisc = Jv 10-5 10-5 10-5
Brownian Diffusion UBrown = DB/rs 10-3 10-7 10-9
Shear Induced Diffusion Ushear = 0.1 γwrs 10-6 10-4 10-3
Inertial Lift Ulift = γw2rs3/v 10-12 10-6 10-3
Table 5-1: Characteristic velocities associated with different particle and macromolecular
forces. Results are in water with the following conditions; Jv = 10-5msec-1 (equation 4), µ
= 0.01kgm-3 (density), γw = 103sec-1 (weight), T = 300K (temperature), ρ= 1.0020 
(dynamic viscosity) cP v = 10-6m2sec-1 (kinematic viscosity is ratio of density and
dynamic viscosity, v = µ/ρ ). DB was determined by Stokes-Einstein equation241, r
indicates radius of the particle, with 100Å representing a protein macromolecule,
whereas a radius of 1µm and 10µm represents particles.
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The adsorption of particulates onto the filter membrane dictates the volumetric filter
capacity, measured using filter blockage models, which can be expressed as a function of
changes in pressure.
5.1.2.Filter Blockage Models to Determine Volumetric Filter Capacity
Ideally, to determine the volumetric capacity of a filter, plasma should be passed through a
scale filter until the volumetric capacity is reached, as defined by a pre-determined maximal
back pressure, or break through of the selected impurities. However, due to a practical
limitation of plasma supply, volumes of up to 3L were passed through a scaled down sized
filter, measuring pressure and volume throughput as described in the Methods Section 2.5.
Blockage models were used to predict the filter capacity as expressed by filter media flux
(Lm2). This flux was then applied to larger scale filters to predict the total capacity for use
with the BAL treatment phase as shown in Table 5-6. To provide a robust filtration system,
high filtration fluxes are desirable to minimise filter fouling and maximise throughput,
allowing greater use of the entire depth of filter media, rather than just the filter surface for
the capture of particles236,238,242,243.
5.1.2.1. Theoretical Model of Liquid Passing through a Filter
Three main filter blockage models are used to describe the most common ways particle
deposit onto a filter media: pore blockage, pore constriction, and cake blockage, illustrated in
Figure 5-1. They are best understood by modifying Darcy’s Law, which describes the linear
flow rate of liquid through a porous filter media, taking into account the viscosity and
pressure drop over the filter media distance, shown in Equation 5-1244.
Equation 5-1: Q= -kA (Pb-Pa)
µL
Where the total linear flow rate Q (m3s-1) is equal to the product of the filter media permeability k
(m2) and filter media area A (m2), and the pressure before Pb (Pa) and after Pa (Pa) the filter
media, divided by the product of the length of the filter membrane L (m) and the viscosity of the
solution µ (Pas).
The permeability (k) of the filter media can be converted into a form applicable to a
filter model by using the assumption that the filter media is formed of a series of
single cylindrical pores. As a result, permeability takes on the dimensions of L2 and
can be expressed as part of Hage-Poiseuille’s law, as an expression of fluid
velocity245:
Equation 5.2: V = r2ΔP 
   8µδm
Page 168
Chapter 5 Scaled Down Model for Filtration Results
Where the velocity (m3) equals the product of the pore radius r (m) squared and transmembrane
differential pressure difference ΔP (Bar) all divided by 8 times the product of the viscosity µ (Pas) 
membrane thickness δ (m2).
From this, the membrane resistance before filtration can be modelled by rearranging the
Hagen-Poiselle’s law to make resistance the subject assuming the membrane resistance is
equal to the transmembrane differential pressure238,246:
Equation 5.3: Rm = 8δm
   Nπrp
4
Where the membrane resistance equals 8 times the filter media thickness δm (m2) divided by the
product of the pore density N (m-2) the radius of the pores rp (m) to the power 4.
The Hagen-Poiseulles law is expanded to predict one of the blockage models below:
 Complete pore blockage shown in Figure 5-1A where particles are larger or similar
size to the pores causing complete blockage, both internally and at the surface of the
filter media.
 Gradual pore blockage shown in Figure 5-1B, where particles are smaller than the
pore and gradually form layers to block the filter.
 Cake blockage shown in Figure 5-1C, where particles are larger than the pores and
form a layer on the surface of the filter.
Figure 5-1: Representation of filter media blockage models. A; complete pore blockage,
where particles completely constrict the cylindrical pore. B; gradual pore blockage,
where smaller particles adsorb and gradually block the cylindrical pores. C; cake
filtration, where particles form a layer over the filer media and do not penetrate the pore.
5.1.3.Measurement of Increasing Filter Resistance to Determine Filter Fouling Model
To establish the mode of blockage the relative resistance can be plotted over filtration time,
producing distributions indicative of the blockage model as illustrated in Figure 5-2. Both
C
A B
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pore blockage and gradual pore blockage models show a concave shaped curve with
increased filtration time, with pore blockage expressing a polynomial curve to the order of 3
and gradual pore blockage to the order of 2. Cake filtration shows a linear increase in
resistance as particulates deposit on the surface of the filter membrane246,247.
Figure 5-2: Representation of change in resistance over time indicating different
filtration blockage models. By applying a trend line to the data, the best R2 value signifies
the equation for the line and corresponding blockage model238,247.
Relative resistance is measured by normalising the resistance from the membrane before
filtration and the resistance during filtration as shown in Equation 5-4:
Equation 5-4: Rr= Rt / Rm
Where normalised Rr (dimensionless) is equal to total resistance Rt (m-1) divided by the resistance
of the membrane before filtration Rm (m-1).
Where Rt is:
Equation 5-5: Rt =  ΔP 
µJf
Where total resistance Rt is equal to transmembrane pressure ΔP (Bar) divided by the product of 
the viscosity µ (Pas) and the filter flux Jf (Lm2).
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5.1.3.1. Measuring Filter Flux for Blockage Models
Once the blockage model has been determined, the volume prediction for capacity can be
made using the time law for each blockage model based on a modified form of the Hagen-
Poiseulle equation (Equation 5-5), incorporating both Equation 5-2 and 5-3238.
Equation 5-6: Jf =    ΔP 
µ(Rm + Rs)
Where the flux Jf (Lm-2min-1) is equal to differential pressure ΔP (Pa) divided by the product of the 
viscosity µ (Pas) and the sum of the internal Rm (m-1) and surface filter media resistance Rs (m-1).
5.1.3.2. Pore Blockage Model
The pore blockage model (Figure 5-1A) is described with a time law for the volume flow
based on equation 5.5, where the filter flux at a given time is calculated from the initial
flux242:
Equation 5-7: Jf (t) = Jf (0) e-At
Where the volume of throughput velocity, Jf (m3s-1), during the filtration time, t (s), equals the
product of the initial throughput velocity Jf (0) (m3s), and e (Euler’s number 2.71828...) to the
power of the -1, multiplied by the product of the filtration time t (s) and complete and intermediate
blockage constant A.
Where A is:
Equation 5.8: A = KAv0
Where the blockage constant, A (s-1), is equal to the product of the surface area blocked per unit of
volume passed through the filter media, KA (m-1), and the mean initial flow velocity, v0 (ms-1).
Where v0 is:
Equation 5-9: v0 = Jf(0)
A0
Where the mean initial flow velocity, v0 (ms-1), equals the initial throughput velocity, Jf(0) (m3s-1),
divided by the porous surface area of the filter media, A0 (m2).
The predicted total volume throughput relative to time was expressed by:
Equation 5-10: V(t) = Jf(0) x (1 – e-At)
A
Where the volume throughput, V(t) (L) is equal to the initial velocity (m3s-1) divided by the
complete and intermediate blockage constant, A (s-1), (Equation 5-4) multiplied 1- e to the power
of the product of A and time, t (s).
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5.1.3.3. Gradual Pore Blockage Model
Particles may arrive at the membrane and deposit onto the internal pore walls causing
gradual pore blockage, as illustrated in Figure 5-1B. The time law for volume throughput is
described by242:
Equation 5-11: Jf (t) = Jf(0)
(1 + Bt)2
Where the volume flow, Jf (m3s-1), is equal to the initial volume flow Jf(0) (m3s-1) divided by the
product of the standard blocking constant B (s-1) and time (s) plus 1, squared.
Where B is:
Equation 5-12: B = KBv0
Where the standard blocking constant, B (s-1), is equal to the product of the decrease in cross
sectional area of the pores KB (m-1) and the initial velocity of volume throughput, v0 (ms-1).
From this, the predicted volumetric flow through is:
Equation 5-13: V(t) = Jf(0)t
1+Bt
Where the predicted volumetric throughput, V (t) (L) is equal to the product of volume flow, Jf (0)
(m3s-1), and time, t (s), divided by the product of the standard blockage constant, B (s-1), and time, t
(s), plus 1.
5.1.3.4. Cake Filtration
Cake filtration describes the process when particles arrive at the surface of the filter media
and block or partially block the filter without penetrating into the media, then other particles
aggregate with the existing particles to form a cake layer, illustrated in Figure 5-2C. The
time law is described by:
Equation 5-14: Jf(t) = Jf(0)
    √(1 + Ct) 
Where the total volume flow velocity, Jf(t) (m3s-1), equals the initial volume flow, Jf (0), divided by
the square root of the product of the constant, C (s-1), and time, t (s), plus 1.
Where C equals:
Equation 5-15: C = (2Rr)Kcv0
Where the constant cake filtration constant C (s-1) equals the products of twice the ratio of the cake
resistance (dimensionless), the area of the cake deposited cake (m-1) and initial mean velocity of
the fluid through the membrane v0 (ms-1).
Where Rr is:
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Equation 5-16: Rr = Rc
Rm
Where Rr (dimensionless)is equal to resistance of the cake Rc (m-1) divided by the resistance of the
clean membrane Rm (m-1).
The volume flow prediction is given by:
Equation 5-17: V(t) = 2Jf(0)    x   (√1 + Ct) -1  
C
Where the predicted volume throughput, V(t), is equal to twice the initial flow velocity, Jf(0)(m3s-1),
divided by the cake filtration constant, C (s-1), all multiplied by the square root of the product of C (s-
1) and time, t (t), plus 1, all subtracted by 1.
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5.1.4. Sieve Capacity
The size exclusion of a filter for particular substances is dictated by the nominal porosity and
structure of the filter membrane. The nominal porosity of the filtration system for the BAL
treatment phase needs to be sufficient to allow passage of circulating and newly synthesised
proteins whilst binding DNA and endotoxin. Common blood components that may be
present in plasma are illustrated in Figure 5-3.
Figure 0-1: Size comparison of common, non-cellular components of blood, showing size
of ions in Å and protein size kDa. Modified from Membranes for Life Sciences237.
The means of measuring the nominal porosity varies as outlined in the Introduction Section
1.6.2.1, although the sieve coefficient can be calculated for specific proteins using Equation
5.17.
Equation 5-18: SC = 2Cf
CBi + CBo
Where the Sieve Coefficient (SC) is equal to twice the concentration of the protein in the filtrate, CF
(ng/ml), divided by the sum of the filter input concentration, CBi (ng/ml), and the filter output
concentration in the blood of the patient, CBo (ng/ml).
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For the purposes of the scale BAL system, the protein concentration in the patient’s blood
(CBo) will be assumed as being identical to filtrate concentration (Cf).
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5.2. Methods
5.2.1.Model for Plasma Filtration
For plasma types outlined in Sections 5.3.3 and 5.3.4, the predicted total volumetric filter
media flux, Vt (Lm-2), was calculated for each filter media using the blockage models
detailed in Section 5.1.1. A predicted volumetric capacity for each filter was determined with
Equation 5.18:
Equation 5.18: Vt = V x A
Where the total volumetric filter media flux Vt (L) is equal to the product of predicted volumetric
throughput V(Lm-2) and filter media area (m2).
Plasma was passed through the filters at 90ml/min, as this is the expected plasma flow rate of
the Cobe Spectra as part of the large scale BAL treatment phase248.
5.2.1.1. Fresh Frozen Plasma (FFP) Filtration
Fresh Frozen Plasma (FFP) (Methods Sections 2.3), was passed through the 3M® Cuno®
30SP and 60ZA05A filters (detailed in the Introduction Section 1.6.2.3) in order to assess
volumetric filter media flux, Vt (Lm-2). The filtration model was assembled as outlined in
Methods Section 2.5, calculating the mode of blockage using the principles outlined in
Section 5.1.1.
5.2.1.2. Plasma from Cobe® Spectra® Therapeutic Plasma Exchange Filtration
Plasma from Cobe® Spectra® therapeutic plasma exchange (CSTPE) was passed through the
3M® Cuno® 10SP, 30SP, 60ZA05A, 60LP and 90LP filters (detailed in Introduction 1.6.2.3)
to determine volumetric filter media flux, Vt (Lm-2). Followed by, using the blockage
principles outlined in Section 5.1.1 to assess filter capacity. In addition to DNA removal,
DNA filter capacity was assessed using the PCR protocol outlined in Methods Section 2.2.4.
5.2.2.ELISA Protocols for Measurement of Circulating Protein
5.2.2.1. AFP, Fibrinogen, Albumin and α-1-antitrypsin Concentration in Filtered Plasma 
During the scale filtration model (Methods Sections 2.5), plasma samples were taken hourly
and analysed for AFP, fibrinogen, albumin and α-1-antitrypsin as described in Methods 
Section 2.4. Table 5.2 shows the dilution factors used to reduce plasma protein concentration
to within the range of the 0-200ng/ml standard curve.
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Protein Sample Dilution Factor Comment
AFP All samples 10 AFP in Cobe Spectra Aphaeresis(CSA) plasma filtrate
Fibrinogen All samples 1,000 Fibrinogen in CSA plasma filtrate
Albumin All samples 10,000 Albumin in CSA plasma filtrate
α-1-antitrypsin All samples 10,000 α-1-antitrypsin in CSA plasma filtrate
Table 0-1: Dilution factors for the specific protein ELISAs in both types of plasma using
the protocol described in Methods Section 2.5, as part of experiments outlined in Section
5.2.1.
5.2.3.BCA total protein
Materials
 Reagent A, (pH 11.25):
o 26mM sodium bicinchoninate (Sigma, D8284)
o 189mM sodium carbonate (BDH, 102404H)
o 87mM sodium tartrate (Sigma, S4797)
o 100mM sodium hydroxide (BDH, 102524X)
o 113mM sodium bicarbonate (BDH, 102474V)
 Reagent B (4% cupric sulphate):
o 4% Cupric (II) sulphate 5-hydrate (BDH, 26270)
 Standard BSA solution, 1mg/ml (Sigma, P0834-10X-1ML)
 96-well micro-plate
 1.5ml Eppendorf® microfuge tubes
 Anthos® Multi-well spectrophotometric plate reader
Bicinchoninic acid (BCA) Protocol
A series of standards were prepared from 31.25µg/ml-1000µg/ml using serial dilution from
the 1mg/ml BSA standard solution in MilliQ™ treated RO water.
Reagents A and B were mixed to a ratio of 50:1, respectively. Samples were diluted 1/1000
in MilliQ™ treated RO water, running both standards and samples in triplicate, adding 20µl
volume for both standards and samples to the 96 well plate. To each well, 200µl of pre-
mixed reagent A and B solution was added, sealing the plate, and gently mixing on a plate
shaker for 30 seconds, followed by incubating at 37°C for 30 minutes. Allowing the plate to
cool to room temperature, the absorbance of the plate was read at 550-570ƞm, using the 
Anthos Multi-well Spectrophotometric Plate reader.
5.2.4. PMAS SBSS Liquid Particulate Counting with Plasma
Particulates in plasma were measured using the PMASS SBSS Liquid Particulate counter,
using the protocol outlined in Methods Section 2.8. Samples were diluted to 1% in MilliQ™
treated RO water, to reduce the incidences of the particulate counter measuring
superimposed particulates. This was confirmed by measuring reduction in particulate
numbers at 2%, 1%, 0.5% and 0.25% dilutions, ensuring a linear reduction of particulates.
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5.2.5.Filters used in the Scaled-down Filtration Model
Table 5-3 shows the filters that were actually used in the scaled down filtration model, where
plasma was passed through the filters to calculate capacity for use with the BAL, using the
filtration blockage models.
ZetaPlus®Formulation
Filter Media Filter Aids PharmaceuticalGrades Primary Application
S Grade Cellulose DE,
perlite
05SP, 10SP,
30SP, 50SP,
60SP, 90SP
Final sterile membrane
protection
Buffer/solvent pre-
filtration
Chromatography column
protection
Reduction of
contaminating DNA
Endotoxin reduction
LP series Cellulose
(optimised for
no β-glucan 
release)
DE,
perlite
30LP, 60LP,
90LP
Blood fractionation
Membrane protection
Endotoxin reductionZA series Cellulose DE, Pre-
extracted
acid
washed
30ZA05A,
60ZA05A,
90ZA05A
Endotoxin reduction in
water
DNA removal
Table 0-2: Filters used in the scaled down filtration model. Plasma was passed through to
assess capacity. DE refers to diatomaceous earth. .
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5.3. Results
5.3.1.Theoretical Filter Capacity for a BAL Treatment Phase
In order to select the appropriate filter for the BAL system the total volumetric throughput
over 8 hours was calculated at different flow rates as illustrated in Table 5.4.
Volumetric Flow rate
(ml/min)
Estimated Total
Volumetric throughput
(L)
10 4.8
40 19.2
60 28.8
90 43.2
120 57.6
Table 5-4: Theoretical volumetric throughput of the BAL system during 8 hours at
different flow rates.
5.3.2.Filtration of Plasma using 3M® Cuno® Filters.
Volumetric filter media flux, V(t) (Lm-2), for each filter media (Methods Section 2.5) was
evaluated as described in Section 5.1.1. The mode of filter blockage was determined by
plotting membrane resistance over time, from which V(t) was calculated using the
mathematical models for the relevant blockage model as shown in Table 5-5. Then filters
were tested for DNA removal capability and large particulate removal (over 1µm). In order
to calculate the V(t) the blockage models were determined as follows.
5.3.2.1. Determination of Blockage Model in Fresh Frozen Plasma (FFP)
As mentioned in Chapter 4, FFP was obtained from whole blood donations, with a
predefined set of cellular constituents. Filtration experiments were first performed with FFP
to establish the filtration capacity with a readily available source of plasma that could
potentially be incorporated into the BAL system for priming.
Both the single layered 30SP and the double layered 60ZA05A filters showed a distinctive
cake blockage curve as illustrated in Figures 5-4 and 5-5 when plotting relative resistance
over time.
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Figure 5-4: Relative resistance over filtration time with freshly frozen plasma passed
through a 3M® Cuno® 30SP filter at 90ml/min, showing a curve indicative of cake
blockage238. The curve shows individual data points over a single experiment, providing a
measure of variance in relative resistance during filtration. 30SP filters have a nominal
porosity of 0.6-3µm. Due to the high frequency of data point collection, the curve shows
individual data points over a single experiment, providing a measure of variance in
relative resistance during filtration. The anomalous measurements not on the line were
attributed to electronic interference and did not affect the results.
Figure 5-5: Relative resistance over filtration time with freshly frozen plasma passed
through a 3M® Cuno® 60ZA05A double layered filter at 90ml/min, showing a curve
indicative of cake blockage238. 30SP filter have a nominal porosity of 0.6-3µm. The
60ZA05A filters are constructed of a “30” filter media with nominal porosity of 0.6-3µm
protecting a less porous “60” filter media with nominal porosity of 0.3-0.75µm. Due to the
high frequency of data point collection, the curve shows individual data points over a
single experiment, providing a measure of variance in relative resistance during
filtration.
5.3.2.2. Filter Capacity with FFP
The 30SP and 60ZA05A filters, shown in Figures 5-4 and 5-5, quickly reached 1.6bar
requiring the filter experiment to be terminated. As a result, the filter volumetric throughput
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in Table 5-5 for the 25cm2 filter was the measured value, using the figure from this to
calculate the flux to apply to the larger filter sizes.
The 30SP filter was identical to the upstream protectant layer of the 60ZA05A filter (the 05A
component), in terms of nominal porosity (0.6µm – 3µm). Although the 30SP filter did show
a higher volumetric filter media flux of 10.8Lm-2 compared with 5.7Lm-2, when calculated
for the larger filter sizes, the capacities were insufficient for large scale application,
illustrated in Table 5-4.
Filter
Type
Mean
Initial
Flow
Velocity
(Jv) (m3s-1)
Mean
Flow
Velocity
(ms-1)
Volumetric
Filter
Media Flux
(Lm-2)
Measured
25cm2
Filter
Capacity
(L)
Predicted
650cm2
Filter
Capacity
(L)
Predicted
1300cm2
Filter
Capacity
(L)
30SP 4.22 x 105 1.35 x 104 10.8 0.027 0.702 1.4
60ZA05A 1.29 x 105 4.2 x 104 5.7 0.014 0.371 0.74
Table 5-5: Prediction of total volume throughput using the filter models with FFP passed
through each filter. Mean initial volumetric flow rate was determined. Due to the filter
quickly reaching 1.6bar, the volume throughput for the 25cm2 filter reflects the
measured volume, calculating the volumetric flow through for the larger filter sizes.
Mean flow velocity was measured from over total filtration time from the volumetric flow
rate, as measured by reaching 1.6bar differential pressure. (n=1)
5.3.2.3. Blockage Model in Plasma from Cobe® Spectra® Aphaeresis.
The plasma derived from Cobe® Spectra® Therapeutic Plasma Exchange (CSTPE) is more
refined than FFP248, illustrated later in Figure 5-16. Accordingly, it would be expected that
the filter capacity should be improved compared to FFP.
Plotting the relative resistance against time, the 10SP filter (nominal porosity of 0.8-5µm),
showed a distribution indicative of gradual pore blockage when filtering CSTPE plasma, as
illustrated in Figure 5-6.
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Figure 5-6: Relative resistance over filtration time with CSTPE plasma passed through a
3M® Cuno® 10SP filter at 90ml/min, showing a curve indicative of gradual pore blockage
as detailed in Section 5.1.2. The curve shows individual data points over a single
experiment, providing a measure for variance of relative resistance during filtration. The
10SP filter has a nominal porosity of 0.8 - 5µm.
As with the 10SP filter, the less porous 30SP filter (nominal porosity of 0.6µm – 3µm),
shows a relative resistance distribution of a gradual pore blockage as illustrated in Figure 5-
7.
Figure 5-7: Relative resistance over filtration time with CSTPE plasma passed through a
3M® Cuno® 30SP filter at 90ml/min, showing a curve indicative of gradual pore blockage.
The curve shows individual data points over a single experiment, providing a measure of
variance for relative resistance during filtration. The 30SP filter has a nominal porosity of
0.6-3µm.
The 60ZA05A filter with CSTPE plasma, showed a relative resistance distribution of pore
blockage, as illustrated in Figure 5-8.
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Figure 5-8: Relative resistance over filtration time with CSTPE plasma passed through a
3M® Cuno® 60ZA05A filter at 90ml/min, showing a curve indicative of pore blockage. The
curve shows individual data points over a single experiment, providing a measure of
variance for relative resistance during filtration. The 60ZA05A filters are constructed of a
“30” filter media with nominal porosity of 0.6-3µm protecting a less porous “60” filter
media with nominal porosity of 0.3-0.8µm 60ZA05A filter have an overall nominal
porosity of 0.3-0.8µm.
Due to the single layered 60ZA filters no longer being available, the LP series were used in
their place due to the same media construction and charge, differing only in lower potential
release of β-glucans from the filter media itself187. Therefore, providing a measure for the
60ZA capacity, without the 05A protective layer. The 60LP single layered filter has the same
nominal porosity as the lower layer of the 60ZA05A double layered filter of 0.3µm-0.8µm.
Passing CSTPE plasma through the 60LP filter showed a relative resistance distribution of
pore blockage, as illustrated in Figure 5-9.
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Figure 5-9: Relative resistance over filtration time passing CSTPE plasma through the
3M® Cuno® 60LP filter at 90ml/min, showing a curve indicative of pore blockage. The
curve shows individual data points over a single experiment, providing a measure of
variance for relative resistance during filtration. 60LP filter have a nominal porosity of
0.3-0.8µm.
The 90LP filter had the lowest nominal porosity of 0.05µm to 0.5µm, and showed pore
blockage model as illustrated in Figure 5-10. This was tested to assess the potential capacity
of a lower porosity filter in case it was necessary to reduce nominal porosity to increase
contamination removal capacity.
Figure 5-10: Relative resistance over filtration time with CSTPE plasma passed through a
3M® Cuno® 90LP filter at 90ml/min, showing a curve indicative of pore blockage. The
curve shows individual data points over a single experiment, providing a measure of
variance for relative resistance during filtration. 90LP filter have a nominal porosity of
0.05-0.5µm.
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5.3.3.Predicted Total Volumetric Filter Flow Through
Having established the mode of filter blockage, the predicted volumetric filter media flux
was calculated as shown in Table 5-6, using the blockage models in Section 5.1.2. As
expected, the 10SP filter with the largest nominal porosity showed the greatest predicted
volumetric filter media flux at 800Lm-2.
The 30SP filter showed a reduced volumetric filter media flux of 612Lm-2 due to the lower
nominal porosity, but was significantly higher than the 60ZA05A filter at 491Lm-2. The
30SP filter has the same nominal porosity as the upstream protective layer of the 60ZA05A
filter (i.e. the 05 layer). Comparing the 60LP (identical nominal porosity as the downstream
60ZA part of the 60ZA05A filter) with the 60ZA05A filter, the volumetric filter flux was
further reduced to 22Lm-2 from 491Lm-2, as shown in Table 5-6. Therefore, the upstream 05
layer of the 60ZA05A filter does bestow some protection to the downstream 60ZA layer.
The 90LP filter followed the trend of reduced volumetric filter media flux with lower
nominal porosity at 7Lm-2, due to tightness of the media.
The volumetric filter media flux provides a predicted capacity as a unit of filter area, when
applied to actual filter sizes the usable capacity was provided. Comparing these values with
the theoretical volumetric throughput of the large scale BAL, described in Table 5-4, only
the 10SP, 30SP and 60ZA05A filter would provide sufficient capacity using the 1300cm2
filter capsule.
Filter
Type
Mean
Initial
Volumetric
Flow Rate
Jv (m3s-1)
Mean
Flow
Velocity
(ms-1)
Predicted
Volumetric
Filter
Media Flux
V (Lm-2)
Predicted
Vt for
25cm2
Filter Area
(L)
Predicted
Vt for
650cm2
Filter Area
(L)
Predicted
Vt for
1300cm2
Filter Area
(L)10SP 6.99 x 10-4 2.1 x 103 800 2 52 10430SP 5.38 x 10-4 1.0 x 103 612 1.5 40 8060ZA05A 1.82 x 10-4 9.6 x 104 491 1.2 32 6460LP 4.31 x 10-4 4.8 x 104 22 0.06 1.4 2.990LP 0.98 x 10-4 1.0 x 104 7 0.02 0.5 0.9
Table 5-6: Prediction of total volume throughput using the filter models with CSTPE
plasma passed through each filter. Mean initial volumetric flow rate was determined over
the first 20 seconds of filtration measured from the time plasma filtrate started to exit the
filter. Mean flow velocity was measured from total filtration time from the volumetric
flow rate.
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5.3.4. DNA removal with different filter Types
Both the ZA (60ZA05A) and LP series (90LP and 60LP) filters showed complete DNA
removal from CSTPE plasma, mostly showing no DNA amplification or amplification
occurring at below the LoQ when analysed by QPCR. However, the S filter series only
showed a reduction in DNA level of 11% and 14% for the 10SP and 30SP filters,
respectively, as illustrated in Table 5-7.
Filter Mean DNA
Concentration
After Filtration
(ng/ml)
Volume passed
through filter
(L)
Total DNA
removal (µg)
% DNA
Removal
60ZA05A 0.0 ± 0.00 0.771 39 100
90LP 0.0 ± 0.00 0.426 22 100
60LP 0.0 ± 0.00 0.523 27 100
30SP 32.98 ± 7.8 0.853 15 14
10SP 46.06 ± 9.7 1.423 65 11
Non Filtered 50.63 ± 5.0 n/a n/a n/a
Table 5-7: total DNA removal capability for each filter, using CSTPE plasma source was
from different patients for each filter experiment, (each experiment representing n=5 for
a single filter type, and error representing standard deviation). Where 100% reduction
indicates DNA level below the LoQ. The total DNA was calculated from cumulative DNA
over the total filter volume throughput, where capacity was limited by filter fouling.
5.3.5.DNA Removal Capacity
As previously mentioned, a 7L large scale BAL with 7x1010 cells was calculated to release
0.553mg total DNA over 8 hours. The 1.325mg DNA capacity of a 25cm2 90SP filter was
therefore sufficient for the large scale BAL system139. In Table 5-8 the DNA capacity of the
ZA and LP series filters was calculated for plasma, using the amount of DNA clearance with
the measured volume throughput from the scale filtration model, then calculating a
multiplication factor (MF) for the predicted volumetric flow though for each filter. The
product of the MF and quantity of DNA actually removed during filter model provided the
theoretical DNA capacity of the filter shown in more detail in Equations 5-19 and 5-20:
Equation 5-19: MF = Vm
V(t)
Where the filter multiplication factor MF is equal to the measured volume throughput,Vm (L),
divided by the predicted capacity, V(t) (L), from the blockage models.
Equation 5-20: VDNA = MF x Total DNA removal
Where the DNA capacity (mg) is equal to the product of the multiplication factor and the total DNA
removal (mg).
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Volume
Passed
Through
(L)
25cm2
MF
Predicted
DNA
Capacity
(mg)
850cm2
MF
Predicted
DNA
Capacity
(mg)
1300cm2
MF
DNA
Capacity
(mg)
60ZA05A 0.771 1.3 0.051 54.5 2.1 107.7 4.2
90LP 0.426 0.047 0.001 1.4 0.031 2.1 0.046
60LP 0.523 0.115 0.003 3.6 0.098 5.5 0.150
Table 5-8: Predicted DNA capacity based on the measured volume passed through the
filter, and the total predicted DNA capacity calculated from equation 15 and 16. The
25cm2 filter was used for the scale filter model; the DNA capacity for larger filters then
calculated from the predicted volume throughput from the blockage models
The DNA capacity of the 90SP filter used for cell broth139 was calculated for 850cm2 and
1300cm2 filter sizes, shown in Table 5-9. After comparing the predicted DNA capacity of the
LP and ZA filter series with CSTPE plasma and the 90SP filter, the LP and ZA filter series
were substantially higher than the calculated amounts shown in Table 5-9.
90SP Capacity
(Lm-2)
Filter Media
Size (cm2)
DNA Capacity
(mg)
53 25 1.325
53 850 45.1
53 1300 68.9
Table 5-9: DNA capacity of the 90SP filters whilst passing cell broth with increasing filter
size. DNA concentration of 10ng/ml was passed through a 90SP filter until breakthrough
was detected at 53Lm-2. This data was adapted from Dorsey et.al paper for different filter
sizes139.
5.3.6. Transit of Proteins through the Filters
5.3.6.1. Total Protein
Initially, total protein concentration was measured by BCA assay detailed in Methods section
5.2.3, to ensure no major reduction in protein by filtration. Figure 5-11 illustrates that there
was no significant change in total protein content in CSTPE plasma through any of the filters
tested (p=0.34, n=6).
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Figure 0-2: Total protein before and after filtration was not significantly different, (using
ANOVA, n=6 for each filter, with error bars representing standard deviation).
5.3.6.2. Specific Protein Measurement by ELISA
Total protein measured by BCA indicated level of protein transit, but this assay was not
sufficient to determine the transit of specific proteins essential for the therapeutic efficacy of
the BAL. Therefore, protein transit was measured by ELISA for specific proteins as detailed
in Methods Section 2.5 and Section 5.2.
Alpha-Feto-Protein (AFP)
AFP, which can be used to monitor HepG2 specific metabolic activity within the BAL, as it
is not normally found in human plasma, was not significantly affected by filtration with any
of the filters used as illustrated in Figure 5-12 (one way ANOVA P=0.99, n=6).
Figure 5-12: Alpha-fetoprotein concentration before and after filtration was not
significantly changed, (using ANOVA analysis, n=6 for each filter, with error bars
representing standard deviation).
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Fibrinogen
Fibrinogen, which is an essential clotting factor often depleted in ALF patients32, showed no
significantly difference after filtration with any of the filters tested (one way ANOVA,
p=0.83, n=6).
Figure 5-13: Fibrinogen concentration before and after filtration was not significantly
changed, (using ANOVA, n=6 for each filter, with error bars representing standard
deviation).
Albumin
Albumin is essential for detoxification as a carrier protein for many poorly soluble
xenobiotics and maintenance of colloidal osmotic pressure, and is often low in patients with
ALF32. No significant difference was observed between unfiltered CSTPE plasma and
plasma filtrate as illustrated in Figure 5-14.
Figure 5-14: Albumin concentration before and after filtration was not significantly
changed, (using ANOVA analysis, n=6 for each filter, with error bars representing
standard deviation).
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α-1-Antitrypsin   
α-1-Antitrypsin is a protease inhibitor, synthesised in the Liver, which neutralises trypsin 
that which may be present following inflammation. No significant difference in α-1-
Antitrypsin concentration was shown after filtration, as illustrated in Figure 5-15 (one way
ANOVA p=0.07, n=6)
Figure 5-15: Alpha 1-antitrypsin concentration before and after filtration was not
significantly changed, (using ANOVA, n=6 for each filter, with error bars representing
standard deviation).
5.3.6.3. Sieve Capacity
To show the ELISA data in a form that can be compared with other filtration regimes, sieve
capacity was analysed236. This showed no significant difference in protein concentration
before and after filtration (Table 5-10).
Filter AFP Sieve Co-
efficient
Fibrinogen
Sieve Co-
efficient
Albumin Sieve
Co-efficient
α-1-
Antitrypsin
Sieve Co-
efficient
30SP 1.00 1.00 1.00 0.96
10SP 1.00 1.00 0.99 1.00
60ZA 1.00 0.99 1.00 0.91
60LP 0.98 1.00 0.99 1.00
90LP 1.00 0.93 1.00 0.95
Table 5-10: Sieve capacity of proteins through each depth charged filter using CSTPE
plasma, showing no reduction in protein content in any of the filtration.
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5.3.7. Particulate Removal from Plasma
Measurement of particulate levels in CSTPE and FFP supported the assumption that CSTPE
would have lower levels (Figure 5-16). This could be attributable to fewer platelets, usually
1-3µm in diameter249, and very few nucleated cells. The 10SP filter with the largest porosity
reduced particulates with less efficiency than 60ZA05A filter, reflecting the much lower
porosity and double layered nature of the 60ZA05A filter.
Figure 5.16: Particulate levels in plasma filtered by depth charge filters. Particulate levels
in plasma filtered by 60ZA05A were not significantly different to 10SP (two tailed paired
t-test, n=5, P=0.2425). Plasma passed through both 10SP and 60ZA05A filters had
significantly fewer particulates than unfiltered FFP (two-tailed t-test, n=5 P<0.0001,
error bars represent standard deviation). Particulate levels were significantly lower in
CSTPE compared with FFP.
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5.4. Discussion
The requirement of a BAL filter system is to both remove DNA and cell debris, whilst
allowing transit to proteins, already in the circulation or synthesised by the BAL biomass.
This includes both volumetric capacity and adsorption capacity for DNA.
5.4.1. DNA removal Capacity
The theoretical DNA capacity calculated in Section 5.1.1.1 showed that a 25cm2 90SP filter
would be sufficient in removing the expected DNA concentration from the large scale BAL
system. The filtration model confirmed DNA removal (but not capacity) with both the ZA
(e.g. 60ZA05A) and LP (e.g. 60LP) series filters of all nominal porosities tested, whereas the
S series (e.g. 30SP) filters did not show the same DNA removal efficiency. This was because
the S series filters are designed for bioprocessing clarification and DNA/endotoxin
reduction; therefore carry a lesser positive charge compared with the ZA and LP series
filters, which are designed for end stage purification and DNA/endotoxin removal138,187,188,250.
Previous literature for the 60ZA05A, 90LP, and 60LP filters showed greater DNA binding
capacity than the 90SP filters previously tested in cell broth138,139,. When calculating the
DNA binding capacity of 60ZA05A, 90LP, and 60LP filters, the assumption was made that
DNA binding capacity would not be reached before the volumetric capacity, predicted using
the filter blockage models. Therefore, the calculation for DNA removal capacity in Section
5.3.5 using Equation 5-19 and 5-20 (plasma passed through the filter divided by the
predicted volume, multiplied by the DNA concentration removed in the experiment)
essentially expressed the DNA binding capacity according to measured volumetric flow-
through relative to predicted flow-through. As a result, although the capacity expressed in
Figure 5-8 show lower DNA binding capacity than those measured by Dorsey et al. in Figure
5-9138,139, the true DNA capacity is likely to be greater due to the 90SP filter having fewer
charged molecules on the filter media compared with the ZA and LP filter series. I.e.
volumetric capacity is reached before binding capacity.
Furthermore, other S series filters did show DNA removal of 11 and 14% for the 10SP and
30SP filters, respectively. The lower nominal porosity increases the DNA removal
efficiency, shown during tests with the 90SP filter removal efficiencies of between 60-80%
in de-ionised H2O containing 100ng/ml of bovine serum albumin139. The answer to the true
DNA binding capacity of these filters will be tackled in the next chapter where a large scale
filter system was used with DNA spikes to assess the DNA capacity of the filter over 8 hours
of filtration with CSTPE plasma.
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5.4.2.Filter Capacity with FFP
The volumetric filter capacity of the 60ZA05A and 30SP filters in FFP was significantly
lower than the CSTPE plasma. The consequence of this was the pressure quickly increased
to 1.6bar during filtration, prompting the termination of the experiment. Using the filter
capacity up to the point of termination with 25cm2, the filter flux was calculated and applied
to the 850cm2 and 1300cm2 filters sizes (Table 5-5), showing a capacity clearly insufficient
for a large scale BAL. The implications of these results are that FFP cannot be used directly
to prime the BAL system. In its place either pre-separated CSTPE plasma must be used, or
whole blood passed through the Cobe® Spectra®, attached to the BAL system, to produce
CPTPE plasma for inline priming. The later technique has in fact been chosen as the current
means of priming the system in the large scale BAL treatment phase. In the large scale pig
model for acute liver failure, blood is obtained from an abattoir for separation by the Cobe®
Spectra® to prime the BAL system.
5.4.2.1. Filter Capacity with CSTPE
Despite the tightly controlled parameters associated with FFP205, filter capacity using CSTPE
plasma was increased in comparison to FFP. This was due to CSTPE plasma containing
lower particulates, as shown in Figure 5-16. These particulates could be attributed to
platelets, which are between 1-3µm in diameter249, which were reduced in number as a
consequence of centrifugation, as part of the CSTPE process.
With the knowledge that the S series filters having less DNA removal efficiency compared
to the ZA and LP filters, the 10SP and 30SP filters were tested in the context of upstream
protectors. Both the filters showed a relative resistance distribution indicative of gradual pore
blockage (Figure 5-4), suggesting sufficient nominal porosity to favour a slow build-up of
particles as shown in Figure 5-1B.
The 10SP filter was placed upstream of the 60ZA05A filter in an attempt to increase the
capacity of the downstream 60ZA05A filter. Unfortunately, the addition of this filter had no
effect on the filter capacity of the 60ZA05A filter, (data not shown). This suggests that the
particles that are causing blockage of the LP and ZA series filters are able to pass through the
10SP filter with nominal porosity of 0.8 - 5µm, which provides an insight into the properties
of these filters in terms of nominal porosity. The filter media within each capsule is made up
of a complex network of permeable channels, therefore giving a large range in nominal
porosity of 0.8 - 5µm. Consequently, it is difficult to draw any conclusions as to the size of
particulates causing downstream blockage based on this information. Transition electron
microscopy could be used to measure particulates on the filter to visualise what is actually
being retained.
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The 30SP filter provided the same nominal porosity (but not charge) as the 05A layer of the
dual layered 60ZA05A filter, thereby testing the effectiveness of the 05A filter media as a
physical protectant to the 60ZA layer within the dual layered capsule. The 60LP has the
same nominal porosity and charge as the 60ZA section of the 60ZA05A filter. Both the
60ZA05A and 60LP filters, with a nominal porosity of 0.3-0.8µm, showed a relative
resistance distribution of complete pore blockage models shown in Figure 5-2A, where
single particles completely block the smaller pores. Importantly, the same distribution of
relative resistance between the 60LP and 60ZA filter shows that the protection from the 05A
layer does not prevent the penetration of all the particulates involved with 60ZA layer
blockage. Therefore, blockage occurs due to a build-up of particles on both layers. Despite
this, the substantial increase in volumetric throughput is a testament to the effectiveness of
the upper protectant layer in reducing extent of particle build-up of the downstream 60ZA
layer.
5.4.2.2. Removal of Contaminants and Protein Transit
An important aspect of a filtration system is the removal of contaminants whilst permitting
transit of proteins synthesised by the BAL biomass. In all cases, the protein concentration
was not significantly affected by filtration. This was reflected by the sieve coefficient, which
provides a comparable measure of protein removal between filters. In all cases, the sieve
coefficient was one or nearly one, illustrating the transit of protein. This is particularly
important for validation of the system, where even large proteins such as fibrinogen can be
systemic and secreted through the alginate and are not removed by the filtration system, such
that that they are available for the patient.
5.4.3.Limitations of the Filter Model
5.4.3.1. For DNA removal
With all the ZA and LP series, filter complete DNA removal was observed. However, two
features of the filtration model limit the application of the data to the final BAL system.
Firstly, the DNA capacity cannot be guaranteed as the assumption was made that the DNA
capacity would be maintained throughout the predicted total volumetric capacity, based on
the results from DNA removal in cell broth139. Secondly, the filtration model is not a
recirculating system taking fresh whole blood to produce plasma for treatment then re-
combining components to whole blood in the way that the large scale BAL does.
Consequently, some of the plasma characteristics may not be representative. For example,
due to freeze thawing of the plasma; platelet aggregation was observed as shown in
Appendix V, despite platelet levels being extremely low. This would not occur during
plasma separating from a patient.
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5.4.3.2. General Limitations
Other issues include dead volume within the large scale filters as part of the design. The
25cm2 filters used for the filtration trials have a dead volume of 39ml. However, the larger
scale filters are designed with a different housing, which contains relatively high dead space.
Despite the 850cm2 and 1300cm2 being 34 and 52-fold greater in media area, the void
volume is 2.2L and 2.8L, respectively. This may have a detrimental effect on the BAL
system as it would require incorporation of a second large reservoir of plasma in addition to
the main circuit volume. The chamber holding the encapsulated HepG2 biomass is currently
4L in volume, the Cobe® Spectra TPE dual needle set carries a tubing volume of 285ml, and
the BAL tubing holds 890ml the total void volume equals 5.285L; an additional 2.2L of
volume space would increase total volume by 41%. As a consequence, the higher the total
BAL volume is, the less effective the biomass may become, due to dilution of the
synthesised proteins and other solutes vital to BAL therapeutic functionality.
In addition, there is a concern with the use of cellulosic filters in a medical setting, due to
potential extractables from the filter itself. When initially flushing the filters before
sterilisation, a significant level of extractables leave the filters causing discolouration of the
water, after which the levels reduce to below the levels documented by the FDA as suitable
levels of particulates for plasma use.
5.4.3.3. Potential for Endotoxin Removal
Endotoxin removal by the ZA and LP series filters was not tested in this chapter due to the
filter model used not providing an endotoxin controlled environment. In Chapter 6, the filter
model was modified to reduce the potential for background endotoxin contamination.
5.5. Conclusions
Of the filters tested, the 60ZA05A filter was the most helpful for BAL application if used at
1300cm2 filter media area and above. However, there remains a concern of the size of the
void volume in the filters of this size, which could be tackled by using the same filter media
in different housing but would require development with our 3M Cuno partners.
Furthermore, the use of cellulosic compounds may be a potential problem in terms of release
of particulates for medical use. If the use of the filter is shown to remove DNA and
endotoxin in a large BAL whilst keeping particulates to below levels found in medical grade
parenterals this may mitigate concerns for use of cellulosic material regulatory approval as
part of a medical device. This will be further explored in the discussion chapter.
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This chapter details the use of a filtration system in
a full scale BAL to remove endotoxin, DNA and
particulates as part of the large scale BAL system.
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6. Large Scale BAL
6.1. Introduction
6.1.1.The Current Liver Group BAL System
The current Liver Group BAL comprises two independent circuits in terms of flow rate. The
primary circuit contains the Cobe® Spectra® Apheresis System, which removes blood from the
patient and provides plasma to the BAL system at a flow rate of between 20-150ml/min,
(90ml/min most often used). Both the outlet and inlet of the Cobe® Spectra® system are
controlled by the same pump with a double head to ensure that the input and output of plasma
into the BAL are identical. The secondary circuit flows at between 100-600ml/min to provide
a 2-fold bead bed height for the encapsulated HepG2 cells housed in the chamber and to
provide a number of treatment cycles for the plasma passing through the biomass, before
returning to the patient.
Figure 6-1: The large scale BAL system. Comprised of two sections, the primary and
secondary circuit. The primary circuit, containing the Cobe® Spectra® therapeutic plasma
exchange unit, operating at between 20ml/min -150ml/min240. The secondary circuit
circulates in isolation at ~400ml/min to create a 2-fold bed height in the chamber holding
the encapsulated HepG2 cells Plasma leaving the secondary circuit re-enters the primary
circuit to rejoin the blood cells for return to the patient.
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6.1.2. Important Parameters to Establish a Filtration System for the BAL
The direction and flow rates around the BAL system dictate the extent of treatment of a
patient’s plasma will receive and is reliant on two factors: firstly, the contact time between the
biomass and a given volume of plasma will dictate the amount nourishment and detoxification
which can be delivered; secondly, the maintenance of a maximum stable bead bed height
within the BAL is crucial in facilitating maximal mass transfer and cell functionality74,75. In
order to model the movement of fluid around the system, pressure measurements were made
with changes to flow rate in the primary and secondary circuit. This data will provide a means
of determining the effect of adding in a filtration system as well as potentially determining the
flow rate to maximise the efficacy during treatment.
6.1.2.1. BAL Circuit with Added 3M®Cuno® Filter
By adding a filtration system to the BAL, the dynamics of the system flow may change. The
measurement of pressure in the system before and after addition of a filter system provided an
invaluable means of predicting potential challenges. One essential modification for the system
was the addition of a reservoir after the filter, as illustrated in Figure 6.4, to mitigate the
reduction in flow due to filter resistance over time. Another important feature of the BAL with
the inline filter was the addition of a bypass circuit to allow the filter to be removed from the
circuit in the event of excess pressure build-up due to filter blockage.
6.1.2.2. Addition of Contaminants
Spiking with Endotoxin
The normal levels of plasma endotoxin in healthy patients are usually between 0.1 - 0.4EU/ml,
rising to 0.6-1Eu/ml with acute liver failure184,232. Endotoxin levels and associated
endotoxemia are related to the levels of gram negative bacteria in the patient’s blood or organ
systems. ALF patients often suffer secondary complications such as septicaemia due to
reduced immunological protection from compromised liver function251,252. The levels of
endotoxin in a patient will therefore rise in line with bacterial presence. To model this
endotoxin increase, the BAL treatment phase would require constant infusion of endotoxin
over the treatment time. This could be problematic due to the large volume of plasma and the
potential for endotoxin to adsorb on to the tubing or other circuit components. Therefore,
several large endotoxin spikes were introduced into the blood at 50EU/ml, 100-fold the native
level found in the ALF patients, thus increasing the likelihood of detecting endotoxin in a
large plasma volume, to show subsequent clearance.
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Spiking with DNA
As previously reported in Chapter 2, 86±4ng/ml DNA was released in plasma by dead HepG2
cells as part of the scale BAL model. At the same time as spiking endotoxin, DNA spikes were
also added, at a concentration of 100ng/ml.
6.2. Summary of Chapter
With the information provided by previous chapters, a large scale BAL experiment will be
performed with a 3M® Cuno® EXP® Filter in place, comparing the results with the BAL
system without a filter.
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6.3. Methods
6.3.1. Measuring Pressure in a Modified BAL system.
Materials
 2L Biomass Chamber
 200ml Empty alginate beads encapsulated using the Jetcutter™ encapsulator system (Methods
Section 2.1.2.6.)
 3L Rhesus negative, group B Fresh Frozen Plasma (FFP)
 20U/ml Heparin
 Three Watson-Marlow® 520DU peristaltic pumps
 BAL treatment phase tubing set up as illustrated in Figure 4.
 Autoclaved 5L beaker,
 100Uml/Penicillin/0.1mg/ml Streptomycin (Lonza®)
 1.25g/ml Fungizone (Invitrogen™)
 5L sterile water
 Medex™ Pressure transducers read using the ADintruments PowerLab® and LabChart4®
system modified as described in Methods Section 2.6.
A large scale model BAL treatment system was set up, as illustrated in Figure 6.2 (replacing
the Cobe® Spectra® with Watson-Marlow® pumps), in order to measure pressures changes at
key points as flow rates were altered.
To a 5L autoclaved beaker held in a category 3 tissue cabinet, Penicillin/Streptomycin,
Fungizone and Heparin were added before pooling 3L of FFP. Pre-autoclaved BAL system
tubing was setup, priming the system with sterile water for calibration the three Watson-
Marlow® Pumps. Water was then removed, purging with air and replacing with plasma.
Moving the chamber to the tissue cabinet, 200ml empty alginate beads suspended in media
were first washed with plasma, by dilution, and then added to the chamber, introducing some
media to the system. Pressure measurements were made using modified Medex™ pressure
transducers as described in Methods Section 2.5, as the flow rate of the pumps representing
the Cobe® Spectra® were changed simultaneously from 20–80ml/min, whilst keeping the
secondary circuit pump at 400ml/min. Then the secondary circuit pump was changed from
100–600ml/min, whilst keeping the pumps representing the Cobe® Spectra® at 40ml/min.
During this, the bead bed height was measured with increased secondary circuit flow rate.
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Figure 6-1: Model BAL treatment Phase to assess changes in pressure with increased flow
rates. The Cobe® Spectra® was replaced by two Watson-Marlow® pumps set at identical
flow rates. The first pump took plasma from a 5L container in a tissue cabinet, at between
20-80ml/min, to the secondary circuit. A second pump re-circulated the plasma through a
2L chamber containing empty alginate beads, at between 100-600ml/min. A third pump in
the primary circuit removed plasma from the secondary circuit as the identical flow rate as
the first pump, returning the plasma to the 5L container.
6.3.2. Adding a Filter to the Large Scale BAL System to Remove DNA and Endotoxin
Materials
 Same materials as Section 0. with the exception of:
 3M® Cuno® EXT® 60ZA05A filter.
 3M® Cuno® EXT® filter top manifold.
 3M® Cuno® EXT® filter bottom manifold.
 3M® Cuno® EXT® small filter holder.
 PTFE Bonded EPDM autoclave resistant Gaskets (Value Plastics®).
 Glass Reinforced White Nylon 1” to 1.5” sanitary fitting clamp (Value Plastics®).
 1.5” sanitary fitting, mini-flange to 600 series 6.4mm barb adaptor, Kynar PVDF.
 Cobe® Spectra® Aphaeresis system
 Therapeutic Plasma Exchange (TPE) set for the Cobe® Spectra® Aphaeresis system
 30L sterile MilliQ treated RO water
 2L Rhesus negative, blood group B FFP, from donations to the NBS
 Red blood cells blood group B, from donations to the NBS
 0.2µm hydrophobic air filter.
 6L total volume (2L plasma, 2L filter, 2L in chamber)
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The functionality of the 3M® Cuno® EXT® 60ZA05A filter as part of the large scale BAL was
tested for removal of DNA and endotoxin, whilst allowing the transit of specific proteins.
Prior to assembling the circuit, the filter was flushed with 10L of sterile water, then autoclaved
alongside the filter manifolds, followed by assembling both the Cobe® Spectra® TPE tubing as
detailed in Appendix VI, and the BAL circuit in isolation, sealing tubes to maintain sterility.
Human blood was reconstituted from FFP and blood cell bags and stored in a sterile 5L
container situated in a sterile tissue cabinet. The Cobe® Spectra® TPE circuit was aseptically
attached the autoclaved BAL circuit, clamping at the inlet and outlet of the BAL system.
Priming of the TPE set was initiated by passing the blood through the Cobe® Spectra® system
to separate into plasma and blood cells, followed by priming the BAL system by first filling
the “Priming Plasma” bag in Figure 6-4. Once the bag was filled with 6L of plasma, the BAL
system was connected for priming from the BAL, setting the Cobe® Spectra® pumps as fast as
possible to reduce priming time. At this stage the filter was bypassed to allow the BAL system
to be fully primed then the waste bag was clamped allowing flow from the Cobe® Spectra®
directly into and out of the BAL, as illustrated in Figure 6-4. During this time, the BAL system
pump was maintained at 400ml/min, and then briefly varied from 100ml/min to 600ml/min to
assess the effect on pressure. Once the system was fully running, the filter was added, opening
the air vent (with a 0.2µm hydrophobic air filter) to allow the filter to be primed. For the large
BAL experiment, no beads were added as in previous experiments, the pressure was
unaffected as a result of beads.
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Figure 6-2: Cobe® Spectra® Aphaeresis system with the TPE set assembled.
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Figure 6-3: Detailed diagram of the BAL treatment phase. Blood was separated from the
Cobe® Spectra® therapeutic plasma exchange unit, passing plasma to the BAL system
where it was passed through the secondary circuit containing the chamber (not containing
beads) at 400ml/min, then passing the plasma back to the Cobe® Spectra® to re-join the
patient.
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6.3.3. Endotoxin Measurement in Plasma using the Lonza® Fluorometeric Limulus
Amoebocyte Lysate Assay.
Measurement of endotoxin in plasma before and after filtration through the 3M® Cuno®
60ZA05A EXT® Filter, as part of the BAL treatment phase.
Materials
 Same materials as Methods Section 2.6.
 1129±465 EU/ml stock endotoxin, isolated from E.Coli as described in Methods Section 2.6.1.
 2ml Cryovials (Nunc™).
 Liquid nitrogen stored in a small Dewar.
The methodology for endotoxin quantification by fluorogenic LAL assay was used, as detailed
in Methods Section 2.6. The blood reconstituted for the BAL experiment (detailed in Section
0) was spiked with 62µl of the 1129 EU/ml to provide 50EU/ml endotoxin in the blood. This
was used to prime both the Cobe® Spectra® and the BAL system prior to addition of the filter
system. Immediately after the filter was primed and filtrate began exiting into the system,
three 1.5 ml samples were taken and immediately snap frozen in liquid nitrogen, then stored at
-80°C until assayed. At 4 and 6 hours, a further 262µl of 1,129,465 EU/ml stock endotoxin
was added.
6.3.4. Extraction of HepG2 DNA for Spiking in the BAL Treatment Phase.
Materials
 T80 Tissue Culture Flasks (Nunc™)
 ND1000 Nanodrop® Spectrophotometer
 27G sterile, DNA, DNAse and RNAse free syringe needle
 2ml sterile, DNA, DNAse and RNAse free syringe
HepG2 cells were initially cultured as detailed in Methods Section 2.1.1.1, using three T80
culture flasks. After seven days, cells were harvested and DNA extracted using the protocol
detailed in Methods Section 2.2.1.2 and Methods Section 2.2.2, respectively. The extracted
DNA was sheared by passing the solution through with a 27G needle ten times. Finally, DNA
concentration was then quantified using the Nanodrop® Spectrophotometer at 260ƞm and 
280ƞm, pooling the DNA from the three flasks giving a total DNA concentration of 876 ± 
39ng/µl.
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6.3.5. DNA Spiking for Alu Repeat Analysis by QPCR
To determine DNA levels from spiking blood used in the BAL treatment phase with the
addition of the filtration system.
Materials
 Same Materials as Methods Section 2.2.4.
 876ng/µl HepG2 DNA extracted as described in Section 0.
Protocol
The same protocol as detailed in Methods Section 2.2.4 was used to analyse DNA in plasma
samples taken from before and after filtration in the BAL treatment phase. At the same time as
spiking endotoxin, 684µl of 876 ± 39ng/µl of DNA was added to the blood as part of the BAL
treatment phase (Section 0 ).
6.3.6. ELISA for Fibrinogen, Albumin and α-1-antitrypsin 
Materials
Same as Methods Section 2.4
ELISA Protocol
Plasma samples were taken hourly and analysed for AFP, fibrinogen albumin and α-1-
antitrypsin as described in Methods Section 2.4. Table 6-1 shows the dilution factors used to
reduce plasma protein concentration to within the range of the 0-200ng/ml standard curve.
Protein Sample Dilution Factor Comment
Fibrinogen All samples 1,000 Fibrinogen samples taken after 6hours before and after the EXT®filter
Albumin All samples 10,000 Albumin taken after 6 hoursbefore and after the EXT® filter
α-1-antitrypsin All samples 10,000 α-1-antitrypsin taken after 6 hours before and after the EXT®filter
Table 6-1: ELISA dilution factors for different proteins. Plasma samples taken at 6 hours of
the BAL treatment phase were tested from Fibrinogen, Albumin and α-1-antitrypsin 
concentration using ELISA protocol detailed in Methods Section 2.4. Dilution factors were
applied to allow the protein concentration to be quantifiable within the 0-200ng/ml
standard curve
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6.3.7. BCA assay
Materials
 Reagent A, (pH 11.25):
o 26mM sodium bicinchoninate (Sigma-Aldrich®, D8284).
o 189mM sodium carbonate (BDH, 102404H).
o 87mM sodium tartrate (Sigma-Aldrich®, S4797).
o 100mM sodium hydroxide (BDH, 102524X).
o 113mM sodium bicarbonate (BDH, 102474V).
 Reagent B (4% cupric sulphate):
o 4% Cupric (II) sulphate 5-hydrate (BDH, 26270).
 Standard BSA solution, 1mg/ml (Sigma, P0834-10X-1ML).
 96-well micro plate.
 1.5ml microfuge tubes.
 Anthos Multi-well spectrophotometric plate reader.
BCA Protocol
A series of standards were prepared from 31.25ug/ml-1000ug/ml using serial dilution from the
1mg/ml BSA standard solution in MilliQ™ treated RO water. Reagents A and B were mixed to
a ratio of 50:1, respectively. Samples were diluted 1/1000 in MilliQ™ treated RO water,
running both standards and samples in triplicate, adding 20µl volume for both standards and
samples to the 96 well plate. To each well, 200µl of pre-mixed reagent A and B solution was
added, sealing the plate, and gently mixing on a plate shaker for 30 seconds, followed by
incubating at 37°C for 30 minutes. The plate was cooled to room temperature, the absorbance
of the plate was read at 550-570ƞm, using the Anthos Multi-well Spectrophotometric Plate 
reader.
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6.4. Results
6.4.1. Physical Characterisation of BAL Pressure Profile
Pressure measurements were made at crucial points in the BAL system containing plasma, to
provide baseline measurements to compare when the filter is added to the BAL treatment
phase. Initially the Cobe® Spectra® was replaced by two pumps set at identical flow rates, as
illustrated in Figure 6-5, but will be referred to as the Cobe® Spectra® for clarity. With a filter
in place plasma was spiked with endotoxin and DNA to assess removal, whilst measuring
filter capacity using pressure measurements.
6.4.2. Measuring Pressures in the BAL System with CSTPE
Pressure measurements were taken at the positions 1-4 independently, shown on Figure 6-4.
Figure 6-4: Locations of pressure measurements across the BAL. Positions of pressure
readings corresponding to
6.4.2.1. Pressure Measurements at Exit and Entrance of Cobe® Spectra®
Position 1 was the pressure measurement taken at the exit of the pump representing the Cobe®
Spectra® and position 4 was the pressure measurement at the return to the Cobe® Spectra®. As
the flow rate of the pumps representing the Cobe® Spectra® increased from 20 – 40ml/min, the
pressures at position 1 decreased by 0.21Bar to -0.0346Bar at 80ml/min, and increased at
positions 4 by 0.115Bar to -0.08Bar at 80ml/min. The secondary circuit flow rate had a greater
effect on pressure changes at positions 1 and 4, increasing from 0.388Bar to 0.389Bar at
600ml/min at position 4 and decreasing by 0.133Bar to -0.134Bar at 600ml/min (Figure 6.6).
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Summary:
 As Cobe® Spectra® flow rate , pressure in secondary circuit .
 As secondary circuit flow rate , pressure at Cobe® Spectra® return , and
the pressure at Cobe® Spectra® outlet .
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Figure 6-5: Pressure measurements taken at the Cobe Spectra exit and entrance to the BAL
(position 1 and 4 as shown in Figure 6-4), representing the entrance and exit of the Cobe®
Spectra® to the BAL system using CSTPE plasma. A; Pressure measurement as the flow rate
of the Cobe® Spectra® pump was increased and the secondary circuit pump staying at
400ml/min. B; Pressure measurement as the flow rate of the Cobe® Spectra® is kept
constant and the secondary circuit pump is increased.
6.4.2.2. Pressure Measurements at Exit and Entrance of Cobe® Spectra®
Position 2 was the pressure measurement taken before the chamber, and position 3 was the
pressure measurement after the chamber. The differential pressure before and after the
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chamber was determined, to assess the extent that the 200µm mesh at the bottom of the
chamber influences the differential pressure. Altering the flow rate of the Cobe® Spectra®
caused minimal changes in pressure at position 2 and 3, decreasing by 0.0685Bar and
0.0605Bar, respectively. As expected, increasing secondary circuit flow rate from 100ml/min
to 600ml/min changed pressures at positions 2 and 3 by 1.197Bar and 0.609Bar at positions 2
and 3, respectively (Figure 6-7).
The rate of pressure change was identical before and after the chamber, as the Cobe® Spectra®
flow rate increased from 20ml/min to 80ml/min, with the pressure after the chamber being
consistently 0.32bar lower than before the chamber, as illustrated in Figure 6-6A. The distance
between pressure gauges was relatively small for such a large change in pressure. Three
parameters could cause this discrepancy: the loss of pressure due to friction from the chamber
and tubing; the elevation of liquid between the bottom and top of the chamber; or resistance
from the 200µm mesh.
Figure 6-6: Pressure measurement before and after the BAL chamber using CSTPE plasma.
A; Pressure changes whilst keeping the secondary circuit flow rate at 400ml/min and
increasing the Cobe® Spectra® flow rate. B; Pressure changes whilst keeping the Cobe®
Spectra® flow rate at 40ml/min and increasing the secondary circuit flow rate.
The change in pressure due to liquid elevation, i.e. gravitational effects, was calculated using
Equation 6-1253:
Equation 6-1:  ΔPs =  Z x ρ x SG 
Where the pressure difference at static fluid flow, ΔPs (kgcm-2), is equal to the product of the distance of
elevation, Z (m), the density of the liquid, ρ (kgm-3), and the specific gravity for the liquid, SG
(dimensionless).
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The specific gravity of Human plasma is 1.0310254, the density of plasma 1025 kgm-3, 255, and
the static pressure difference was measured as 0.1002Bar.
 0.251m x 1025kgm-3 x 1.031= 265 kg/m2 = 0.0265Bar
Therefore, the height of the chamber provides approximately a quarter of the contribution to
the pressure differential of the plasma before and after the chamber.
Pressure loss due to friction was calculated using the Darcy-Weisbach law in Equation 6.2:
Equation 6-2:  ΔP = λ x    1    x   (ρ x v2)
dn 2
Where the loss in pressure, ΔP (Pa), is equal to the product of D'Arcy-Weisbach friction coefficient, λ 
(dimensionless), and the inverse of the hydraulic diameter, dn (m), multiplied by the product of the
liquid density, ρ (kgm-3), and the volumetric flow rate, v (m3s-1), divided by 2.
Where the friction coefficient λ is dependent on the roughness of the tubing and whether the 
flow is laminar, transient or turbulent. This is dictated by Reynolds number as part of the
parameter below256:
 laminar when Re < 2300
 transient when 2300 < Re < 4000
 turbulent when Re > 4000
Reynolds number is calculated using Equation 6.3256:
Equation 6-3: Re =  ρ x u2
   μ x (u / L) 
Where Reynolds number, Re (dimensionless), is equal to the dynamic pressure expressed by the product
of the solution density, ρ (kgm-3), and the liquid velocity squared, u (ms-1), divided by the shear stress as
defined by the dynamic product of the dynamic viscosity, µ (Pas), and the liquid velocity divided by the
length of the tubing.
 1.25kgm-3 x 7.02x10-4ms-1 = 554
3x10-3Pas x (7.02x10-4ms-1/0.231)
The plasma in this scenario has a low Reynolds allowing the calculation of the friction factor
using Equation 6-4:
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Equation 6-4:  λ =  64/ Re 
Where λ = 0.1155, and Re is Reynolds number expressing the ratio of inertial force to viscous 
force for a given solution.
 0.1155 x 1 x (1025kgm-3 x (7.02x10-4)2) = 3.0 x 10-9 Bar
0.11m 2
As a result, the level of pressure loss due to friction was negligible, leaving the main source of
loss in pressure to be caused by the presence of the 200µm mesh as illustrated in Figure 6-6.
6.4.3. Bead Bed Height in the BAL System with CSTPE
As flow rate increased, the bead height increased with a polynomial distribution, using empty
beads in CSTPE plasma. A flow rate giving a 2-fold increase in bead bed height from the
initial height with no flow had been established with alginate beads containing HepG2 cells
with 2% glass bead concentration encapsulated. Using the Jetcutter system described in
Methods Section 2.1.3, this was achieved at 349ml/min using empty beads in CSTPE plasma
(Figure 6-8). This figure is variable depending on the overall density of beads, altered by
changing the percentage glass beads in the alginate mix.
Figure 6-7: The alginate beads bed height, with CSTPE plasma passed through 35ml beads
at between 0ml/min and 600ml/min, contained in a 2L chamber.
6.4.4. Large Scale BAL with In-line Filter
Testing the large scale BAL with the 3 M® Cuno® EXT® 60ZA05A filters evaluated any
changes to the BAL system as a consequence of the alterations within the system, illustrated in
Figure 6-8. These changes would predominantly originate from the back pressure that may
build up behind the filter and the addition of a spare volume bag after the filter, as part of the
primary circuit.
y = 0.0003x2 - 0.0172x +35.939R² = 0.9974
02040
6080100
120140160
0 100 200 300 400 500 600B
ed
H
ei
gh
t(
m
m
)
Flow rate (ml/min)
Bead Bed Height
Page 211
Chapter 6 Large Scale BAL Results
Cobe spectra
RBC mixes
with treated
plasma
RBC
Two
way tap
Two
way tap
Pressure
gauge
Pressure
gauge
Pressure
gauge
Pressure
gauge
Anti-
Coagul
ant
Saline waste Priming
plasma
Spare
Volume
Bead
traps
Pump at ~400 ml/min
Pump at
~90 ml/min
Spare
Volume
1
2
3
4
Figure 6-8: BAL treatment phase with an inline 3M® Cuno® EXT® 60ZA05A filter. In the
primary circuit, blood was separated into plasma and cells by the Cobe® Spectra®
aphaeresis system, to be passed into the secondary circuit at between 20-90ml/min, with
the secondary circuit pump being maintained at between 100-600ml/min. Pressure
readings were made at the exit and entrance of the Cobe® Spectra®, position 1 and 4, as
well as before the chamber, at position 2, and before the filter, at position 3.
6.4.5. Pressure Changes in the BAL Over 8 Hours of Perfusion
As a result of modifying the BAL system with the addition of the filter, a pump and another
spare volume bag, the distribution of pressures around the system were profoundly altered.
Consequently, the flow rates used in the large scale BAL to test changes in flow rate, detailed
in Section 0, could not be replicated in the large scale BAL with the added filter. Despite this,
the changes in pressure were monitored throughout the experiment to evaluate the potential
mechanism for changes in pressure.
Page 212
Chapter 6 Large Scale BAL Results
Figure 6-9: Pressure changes over 8 hours in the large scale BAL with an inline filter. Labels indicate changes to flow rate of either the Cobe ® Spectra® denoted
by C, and the BAL pump denoted by B. The experiment was run for 8 hours after which a 25L sterile water flush was performed of the whole BAL system and
the filter. The TPE tubing as part of the Cobe® Spectra® was disposed of as described in the essential Cobe ® Spectra® user guide257. Samples were taken after 30
minutes, with DNA and endotoxin spikes added to the blood before filtration, at 4 hours and 6 hours.
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During the experiment, the distribution of liquid in the two reservoir bags seemed to be
dictated by two parameters: the distribution of pressure producing a lag between the change in
flow rate and pressure; air space within the filter may have caused changes to pressure build
up in each reservoir, causing the bag to either fill or empty depending on its gravitational
position of the bag and flow rate of the Cobe® Spectra®. For example, at 2 hours the Cobe®
Spectra® flow rate was increased from 37ml/min to 90ml/min and the BAL flow rate was
increased from 55ml/min to 349ml/min. During the experiment without the filter, this would
have caused a large increase in BAL pressure, a more negative pressure at the Cobe® Spectra®
exit, and a less negative pressure at the Cobe® Spectra® entrance. The pressure readings in
Figure 6-6 showed an increase in pressure coming out of the Cobe® Spectra® (before BAL),
whilst the pressure either side of the filter decreased. The pressure was being transmitted into
the reservoir bag in the secondary circuit, which rapidly filled with plasma. When the
secondary circuit flow rate was increased to 600ml/min and the Cobe® Spectra® was decreased
to 40ml/min, the pressure after the Cobe® Spectra® decreased and the pressure before and after
the filter increased rapidly, whilst the spare volume bag in the primary circuit began to fill.
The implication of this is the distribution of plasma in the circuit and extent of contact with the
biomass has with a given volume of plasma, potentially altering detoxification and
nourishment efficiency.
In terms of backpressure due to filter blockage, with the large filter flux, little pressure build-
up was observed. At 3.5 hour when all the pumps were turned off, the pressure before the filter
registered a lag in declining pressure compared with the pressure after the filter, possibly due
to the resistance of the filter media. Despite this, when the system was allowed to stabilise for
pressure setting the flow rate at 90ml/min for the Cobe® Spectra® and 349ml/min for the BAL
pump, there was no detectable pressure differential before or after the filter, being identical to
the pressure coming out of the Cobe® Spectra®. One point of pressure build up did occur,
when the spare volume bag in the primary circuit was held below the height of the filter to
assess the effect of gravity on the pressure within the system. As a result, the backpressure
before the filter was increased as the reservoir volume reached its maximum.
Despite the changes to the BAL system, the filter showed little build up in pressure or
resistance over the 8 hours of perfusion, owing to the large filter area utilised.
6.4.5.1. Filter Capacity
Unlike the experiments in chapter 5, the filter capacity does not require prediction for total
capacity, as significant differential pressure was not produced during the 8 hours of perfusion
with plasma. The capacity was sufficient to be able to reduce the filter size significantly from
the 0.23m2 to a 0.1m2 filter or possibly less. At the end of the filtration experiment, the total
volume throughput was 49.23L according to the Cobe® Spectra® readout.
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6.4.6. Endotoxin and DNA Removal in the BAL Treatment Phase
6.4.6.1. Endotoxin and DNA Removal in the BAL Treatment Phase
Spiked endotoxin levels, as detailed in Section 0, were reduced to unquantifiable levels by the
3M® Cuno® EXT® 60ZA05A filter over the 8 hours of the BAL treatment phase (Figure 6-11).
As a result, the endotoxin capacity of the filter was calculated to be 1.152 x 106EU total
endotoxin binding. According to previous studies, a depth charged filter similar to the
60ZA05A filter would have a capacity of 29.9µg of endotoxin258. However, during this
experiment a total of 76.13µg of endotoxin was added to the blood, all of which was removed,
showing no breakthrough, even towards the end of the 8 hours.
Figure 6-10: Endotoxin concentration in CSTPE plasma over 8 hours of the BAL treatment
phase, adding endotoxin spikes before the experiment, after 4 hours and 6 hours. Double
time points represent samples were taken before and after the filter in the BAL circuit
after 15 minutes of endotoxin addition. (n=5)
6.4.6.2. DNA Removal
Spiked DNA levels were reduced to below the LoD by filtration with the 3M® Cuno® EXT®
60ZA05A filter (Figure 6-11), spiking with DNA before, at 4 and 6 hours of the BAL
treatment phase, as described in Section 0. The DNA capacity calculated in Chapter 5,
predicted a total DNA removal capacity of 39µg of DNA for a 25cm2 3M® Cuno® 60ZA05A
filter. A 0.23m2 filter with the same filter media would provide a 3.59mg of DNA capacity.
During the experiment, a total of 1.56mg of DNA was added to the system, which would have
been representative of the level expected with plasma from an ALF patient and with a HepG2
cell viability of 73% (resulting in a potential DNA release from ~30% of the BAL cell
content). Therefore, even if double the level of DNA was released into the system, the filter
would still have sufficient capacity, based on the calculations in Chapter 5.
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Figure 6-11: DNA concentration in CSTPE plasma in the BAL treatment phase over 8 hours,
adding DNA spikes before filtration, at 4 and 6 hours, as detailed in Section 0. Double time
points represent samples were taken before and after the filter in the BAL circuit after 15
minutes of DNA addition. (n=5)
6.4.7. Protein Transit through the 3M® Cuno® EXT® 60ZA05A Filter
Protein transit was measured by analysing plasma samples taken after 6 hours of filtration
through the EXT® filter. In all cases, there was no significant difference in specific proteins
before or after purification measured using ELISA, detailed in Section 0, and total protein
using BCA assay, as shown in Figure 6.13.
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Figure 6-12: Plasma samples taken at 6 hours from the BAL treatment phase, detailed in
Section 0, were analysed by ELISA showing no significant difference before and after
filtration with p<0.99 for fibrinogen, p<0.88 for Albumin, p<0.98 for α-1-antitrypsin, and 
0.99 for total protein with all proteins analysed in isolation (paired two-way t-test with
n=5, error bars indicate standard deviation). Samples were taken before and after the
filter.
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6.5. Discussion
The BAL system without the inline- filter showed the dynamics of the complete circuit with
changing flow rates. By adding the filter and introducing the subsequent modifications to the
BAL system, the dynamics of the system were significantly altered, which would be expected,
but required confirmation and quantification in order to be able to move towards pre-clinical
trials.
In the BAL system without the filter, the greatest effect on the pressure was the flow rate of
the BAL pump, whereas changing the flow rate of the Cobe® Spectra® had a relatively minor
effect on the pressures within the system. Another important characteristic of this system was
the resistance imparted by the 200µm mesh at the bottom of the chamber. When changing the
BAL chamber flow rate, the pressure either side of the chamber did not change proportionally,
with a 1.197Bar increase before that the chamber and a 0.6087Bar increase after.
Consequently, the importance of ensuring the 200µm mesh within the chamber does not block
is of vital importance to the robust function of the system. The maintenance of effective
heparin concentration to avoid thrombin formation is the only means of preventing any clot
formation, as other frequently used anticoagulants also chelate divalent cations, which would
cause the alginate beads to dissolve.
An added dimension that could be combined with the analysis of the changes in flow rate
around the BAL system is mathematically modelling the amount of biomass exposure a given
plasma quantity received, providing a single unit of measurement to optimise the system and
to quantify the implications of altering the system. In order to do this, computational fluid
dynamics should be used, incorporating many of the principles covered in this thesis.
One way that a computational fluid dynamics program would provide vital information as to
changes in the BAL system is by evaluating the changes to flow as a result of adding the filter,
pump and the spare reservoir bags to the BAL system. Clearly, the addition of these
components dramatically altered the pressure conditions in the system, illustrated by the slow
and unexpected responses to changes to flow rate. An inference can be made that the spare
volume bags were dictating the way the flow was distributed across the system, as observed
during the large scale experiment. Previously a single spare volume bag in the secondary
circuit mitigated any flow discrepancy between the inlet and outlet of the Cobe® Spectra®
pump pushing plasma into and out of the circuit. However, with the addition of a new pump
into the system, which was not controlled by the Cobe® Spectra®, and a second reservoir bag,
the pressure in the system resulted in one bag to filling whilst the pressure increased in the
secondary circuit, as illustrated Figure in 6-1. When the flow rates were changed and the
pressure balance was shifted to the primary circuit the spare volume bag in the primary circuit
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began to fill and the other bag began to empty. During the experiment, efforts were made to
reach equilibrium for flow in and out of the two bags, achieved after 4.5 hours. However, to
ensure that the plasma was maintaining the same level of BAL exposure as a system without
the filter, computation of fluid dynamics could evaluate the theoretical treatment contact a
given proportion of plasma would receive with different BAL designs, determining the extent
to which the inclusion of the reservoir bags affect the system.
The increase in backpressure due to the reservoir bag filling showed the sensitivity of the
system in terms of the effect of using two reservoirs. Furthermore, the addition of an extra
pump not controlled by the Cobe® Spectra® system potentially introduced a discrepancy
between the two systems, despite accurately calibrating both during system assembly.
Accordingly, alternative system designs could be attempted to mitigate the issues raised.
One potential way of bypassing the necessity of having an extra pump and a spare bag may be
to use the filter in a slightly different way. The 3M® Cuno® EXT® filters have four ports: a
fluid entrance, a fluid exit and two air vents either side of the filter membrane. If the
secondary circuit fluid is passed into the filter entrance and on the same side as the filter
membrane, using the air vent, a fluid exit is provided as illustrated in Figure 6-13. As a result,
the flow will still pass throughout the secondary circuit at between 100-600ml/min, as the
easiest exit through the filter would be over the top and out of the air vent. At the same time,
the Cobe® Spectra® would provide negative pressure downstream of the filter in the primary
circuit, encouraging some of the liquid to pass through the filter. In previous experiment,
60ZA05A filters were tested for the ability to pull liquid through in this manner, rather than
pushing, i.e. placing the pump downstream of the filter. This caused the liquid to degas.
However, if the filter experiences an upstream positive pressure from the secondary circuit,
with a negative pressure from the Cobe® Spectra®, the negative pressure may not be sufficient
to cause degassing. However, this would need to be explored empirically.
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Figure 6-13: Large scale BAL design with the filter placed in the secondary circuit. Both the
entrance and exit of the filter are positioned on the same side of the filter media, therefore
causing the plasma to preferentially bypass the filter due to negative pressure downstream
of the filter due to the Cobe® Spectra® some plasma will be encouraged to pass through
the filter.
6.6. Conclusions
Despite the changes to the BAL system, the capability of removing endotoxin and DNA were
extremely encouraging. In both cases, all the biological challenges were removed, reducing
concentration to background levels. The DNA capacity was twice that predicted in Chapter 5,
using the blockage models. In addition, the endotoxin capacity of the EXT filter in this chapter
exceeded the calculated capacity for depth charge filters in previous studies258, although the
filters in these studies were preliminary versions of the S series filters, which have been shown
to have a lower binding capability (Chapter 5). In the final filter design, there would need to be
two filters, to mitigate any malfunction in one filter and to meet regulatory requirements if
there was complete cell death, and then a second filter will be needed to ensure that no
contaminant reached the patient. Although in the event of such a malfunction, the treatment
would be prematurely terminated.
Since the start of writing this thesis, the large scale BAL system, without the filter, has been
used as part of pre-clinical trials in a pig model for acute liver failure. The use of this system
has shown successful integration of the Cobe® Spectra® and BAL systems, perfusing the
biomass with plasma from the pig for up to 12 hours.
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Overall Discussion
This chapter will discuss the main outcomes of the
previous results chapters and indicate areas for
further development.
Page 221
Chapter 7 Overall Discussion
7. Overall Discussion
7.1 Initial Aims
The initial aims of the project were to establish a system to maintain plasma quality returning
to the patient, focusing on contaminants from the BAL biomass as part of the treatment
phase and particulates in alginate as a starting material. For the BAL treatment phase, the
central requirement was to remove DNA and endotoxin from the BAL system whilst
allowing transit of essential components synthesised by the biomass. Using 3M® Cuno®
Zeta® plus charged depth filters, DNA and endotoxin were removed whilst allowing transit
of specific proteins measured by ELISA and maintenance of total protein as measured by a
BCA assay.
Alginate particulate content was reduced using both sand and charged depth filtration, but
both caused detrimental changes to alginate properties causing the cell function and
proliferation to be altered. Preliminary results from gas cyclonic filtration, reduced
particulates to a comparable level to depth charged filtration and sand filtration whilst
maintaining the alginate properties important for maintaining bead integrity, cell
proliferation, and cell function.
7.2 Filtration system for BAL treatment Phase
The application of the 3M® Cuno® Zeta® plus charged depth filters to the BAL system
showed sufficient capacity for the BAL treatment phase in both model and large scale
experiments. In addition to this, DNA and endotoxin binding capacity was shown to be
adequate for BAL treatment phase application. However, further developments are required
to advance the system. Firstly, the measurement of specific proteins ensured that core
synthetic proteins from the BAL system were not depleted; to complete this analysis other
compounds important to therapeutic action of the BAL need to be assessed, to evaluate any
changes in plasma composition beyond protein content.
7.3 Future Adaptation of Current Methods
Some of the methods used in modelling the system could be further expanded to other
aspects of the project.
7.3.1. Scale BAL Growth Phase
The Scale BAL model was used to replicate the treatment phase, over 8 hours of perfusion. It
could potentially be altered to model the growth phase, which provides an environment for
encapsulated HepG2 cell growth, over 8-12 days using microgravity to promote mass
transfer. However, a number of developments would be necessary. Firstly, two layers of
silicon tubing line the inside of the large scale BAL chamber, passing oxygen into the BAL
biomass. The glass columns used for the scale BAL model are too small to incorporate a
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similar oxygenation system, instead incorporating it into the reservoir, holding the culture
media. However, this would have 4 tubes entering and exiting a relatively confined space of
the reservoir (even if larger reservoir bottles are used). Furthermore, with the potential of
having nine replicates, the tubing could easily become tangles and twisted during the 10
days, potentially reducing fluid movement and increases in pressure leading to leakage.
To circumvent this challenge, a “circuit board” of tubing could be developed in the same
manner as the Cobe® Spectra® system, where tubing is held in place so that connections are
made correctly, any blockages are easily located and that tubing cannot kink. In addition to
this, pH buffering may need to be transferred from exclusively using 5% CO2 concentration
in the incubator, to a combination of 5% CO2 and a chemical solution. In the large scale
bioreactor system CO2 and N2 are bubbled through the culture media, causing a decrease or
increase in pH, respectively. After ~ 8 days when the cell density becomes greater, a feed of
7.5% bicarbonate is used to increase the pH. These three pH control methods are
automatically controlled by the bioreactor system, using a pH probe in the bioreactor
reservoir. The current scale BAL system design would rely on changes in the culture media
to control pH, which may not be adequate for long term experiments over days. As a result,
the design of the scale BAL model system could be changed to incorporate small pH probes
connected to the ADintruments® PowerLab® system (used in the filter model), which could
be used to control a pump for feeding bicarbonate into the reservoirs. Miniature pH
electrodes are available that could be incorporated into the reservoir, measured at 14.6mm by
1mm, allowing real-time precise feedback pH control analogous to the large scale BAL.
7.3.2. Pressure Measurements across the Large Scale BAL Treatment Phase
Pressure measurements performed as part of the scale filtration model could be adapted to
the large scale BAL treatment phase, to model the movement of fluid and relate it to mass
transfer between the plasma and the cells. Mass transfer is crucial to successful treatment,
and is reliant on the functionality of cells, the properties of the alginate, the speed of the
plasma passing through the biomass, and the height of the biomass. By measuring the
pressure, the plasma flow through the system can be monitored, allowing the contact time
between cells and plasma to be calculated. Incorporating the contact time between a given
portion of plasma and the cells into a mathematical model of the system with the other
parameters mentioned could allow the development of the optimum mass transfer conditions
and BAL design.
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7.4.1 Regulatory Requirements for Alginate as a Starting Material
The use of alginate in biomedical and pharmaceutical applications is well established, in
artificial organs such as artificial pancreas259,260 and artificial kidney261, drug delivery for
treatment of Parkinson’s disease262, and cell matrix for nerve regeneration233. Furthermore,
alginate is featured on the Generally Recognised as Safe264 (GRAS) list compiled under the
FDA Code for Federal Regulation265 (21 CFR 184.1724). This states that sodium alginate,
but not magnesium, is suitable for human consumption, but does not guarantee use as a
pharmaceutical product. The ASTM, originally known as the American Society of Testing
and Materials, have been accepted as the international standardisation body, who outline the
use of alginate as a pharmaceutical product, with a dedicated division for tissue engineering
medical devices266. The standard set by the ASTM form the basis for medical application of
alginate as part of cGMP, cGLP and cGTP, and FDA approval267.
Two documents from the ASTM specifically relate to alginate as a starting material23 and
alginate in the context of cell encapsulation159. Neither stipulates specific requirements to
achieve medical grade alginate, instead stating the necessary measurements of alginate
parameters for regulatory submission, mainly referring to requirements relating to alginate
used as a parenterals for drug delivery and for tissue implantation, and crucially requiring
illustration of biocompatibility with the specific parameters measured.
An important alginate parameter stipulated under “alginate as a starting material” is impurity
levels, defined as the presence of extraneous substances and materials in the alginate,
including endotoxin, particulates, microbial burden, heavy metals, and protein. Of these
impurities, endotoxin levels permitted in alginate are identical to parenterals, as described in
Chapter 5 (5EU/kg of body mass) and are directly related to microbial burden in the alginate,
relating to potential patient reaction to endotoxin251. Protein contamination in parenterals
have been linked to hypersensitivity in patients268, and the marine source of alginate presents
a risk of heavy metal contamination, including lead and mercury269.
In response to these regulations and the potentially detrimental clinical consequences,
purification of alginate as a starting material is essential in moving towards a product
certified as medical grade for use with human patients. Many other groups who aim to
produce medical grade alginate go through multi-stage purification protocols which often
alter the properties of the alginate156,162,183. However, many of the studies focused on alginate
for cell transplantation into human to prevent immune access to the cells, and thereby
prevent immune rejection. It is therefore likely that such an extensive alginate purification
protocol will not be necessary to gain approval for use of alginate as a starting material for
the BAL system.
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7.4.2. Alginate Purification by Filtration
Alginate testing in this thesis initiated the process of creating medical grade alginate for the
purposes of the BAL system. Filtration of alginate in solution caused changes to alginate
properties for encapsulation. Whereas preliminary results of air classification (gas solid
cyclonic filtration) in dry state showed no difference in alginate properties as defined by
viscosity, cell function and proliferation.
Prior to going into an extensive study of gas solid cyclonic filtration, the particulates need to
be characterised to know the composition and nature, in addition to measuring the other
parameters outlined. The process of air classification uses two processes to separate dry
components of a heterogeneous mixture: sieving, which utilises a variety of meshes to
remove large particulates; air stream classification, which uses air flow to separate
components based on particle size and density, into grades based on predefined cut off
points270. It has been shown that protein levels can be manipulated using this method,
although these reports concern protein recovery in food manufacturing271. Despite this,
protein content, which is an important parameter of alginate purity, may be controlled using
this method. As a result, the protocol could be an important improvement on filtration of
alginate for other industrial applications.
Characterisation of particles should be performed in accordance with ASTM F-1877
(2010)272, entitled “Standard Practice for Characterization of Particles”. It details the
methods for particulate composition, morphological characterisation, number, size, and size
distribution of particles; including sieve analysis, optical, SEM (scanning electron
microscopy), NMR (nuclear magnetic resonance) and HPLC.
7.5. The Development of the BAL System as a Medical Device
One of the main reasons for pursuing a system that manages plasma quality returning to the
patient is to remove contaminants, which may have adverse clinical effects, and to initiate
the process of regulatory compliance. Therefore, by reviewing some of the regulatory
requirements the project can be better directed for eventual market approval. This
development will require the implementation of a wide variety of management practices and
detailed analysis of the BAL parameters. An overview of regulatory issues will be discussed,
focusing mainly on analytical method development, medical device manufacture, and
guidelines pertinent to the Liver Group BAL.
7.5.1. Overview of Regulatory Documents
Four main types of standards are internationally recognised for specific levels of medical
device accreditation, ISO9001:2000, ISO17025:2005, ISO15189:2003 and cGLP (including
cGMP and cGTP). The ISO standard (International Standards Organisation) guideline
ISO9001:2000 mainly focuses on quality management systems for manufacturing
concerning overall processes involved with administering the manufacture, quality
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management, and delivery of the device273. As part of this, inspections take place from
relevant organisations, depending on the location of market approval and with whom the
certification is held, for example the BSI (British Standards Institute) in the UK.
With the relatively generalised nature of ISO9001:2000, ISO17025:2005 dictate many of the
management criteria that need to be met in ISO9001:2000 but provides specific technical
guidelines principally concerning topics such as calibration and testing laboratories. Again,
inspection regimes ensure compliance, for example UKAS (United Kingdom Accreditation
Service) in the UK. The third document which links both ISO9001:2000 and ISO17025:2005
is ISO15189:2003, which specifically concerns medical laboratories, being particularly
pertinent for the BAL manufacture and further development. It matches the quality
management requirements of ISO9001:2000 with the technical requirements of
ISO17025:2005, covering details such as method development and validation, sampling
regimes and, patient medical outcome, cost effectiveness, ethics and many other aspects of
pre-and-post investigative issues. Finally, the most stringent standard is cGLP (current Good
Laboratory Practice), which is maintained by cGLPMA (GLP monitoring authority) in the
UK, incorporating all the ISO regulations mentioned and is crucial for manufacture and
distribution of medicinal goods. In actual fact, depending on the application of GLP,
different permutations of these guidelines are applicable, for example, cGMP,
(manufacturing) and cGCP (clinical) each certification requiring extensive validation, in
depth documentation of management processes and analytical methods, and strictly
controlled facilities118,186,274,275.
The implementations of these regulatory requirements depend upon the stage of
development. The Liver Group BAL development is perfectly adequate for preclinical trials.
To progress to clinical trials involving humans, the European Parliament and Council
Directive 2001/20/EC276 have stipulated requirements concerning implementation of cGCP
(current Good Clinical Practice), which have become standardised across the European
Union with introduction of this legislation in 2004. As a consequence, clinical trials must be
conducted with the focus on safety of the participants with the manufacturing process
complying with local GMP standards. Therefore, core analytical methods used for the
clinical trials must focus on process validation with the specific requirements for validation
being dependant on the stage of the device development. Throughout this development a
comprehensive scope must be presented for each method at each stage of medical device
development, within this scope relevant documentation substantiating the case for validation
and regulatory compliance can be presented277.
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7.5.2. Application of Regulations to the BAL System
The transition of a device from research to a medical device can be a long and expensive
process, often requiring years of pre-clinical testing to obtain the required data for regulatory
approval by organisations such as the FDA118. As a result integrating processes to facilitate
regulatory submission is important to prevent the need to repeat data and to speed the
development of the project.
The validation of the QPCR protocol is adequate for research and pre-clinical trial purposes,
to confidently show reduction or elimination of DNA in plasma. In addition to this, due to
the incorporation of traceability of both method development and the source of components
used in method validation the protocol could easily be extended for incorporation into
clinical trials. The ELISA protocols and Nucleocounter® cell number protocols too could be
extended for use in clinical trials, as a result of prior validation performed by others.
Furthermore, many of the Liver Group BAL components are currently being documented for
the purposes of traceability and are in the process of development for eventual validation.
Finally to prepare for clinical trials, data gathered from pre-clinical trials must comply with
21CFR312, which outlines the process of applying for a new drug application, including
drugs intended to treat life-threatening and severely-debilitating illnesses, such as the Liver
Group BAL.
An overview will be presented of some developments that will facilitate progression of a
project for use with clinical trials and beyond.
7.5.2.1 Quality Manual (QM)
A quality manual (QM), forms the core for further development, including the next
significant step of producing a small scale manufacture process for clinical trial. It provides
the governance for other related documents stipulating management responsibilities,
infrastructure of the organisation, health and safety, quality procedures, and SOPs. For
example, the scope of the SOPs in the QM incorporates instructions describing the
laboratory environment that match the regulatory requirements for all subsequent SOP’s199.
7.5.2.2. Protocols used with the BAL System
As part of the QM, a battery of analytical methods used to evaluate specific therapeutic and
contaminant parameters, would need to be incorporated into an in-depth management
system. This must include detailed and robust documentation and tightly controlled
environments for analytical detection of all the BAL parameters including DNA and other
contaminants. In addition to this, the laboratory will have to comply with certain regulatory
compliances to attain accreditation to guarantee the quality of the results199.
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Traceability
The central concept of validating an analytical protocol is traceability, of which two levels
exist. Experimental traceability of an entire methodology includes reagents, sample
identifiers, and analytical instruments, using documentation to detail batch numbers, source
of samples and servicing logs. Metrological traceability relates to the ability to trace the
experimental development back through different comparisons and justifications, and
validation using reference standards199. Both aspects of traceability are important in
producing a valid analytical protocol, forming part of a much wider network of traceability
and documentation that can encompass management structures, training records, instrument
maintenance and ownership, and laboratory design. For example, a pharmaceutical
manufacturing plant will have specific requirements from an analytical method and
management structure around traceability, which would be excessive and far too costly for a
University research group. The important aspects of these concepts must be chosen and
applied to the needs of the organisation.
Management Structure
A management structure is core to the implementation of the specific aspects concerning
both types of traceability. A distinct management structure carrying out defined aspects of
documentation aids the process of developing a compliant product, including staff training,
maintenance of standard operating procedures (SOPs). For example, SOPs should be
monitored by a number of proficient individuals at different levels of management, including
people who are not directly involved with the methodology, to ensure that the protocol is
followed in a compliant manner on all levels, from the bench to the documentation.
Equipment must be fit for purpose, requiring evidence in the form of experience of members
of staff using it, standard instruments used by others, adequacy of the instrument for the task,
validation of software. Ownership of equipment is necessary to ensure that instruments are
properly maintained in both in terms of day to day use and servicing. The owner needs to be
properly trained, with supporting documentary evidence.
Calibration underpins metrological traceability, ensuring experimental values agree with
values of CRM (certified reference material), where available. For both GLP and
ISO17025:2005 evidence of system suitability is required, requiring validation in the same
manner as the QPCR protocol in Chapter 5. A schedule of calibrating and recording
calibration must be put in place. Testing the performance of equipment independently is also
necessary.
All reagents including all water used must be documented and fit for purpose and sufficient
grade for the task in hand, incorporating complete traceability of all components, including
storage conditions and stability of the reagents.
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Implementation of Quality Management Principles for QPCR
The depth at which each of the management processes are implemented depends on the
requirements of the project. For the purposes of developing and validating a QPCR protocol
for use within a pre-clinical research setting, a number of management systems were put in
place. This was in preparation for further more detailed development for clinical trials. These
included laboratory environment, instrumentation used, and method validation performed
around the framework of traceability.
The environment was strictly controlled by using separate areas for PCR reaction setup,
amplification process, and analysis; separated not only in location but also in the
consumables and instruments. This ensured that no accumulation of template could occur to
cause contamination of samples and false positives. In addition, records of batches and
material numbers, as well as detailed account of each experiment fulfilled the same aspects
of metrological and experimental traceability.
All areas of the BAL process will need to be managed in the same manner as the QPCR
protocol, to collect appropriate data for regulatory submission to carry out clinical trials.
Many of these processes are in place or are in development in-line with the needs of
improving the system. For example, the growth phase of the BAL system is performed in a
clean room to reduce likelihood of contamination, although to gain regulatory approval the
clean room would require certification, as well as continuing to document all data and
materials used for both meteorological and experimental traceability.
Specific Principles for Developing the BAL System Manufacturing Device
As mentioned the development of the BAL system to a clinical setting requires the
implementation of a variety of processes and quality management systems. This thesis
mainly focused on specific contaminants, namely DNA, endotoxin, and particulates, which
form part of the banner of biocompatibility. An ASTM guideline (ASTM F748 2006)
outlines selecting biological tests to establish biocompatibility.
The central theme of ASTM F748 2006, is the biocompatibility of the medical device. It
states that each device is considered on individual merits regardless of what other
applications of similar technologies have shown. The use of animal models (using as few as
possible) is central to this, ensuring that the components of the device do not affect the
outcome of the health. The tests performed do rely on the nature of the device or product and
the exposure time, with the BAL treatment phase categorised as an inter-operative device,
due to its relatively short treatment time. As an indication of minimal requirements necessary
for a BAL, the following tests must be complete:
 Cell culture cytotoxicity
 Sensitization studies
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 Systemic toxicity, acute or sub-acute
 Blood compatibility
 Haemolysis
 Pyrogen testing
 Immune response.
Initial screening tests of biomaterials are also essential, as if any adverse tissue response is
detected later, it may be impossible to ascertain which component of the device caused the
issue. For the BAL this includes the alginate and the impurities. The entire encapsulation,
growth, and treatment phase and all of the components involved, such as media components,
polymerisation buffers and other preparation fluids. Furthermore, parameters such as sterility
must be determined.
Biocompatibility testing requires evaluating the levels of extractables from the constituents
of the device, using methods with sufficient sensitivity to detect to trace levels, if possible,
such as HPLC (High Performance Liquid Chromatography), GC (Gas Chromatography), or
AA (Atomic Absorbance Spectroscopy). Following this, the biocompatibility of the extracts
from components of the medical device and the device itself should be undertaken, to ensure
that even undetectable levels of extractables are not causing adverse effects.
Two other guidelines provide further information for safety and toxicology testing278,279: ISO
10993, called “Biological evaluation of medical devices”; ASTM F748 – 06 (2010) entitled,
“Standard Practice for Selecting Generic Biological Test Methods for Materials and
Devices”. These document detail studies, which relate to the whole BAL project in addition
to the alginate as a starting material and as a matrix for cell encapsulation, Analysis such as
reproducibility in the manufacture of compounds is extremely important and is explicitly
outlined in the Code for Federal Regulation 21CFR211274.
7.6. Conclusions
Adding a filter to the Liver Group BAL system could represents a significant change in the
fluid dynamics of the system. Consequently, the work in this thesis represents preliminary
work to be used to allow focused testing using customised filters and ensuring that the
analytical methods work correctly when applied to more realistic situations. For example,
using plasma from many different patients to provide statistical power and test cells in both
small and large scale that have previously been cryo-preserved. The BAL circuitry needs to
be adjusted to prevent a filter changing the amount of treatment patient plasma gets. These
dynamics need to be modelled, as well as testing more filters on a small scale to provide
statistical power. Finally, the Alu repeat PCR protocol has the potential to become an early
diagnostic tool for liver damage. If this protocol is tested with different patient plasma
samples and optimised for diagnostic purposes, it could provide a new tool in diagnosing
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specific types of liver cell damage, thereby helping clinicians provide the correct treatment
as soon as possible.
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Jetcutter™ encapsulation
Materials
 GeniaLab® Jetcutter™
 2% alginate solution in PBS (section Error! Reference source not found.)
 Polymerisation buffer (section Error! Reference source not found.)
 25 mM glucose complete alpha- MEM culture medium (section Error! Reference source
not found.)
 D-MEM medium with:
o 10% FCS
o 100 U/ml Penicillin, 0.1 mg/ml Streptomycin
o 1.25 µg/ml Fungizone
 Pyrex beakers baked (180 °C for 3 hours)
 Autoclaved Jetcutter™ components:
o pressure vessel
o inline filter
o nozzle holder nozzle assembled and autoclaved
o cutting tool, cutting disc, collection cover
 Autoclaved 5 L stainless steel basin
 Baked funnel for filling pressure vessel
 Plastic beaker for collecting waste from Jetcutter™
 25 ml measuring cylinder for calibration of alginate flow rate
 Plastic bottomless beaker and elastic band
 200 µm nylon mesh
 200 µm glass beads
 Magnetic Stirrers
 Stainless steel spatula
 Sterile consumables including, 15 ml Nunc™ tubes, 50 ml Nunc tubes, 50 ml syringes,
25ml serological pipettes, Gilson tips and Nunc® triple culture flasks
Jetcutter™ principle
The JetCutter™ encapsulation enables the production of large volumes of beads, and is currently the
method of choice for encapsulating cells for use with the full scale Bioartificial Liver system.
The Jetcutter™ system consists of a pressurised chamber which forces the alginate/cell/media mix
through a nozzle at a controlled rate. The stream then passes through a cutting tool with
asymmetrically arranged of wires, which are inclined relative to the vertical solid stream of liquid,
resulting in a horizontal cut as the tool passes through the liquid stream. The cylindrical segment then
forms a bead due to surface tension whilst descending to the polymerisation buffer. This machinery is
operated by more experienced colleagues.
JetCutter™ Set Up
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HepG2 cell culture for the Jetcutter® system was the as the Inotech®, in terms of preparation of
HepG2 cells, the alginate and cell mix, and the media used to encapsulate, but to a larger scale. Cells
were cultured in triple Nunc® flasks, described in section Error! Reference source not found., and
mixed with 2% alginate to a 1:1 ratio, giving 1% alginate, cell in high glucose medium mix (high
glucose medium in section Error! Reference source not found.), to which 2% 200µm sterile glass
beads were added, thoroughly mixed, and immediately poured into the pressure vessel. The lid of the
pressure vessel contains a propeller unit, which is driven from the top by a motor set at 50 rpm,
allowing constant agitation of cell, alginate and glass bead mix. Air pressure was provided using an
air pump connected through a vent in the lid, then by opening an outlet located at the bottom of the
vessel, the mix is forced out and the flow begins.
Figure i: Schematic diagram of the jet cutter system where the air pressure is produced to force
the alginate, medium and cell mix through a 350 µm nozzle. The flow is cut by 100 µm wires on
a circular cutting device to form beads by surface tension. The beads then descend into the
polymerisation buffer containing Ca2+ causing cross linking between the alginate
homopolymeric blocks, consisting of β-D-mannuronate and its C-5 epimer α-L-guluronate.   
The flow passed through a 350 μm nozzle, which was calibrated to 0.33 ml/sec by adjusting the 
pressure, followed by temporarily discontinuing the flow to attach the cutting disk in the path of the
flow.
A number of parameters relating to the cutter and the flow, directly impact bead characteristics as
shown in Figure ii: the cutter, spreads the descending path of the beads reducing the probability of
multiple beads forming; the angle of inclination of the flow to the cutting disk alters the size of the
beads and the efficiency of encapsulation in terms of waste (Figure ii); lastly, the motor speed of the
cutter set at 3600rpm, alters the size of the beads, by changing the volume of alginate mix that passes
before cutting again.
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Figure ii: The inclination of the alginate flow to the wire cutter affects the amount of alginate
cell mix wasted by the cutting process. Optimal inclination angle is determined by the
GeniaLab® Beadsim™ program.
Optimal conditions were set using an algorithm provided by the BeadSim™ software which calculates
the required flow rate, cutting speed and inclination angle for the required bead size of 500 µm.
“Feed and Bleed system”
We routinely produce between 500 and 1000 litres of beads for large scale experiments and treatment,
which is measured after polymerisation, using the settled volume of beads. To polymerisation this
volume, a 5 L container with 3 L of polymerisation buffer and a magnetic stirrer was placed beneath
the flow of beads. We have previously observed that calcium ion concentration affects the rate of
polymerisation and subsequently the quality of beads. When encapsulating high volumes of beads,
however, the alginate sequesters the calcium in the buffer as well as causing a dilution effect. This
was controlled by slowly bleeding 70% CaCl2 into the 5 L container over the period of encapsulation,
simultaneously an overflow pipe is located immediately above the 3L mark to remove excess
polymerisation buffer, and reduce the dilution effect of the beads. The flow rate of the concentrated
calcium infusion was identical to the flow rate of beads from the Jetcutter™, typically between 19.5
and 21ml/min.
Bead Collection
To begin the encapsulation, the outlet tap on the pressure vessel was opened to begin alginate mix
flow and the Jet cutter motor was started. Prior to bead collection, the initial flow through was
discarded whilst a clean alginate mix flow was established. After which the beads were collected into
the polymerisation buffer over 1 hour, then poured from their collection basin through a beaker with a
200μM mesh bottom, retaining the beads on the mesh. To remove the polymerisation buffer, the beads 
in the mesh were placed at the bottom of a container, where D-MEM with 10 % FBS was poured over
the beads whilst mixing gently, followed by transferring the beads into 50 ml centrifuge tubes to be
used as required. Once beads had settled, the volume collected was estimated from the graduations
marked on the side of the tubes. .
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Appendix V Platelet Aggregation
Figure I: Platelet aggregation in FFP under phase contrast microscopy.
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